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Western medicine is based on a wide variety of disease management strategies that are 
employed with great success. For instance, the mortality of heart disease, stroke and cancer 
patients has dropped dramatically (Jemal 2009, Eheman 2012). Still, there is much room for 
improvement in various areas of medicine and care. Recently, within the American medical 
system medical interventions have become the leading cause of death with over 750.000 
iatrogenic deaths each year (Null 2003). Alan Roses, past vice president of GlaxoSmithKline, 
reported in 2003 that 90% of the drugs work in only 30-50% of the patients. This means that 
large numbers of people receive medication that doesn't contribute to their health, leading to 
further hospitalizations due to adverse drug reactions and side effects. 
Current Western drug development is based on the golden standard of randomized placebo 
controlled double-blind clinical trials. This type of study design is only suitable to discover 
average drug effects over large, homogenous groups of patients. However, when a drug enters 
the market it is largely unknown whether the drug is effective or toxic in the individual 
patient. On the other hand, drug candidates that might be very beneficial to a certain 
individual, will not reach the market when the average effect does not rise above a placebo 
effect in a large group of patients. In reality, drugs are developed for a statistically average 
patient which in reality doesn't exist, and not for the individual patient. 
 
Personalized medicine 
Personalized medicine has appeared on the horizon as a new drug development strategy, 
which aims to get the right drug, to the right patient, at the right time, in the right dosage, etc 
(van der Greef 2006) (Figure 1). The development of this type of medicine requires an 
entirely new way of conducting clinical trials and evaluating efficacy and effectiveness (Witt 
2009). The effectiveness of drugs can be improved enormously when they are targeted to the 
right patients, and especially when they are developed for a specific sub-group of patients. 
Personalized medicine can only be developed in combination with proper diagnostic tools 
that are essential for matching individuals with a specific drug combination or treatment. This 





Figure 1. The concept of personalized medicine. Extensive diagnosis is the key for recognizing sub-groups of 
patients (differently colored unhappy characters on the left side of the figure). Medication is optimized for 
specific patient groups and eventually for the individual patient. 
 
Better diagnostic tools can lead to better disease prevention strategies, and eventually to 
health promotion strategies. Health promotion is a largely unexplored area of science that for 
instance aims at improving the resilience of the system, and has the potential to offer 
enormous opportunities for improving quality of life and preventing diseases (Lindström 
2005). Health promotion contrasts with current disease management strategies, which are 
mostly aimed at suppressing certain symptoms such as lowering cholesterol levels, reducing 
inflammation by suppressing the immune system, using insulin to control glucose levels, etc.  
An intriguing challenge for scientists is how to measure health and health promotion. One 
step in this direction is the use of challenge tests such as the oral glucose tolerance test, 
exercise, or a high fat diet in healthy volunteers to measure the resilience of the system 
(Wopereis 2009). Not surprisingly, health is a very personal condition, each of us having to 
do with certain genetic predispositions, a constitution with certain strong and weak points, 
and more or less effective acquired behavioral patterns. Health can be promoted by certain 
life style changes that are generally good for everyone such as having a healthy diet and 
having a minimum of daily exercise. However, major improvements will be made possible by 
a personal targeted set of life style behaviors closely matched with the personal condition. 
Consequently, detailed diagnosis of the system is essential for the development of both 





Systems thinking, systems biology & systems diagnosis 
In the currently popular disease management mode of the health care system, people mostly 
wait to seek help until some serious symptoms are observed. For instance, when the pancreas 
function has already dropped dramatically, elevated blood glucose levels are detected, and 
diabetes type 2 can be diagnosed. This underlines that the body is quiet good at keeping 
processes within certain well-controlled boundaries without generating feelings of illness. 
This is called homeostasis. However, it might well be the case that other parts of the body are 
compensating for loss of function, while no changes in blood parameters are measured  yet. 
In a disease management mode, it will be very hard to detect and prevent movements of the 
system towards unhealthy states. 
It becomes increasingly clear that many chronic diseases are characterized by a combination 
of disturbances in various systems, such as the immune system, the autonomic nervous 
system, the gut microbiome and mental processes (Irwin 2011, Sterling 2011). For instance, 
deregulation of the cortisol circadian rhythm due to shift work or sleep disturbance has been 
found to increase cortisol levels in certain tissues, which can lead to immune system 
disturbances and diseases such as metabolic syndrome, cardiometabolic diseases and stroke 
(Cutolo 2012). In rheumatoid arthritis the role of gut microbiota in relation to joint problems 
'the gut-joint axis' is becoming more and more important (Scher 2011). Studies such as these 
show that systems thinking, considering the interactions between various systems in the body, 
is essential for understanding complex diseases.  
Systems thinking requires a shift in focus from objects to relationships. The quality of the 
organization of the system is more important than the quantity of the separate objects. At 
higher levels of the organization new properties emerge that cannot be observed at a lower 
level. For instance, cells working together in an organization called a liver show specific liver 
properties, which cannot be observed in the liver cells individually.  
Current prevention strategies are generally based on treatment of populations at risk. For 
instance, the tendency is to prescribe statins for individuals with a 10 percent increased risk 
for cardiovascular diseases. This means that 90 percent of those individuals are receiving 
medication but will never develop the disease. However, these individuals might experience 
side effects. On top of that, statins work in only 25 percent of the patients and compliance is 
usually not very high, resulting in only one or two out of a hundred patients who would 
benefit from this prevention strategy. This leads to a medicalization of the society. Systems 




and finding the people who can really benefit from the drug. Changes in the relationships 
between processes are much more likely to be predictive of unhealthy conditions than single 
biomarker concentrations. 
Systems biology is a biology-based interdisciplinary field that studies complex interactions in 
biological systems. Systems biology is based on the comprehensive measurement of 
processes for which a large variety of measurement techniques have been developed, ranging 
from genomics, proteomics and metabolomics to physiological measurements such as heart 
rate variability, blood pressure, ultra-weak photon emission and clinical chemistry 
parameters. Following the measurements, the data needs to be processed and analyzed, which 
requires specific statistical tools and approaches that deal with large numbers of features or 
variables compared to samples (Bijlsma 2006). Principal component analysis (PCA) is a key 
tool that is employed to search for the main sources of variation in datasets in which the 
variables are linearly related. Because most processes in nature are nonlinear, it is often more 
suitable to employ nonlinear principal component analysis techniques (Meulman 2003). 
Often unsupervised methods such as PCA are followed by supervised analysis methods. 
Classification and prediction of groups can be accomplished by applying for example partial 
least squares discriminant analysis (PLS-DA) (Barker 2003). Prediction based on large 
numbers of variables is susceptible to over-fitting (Westerhuis 2008), which requires 
extensive validation strategies such as double cross-validation and permutation testing 
(Hendriks 2007). The final step in the systems biology pipeline consists of the interpretation 
of the data analysis results. This non-trivial step usually involves extensive literature search, 
functional enrichment tools for -omics data and network analysis (Calvano 2005, Cline 2007, 
Bouwman 2012). The history, developments, and future perspectives in the field of 
metabolomics are discussed in Chapter 3. 
The complex interactions in living systems, and between such systems and the environment 
are at the core of Chinese medicine. Chinese medicine evolved as a systems science with an 
emphasis on describing instead of explaining, which is the emphasis of the Western sciences. 
The following quotation from the Neijijng Suwen, the oldest classical Chinese medical text 
written around 3000 years BC, beautifully captures Chinese medical thinking: 
'Huang Di stated, “People and nature are inseparable. In nature the cyclical movement of the 
heavenly bodies produces atmospheric influences that exert control over the rhythms of the 
seasons and is responsible for change to the myriad living and nonliving things. These cycles 




towards chaos. It is this chaos in the macrocosm that upsets the balance of the delicate 
ecology within people that produces disease.” (Ni 1995) 
The Chinese descriptive approach is actually another systems biology approach in which 
patterns of complex organization are described and treated. For instance, in Chinese medicine 
a headache by itself is not treated, because it is a single symptom without context. Only when 
headache appears in a combination with other symptoms such as irritability, dry eyes, painful 
menstruation and an oppressed feeling in the chest, the pattern acquires a meaning and can be 
treated. More or less stable patterns of symptoms are recognized. In fact Chinese diagnosis 
can be termed a systems diagnosis approach. Treatment of these patterns or syndromes is 
aiming for a change or shift towards another more favorable or healthy state of the system. 
This concept of health closely relates to the attractor and bifurcation concepts from 
complexity theory (see introduction texts by Steven Strogatz (Strogatz 2001) and James 
Bassingthwaighte (Bassingthwaighte 1994)). 
Further development of personalized and preventive medicine will require  both Western and 
Chinese system thinking approaches. The key issue is how to communicate between the two 
sciences and how to translate and integrate the advantages of both sciences into one new 
future systems science. This is a major issue explored in this thesis. Two symbols of systems 
biology are shown in Figure 2 to illustrate this challenge. On the left side is a network model 
of the interactions between genes, proteins and metabolites measured in an atherosclerosis rat 
model using modern -omics techniques. On the right side a Chinese functional description of 
the body is presented in which the persons and the relationships between them represent 
organ functions and the relationships between the organs. Both sides of the picture show 
regulatory systems and the organization of regulation. The descriptive approach is therefore a 





Figure 2. Illustration of systems thinking in Western science and the Chinese Taoist traditions. The left panel 
shows a network of correlations between metabolites, genes and proteins revealing the complex interactions 
related to the onset of atherosclerosis. The right panel shows the Neijing Tu, a chart of the inner landscape of the 
body from the White Clouds Taoist temple in Beijing. The Taoist school of Highest Clarity envisions the body 
as a complete world onto itself that is also a reflection of the world.  
 
Sub-phenotyping approach for targeted care 
In this thesis a step is taken in the direction of personalized medicine by integrating Chinese 
diagnosis with systems biology. The main focus of the research was to find relevant sub-types 
of rheumatoid arthritis (RA) patients. The patients in the studies were diagnosed according to 
the official American College of Rheumatology classification criteria for rheumatoid arthritis. 
On top of that a Chinese diagnosis was obtained for each patient and used for assigning 
patients to sub-groups. Systems biology, especially metabolomics and transcriptomics 




The next step was to design new studies to test the clinical relevance of the possibly newly 
discovered sub-groups of RA patients. 
Several sub-types of RA patients have been identified based on particular clinical and 
molecular features (van Baarsen 2010, van der Pouw Kraan 2007). Factors such as disease 
duration and age have been identified that predict response to treatment (Anderson 2000, 
Wolfe 1991). Although some molecular markers have been found to predict functional and 
structural outcomes, these markers rarely find their way into clinical practice. One reason is 
the difficulty to translate markers found in trial populations to routinely measurable and cost-
effective predictors for individuals (Conaghan 2011). Another reason is that the discovery of 
novel relevant sub-types of RA patients is hampered by the unsupervised nature of the 
currently employed research strategies. Without prior knowledge it becomes very hard to sift 
through large amounts of gene expression, proteomics and metabolite information and come 
up with useful models and interpretations. This indicates that there is a need to develop new 
robust and reliable clinically applicable tools to identify sub-types of patients for rheumatoid 
arthritis.  
 
Outline of the thesis 
Chapter 2 gives an in-depth exploration of how personalized medicine can be envisioned and 
developed. Diagnosis is discussed as a key concept in this endeavor. A further integration of 
systems thinking into the life sciences and medical sciences is proposed aiming to further 
develop a systems science. Additionally, the value of Chinese systems thinking for 
personalized medicine is extensively discussed and methods for integration with Western 
science are described. 
In Chapter 3 metabolomics as a key systems biology technology is reviewed in the light of 30 
years of metabolomics at TNO. The chapter shows how metabolomics started out from a 
technology push that turned into a biology pull around the year 2000. A large variety of 
metabolomics applications that have been developed over 30 years illustrates this. The review 
is concluded with future perspectives for the metabolomics field and how the field can 
contribute to changing views on health care and healing. 
Chapter 4 provides deeper insights in metabolic processes that are related to rheumatoid 
arthritis. This literature overview attempts to provide a comprehensive view of these 




enrichment tools are used to integrate the information and find the dominant biological 
processes. 
In Chapter 5 the first clinical study is described in which two sub-types of rheumatoid 
arthritis patients are found based on a Chinese diagnosis. The two sub-types of patients are 
characterized by gene expression profiles measured in CD4+ T-cells and by a GC-MS 
metabolomics analysis of plasma. This chapter provides the first evidence for biological 
differences between two sub-types of RA patients based on a combination of Western and 
Chinese diagnosis. 
Chapter 6 describes an important step following the study presented in the previous chapter, 
namely the standardization of the Chinese diagnosis used to sub-type the patients. This step 
involves the development and application of a systems diagnosis questionnaire that allows the 
collection of extensive symptom patterns of arthritis patients. These symptom patterns are 
explored for 49 patients who filled in the questionnaire. 
In Chapter 7 a more extended clinical study is described in which the same two sub-types of 
rheumatoid arthritis patients are explored. In this study the patients are classified by a 
Chinese medicine expert, but in addition the systems diagnosis questionnaire was completed 
by the patients as well. Extensive untargeted LC-MS metabolomics measurements were 
performed in addition to standard clinical chemistry measurements to characterize the sub-
types of patients. 
Finally, in Chapter 8 the contribution of this work towards personalized medicine is 
discussed. In addition ideas for future studies that could follow from this work are presented. 
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2. Systems biology-based diagnostic principles as the 




Innovative systems approaches to develop medicine and health care are emerging from the 
integration of Chinese and Western medicine strategies, philosophies and practices. The two 
medical systems are highly complementary as the reductionist aspects of Western medicine 
are favorable in acute disease situations and the holistic aspects of Chinese medicine offer 
more opportunities in chronic conditions and for prevention. In this article we argue that 
diagnosis plays a key role in building the bridge between Chinese and Western medicine. 
Recent advances in the study of health, healing, placebo effects and patient physician 
interactions will be discussed pointing out the development of a system-based diagnosis. 
Especially a systems biology based diagnosis can be used to capture phenotype information, 
leading towards a scientific basis for a more refined patient characterization, new diagnostic 
tools and personalized heath strategies. Sub-typing of rheumatoid arthritis patients based on 
Chinese diagnostic principles is discussed as an example. New insights from this process of 
integrating Western and Chinese medicine will pave the way for a patient-centred health care 
ecosystem. 
 
Based on: van der Greef J, van Wietmarschen H, Schroën J, Wang M, Hankemeier T, Xu G (2010) Systems 
biology-based diagnostic principles as pillars of the bridge between Chinese and Western medicine. Planta 




The health care system in Western societies and one of its pillars, modern medicine, are 
increasingly under debate. The increasing costs of health care are reaching the level where it 
will not be sustainable in the near future. Recent estimates for the US health care system 
show an increase from 17% of the gross domestic product (GDP) in 2009 to over 20% of the 
GDP in 2018, when the total cost will reach 4.35 trillion USD [1]. At the same time, hopes 
for developing medicines that are more effective are fading away, since the pharmaceutical 
industry produces fewer new chemical entities (NCE’s) that reach the market every year. 
In this era, crucial global issues have surfaced in various domains, including the financial, 
ecological, political, educational, religious/spiritual, and social realms. Mechanisms that 
previously functioned effectively must be replaced by new approaches. These challenges are 
not local, but global, and system thinking will be mandatory in the future. In such times of 
change, one must reflect and focus on the driving force of the system that needs to evolve. In 
health care, there must be a shift from an emphasis on economics, technological 
developments and political agendas back to a patient-centred health care environment. 
In health care, the paradigm of system thinking has emerged as systems biology. It is limiting 
to develop interventions on how a single compound interacts with single target that is linked 
to a specific symptom. This “one-drug-fits-all” paradigm has shifted to an idea that patients 
require personalized medicines. Some successful examples have been used to treat cancer, 
including Herceptin® (trastuzumab), Gleevec® (imatinib mesylaat) and Iressa® (gefitinib). 
However, a thorough systems approach has not yet been applied to design new drugs. 
Moreover, the patient is not yet seen as a unique individual. Treatments focus on a disease or 
a disease phenotype rather than the person, even though effective treatments rely on a proper 
systems diagnosis. 
In this paper, we describe how the global nature of challenges must be recognized to develop 
global solutions. These solutions must integrate diverse concepts and intuition to bring about 
a new understanding. Our discussion begins with a reflection on how Chinese and Western 
Medicine evolved over time. In the second step, we consider the diagnosis as the basis in 
each medical system, and then we consider new ways of merging knowledge from both 
systems. This information is used to provide a deeper insight into personalized health 
diagnostics, and we envision the development of a future system. This type of process 
requires multiple steps. As an example, we use rheumatoid arthritis (RA) to describe how to 
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diagnose and ultimately establish a personalized health care ecosystem. 
 
Bridging Chinese and Western medicine: a philosophical and historical view 
 
 
Figure 1. Systems biology as a bridge between Chinese and Western medicine. As migration moved populations 
apart in space and time, the Western and Chinese cultures evolve separately, giving rise to specific cultural 
philosophies. These philosophies  gave rise to philosophies of science, which led to types of science. This 
evolution allowed different types of science to exist alongside one another (Figure 1) [2]. 
 
Medicine has been practiced since prehistoric times, and over time, a variety of medical 
traditions developed. In ancient Greece, biological theories were focused on solving one 
problem, that of the relationship between the “one” and the “many.” This union between the 
many phenomena formed nature, which was rationalized in the theory of the four humours. In 
Hippocrates' and Galen's times, disease was still perceived as a natural or physiological 
process, and diagnoses were made by knowing this story of transformation [3]. Centuries 
later, Paracelsus developed a new concept of disease based on pathological, anatomical and 
metabolic changes, which resulted in a new diagnostic practice that was based on the 
classification of diseases [4]. Thus, the perspective of disease as a process and a relation 
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between the one and the many shifted towards viewing disease as a structure located in an 
individual. 
 
Figure 2. Tai Ji symbol 
 
Chinese medicine developed in a Taoist, Buddhist and Confucian culture. Many of the key 
aspects of Chinese medicine are explored in one of the oldest classical Chinese texts, the Yi 
Jing, a book that is still considered essential when studying and practising Chinese medicine 
today [5]. The Yi Jing presents what we would today refer to as a systems view of life, health 
and society. This view is represented beautifully in the Tai Ji symbol (Figure 2). In the Tai Ji 
symbol, Yin (female, earth) and Yang (male, heaven) grasp each other but are also present 
within each other, as represented by the small dots. The Tai Ji symbol is the oldest known 
example of fractal thinking because the small dot of Yin within Yang is actually another Tai Ji 
symbol [6]. This relates to the view expressed in the Yi Jing that the world inside the body is 
a reflection of and thus connected with the world outside the body (Figure 3).  In the classical 
text on Chinese medicine Neijing Suwen, Qi Bo answered the Yellow Emperor saying, 'The 
most important element in clinical diagnosis is to know the relationships between heaven, 
earth and humankind' [7]. Both the body and the world are complex, dynamic systems with 
fractal relationships to one another. In a healthy situation, Yin and Yang are in balance. This 
concept of balance, movement and connection was developed further in the Zang Fu (organ 
theory) and Five Phases theories. 
Although the ancient Greek and Chinese ideas on health and medicine show many 
similarities, the variations in cultures and philosophies gave rise to the differences between 
the medical systems that we perceive today [2]. For instance, during the 17th century, 
Descartes proposed that there was a division between the mind and body, and this idea had an 
enormous impact on Western science and medicine. Western science evolved into an 
objective methodology where the scientist explained and analysed, but aimed not to be part of 
the studied object. Subjects related to matter became the province of science, while subjects 
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related to the mind and spirit entered the domain of religion [8]. Physicians were educated to 
treat patients as material systems, or physical machines, with medications and interventions 
for physical problems [9]. Illnesses and diseases were perceived as being located in the 
patient, rather than being embedded in networks, relationships, the environment and culture. 
As a result, the modern Western scientific method was used to gather a tremendous amount of 
knowledge about, anatomy, physiology, cells, genes, proteins, metabolites , etc. Over the last 
decades, various thinkers, who were interested in how all of these aspects worked together, 
began combining theories from many disciplines into a systems view on life. One intriguing 
example is the Santiago theory of cognition in which the mind-body dualism is overcome by 
identifying cognition, the process of knowing, with the process of life and the body as the 
material structure to accommodate this process. Mental activity or the mind is an organizing 
function of living systems which is connected and interacting with the body, which plays a 
more structural role in living systems [10]. Additionally, the concept of health is shifting back 
to interpretations that are more comprehensive. For instance, the concept of salutogenesis 
defines health in terms of movement and connection [11].The capacity to move in a health-
promoting direction is determined by comprehensibility, meaningfulness and manageability 
[12]. 
The systems approach to medicine that is now developing in the West has the potential to 
integrate with Chinese medicine [13]. In particular, the systems biology approach of patient 
profiling using modern genomics, proteomics and metabolomics technologies [14,15] is a 
perfect match for the systems diagnosis in Chinese medicine. Integration of these approaches 
may reveal different groupings or sub-phenotypes of patients, which require different 
treatments. Additionally, knowledge about the biological mechanisms behind the 
personalized herbal formulas used in Chinese medicine is expanding through modern herbal 
chemical profiling techniques [16,17].  
Figure 3 illustrates the Western systems biology view of the body and the Chinese view of the 
body as a landscape [15]. The correlation network in the left panel shows the relationships 
between metabolites, proteins and genes during an early stage of atherosclerosis. In the right 
panel, a drawing illustrates the relationships within the body. By zooming in elements can be 
found that have a relationship with Western perspectives. For example, the fire in the 
cauldron in the lower part in Figure 3 is called MingMen (the gate of life), which can be 
compared to the adrenal glands. MingMen catalyzes and supports processes in the body, such 
as temperature and metabolism, which is similar to adrenal hormone function. 
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Both Chinese and Western science describe life as a complex, dynamic, non-linear system. As 
Western scientists discovered the non-linear behavior of cytokine networks, Chinese 
practitioners have recognized non-linear patterns in how symptoms change in patients [18]. 
The fractal properties of the arteries, lungs and heart rate resemble the fractal thinking in 
Chinese medicine [19]. In both sciences, life is considered a self-organizing system that is far 
from equilibrium. Systems thinking can build the cultural, philosophical and scientific 
bridges that are necessary to share understanding between the two sciences. By studying tools 
and techniques developed in both the Chinese and Western medical systems, new insights 
will emerge that are necessary to heal the patient, his environment, and the world he lives in.  
 
Figure 3. Illustration of systems thinking in Western science and in the Chinese Taoist traditions. The left panel 
shows a network of correlations between metabolites, genes and proteins revealing the complex interactions 
related to the onset of atherosclerosis. The right panel shows the Neijing Tu, a chart of the inner landscape of the 
body from the White Clouds Taoist temple in Beijing. The Taoist school of Highest Clarity envisions the body 




Both Western systems biology and Chinese Taoist science consider the complete body and its 
relationships and connections to its environment. These similarities bring the two sciences 
closer together. Essentially, the world inside and outside the body are the same. Mapping 
relationship patterns has become an important strategy in modern systems biology research. 
For instance, advanced -omics technologies can be used to reveal diagnostic insights or 
indicate the impact of interventions [14]. 
Traditionally, the focus of the systems view in Chinese medicine has been directed towards 
health promotion. In recent Western terminology, this is known as strengthening the resilience 
of the homeostatic process, or salutogenesis. Typically, Western medicine has focused on 
disease management.  
 
Figure 4. The schematic representation of a dynamic system losing its homeostasis and developing into a 
disease state. The effects of (*1) a reductionist intervention and (*2) a system intervention are illustrated. 
 
Figure 4 illustrates a healthy dynamic situation that loses its control capability (homeostasis) 
and develops into a disease state [20]. The schematic is oversimplified, since the border 
between health and disease depends on the individual and may not always be clear. 
Moreover, the process is multidimensional, so the two-dimensional representation is limited 
for evaluation. The chart represents a typical readout if the diagnostic tool for monitoring 
health is based on a reductionist principle, such as blood pressure or glucose level 
measurements. When the system is incapable of maintaining health, a disease state occurs. In 
this scheme, a reductionist intervention (*1) can be applied to reduce the given symptom. 
While the reductionist intervention may appear promising, when the medication is stopped 
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the system cannot maintain control, and the disease state recurs [21]. In contrast, application 
of a system treatment (*2) allows the system to regain its resilience. Eventually, when the 
treatment is stopped, the system remains within the healthy range. Instead of monitoring a 
single variable, use of a system dynamics approach is more effective, which is noted 
especially in chronic conditions or during prevention strategies. In acute states, reductionist 
approaches can be very effective for releasing the immediate danger; however, strengthening 
the system provides a powerful additive value. For instance, during chemotherapy, Chinese 
medicine can protect or reduce potential side effects and strengthen immune function.  
Therefore, Figure 4 illustrates the bridge between Chinese and Western medicine shown in 
Figure 1 from a different angle. In Figure 4, major emphasis from Western medicine is on 
disease management while the major emphasis on health promotion comes from Chinese 
medicine. 
 
System-based diagnosis, building the bridge 
Today, the term diagnosis has a wide variety of meanings depending on its context. The word 
originated from a combination of the Greek words “dia-,” meaning "apart” or “split" and 
“gnosi,” meaning "to learn” or “knowledge." Therefore, a diagnosis is related to a 
recognizable separation (or split) from the whole. In a medical context, a diagnosis is 
typically used to describe a certain condition or syndrome that is characterized by a 
combination of specific features that occur simultaneously and vary from “normal” 
functioning. A diagnosis can lead to the recognition of a specific disease or syndrome based 
on a group of symptoms or signs that characterize an “abnormal” condition. In Greek, the 
word “symptom” refers to a feeling of misfortune that has befallen a patient. The experience 
of confronting disease symptoms varies substantially in different cultures and in people with 
different worldviews, as discussed below. A differentiation can be made between symptoms 
that are described by the patient (subjective) and signs that are observed or measured by 
others (objective). For instance, a symptom could include pain sensations, and a sign could 
include glucose or cholesterol levels. 
From a system view, there is an implicit danger while making a diagnosis because by 
characterizing a person using a selection of symptoms and signs and emphasizing the 
difference from what is believed to be normal or healthy, there is a loss of context 
information. As mentioned previously, this is one of the major differences between Chinese 
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and Western medicine. In Western medicine, the basis for developing therapeutic 
interventions often involves reducing a generic observation of a condition to the lowest 
number of possible combinations of symptoms and signs. For instance, type 2 diabetes is 
diagnosed by one sign, a person’s glucose levels. As such, Western medicine has become 
successful in reducing symptomatic effects, which is relevant in acute or relatively 
threatening conditions. Corrective treatments focus on specific aspects rather than stimulating 
or guiding endogenous (homeostatic) regulatory processes, which is typical in systems-based 
approaches. The reductionist approach aims for simplified diagnosis-therapy protocols that 
have become the basis for quality management in health care.  
This focus has advantages, but it also has clear limitations, which are evident in patients with 
chronic diseases or in situations requiring personalized medical approaches. Previously, these 
limitations were discussed from a systems perspective for drug discovery and drug 
development [22] and from a personalized medicine perspective [23]. At present, a clear 
diagnostic differentiation combined with a specific therapy has become a new driving force 
known as companion diagnostics or theranostics. This approach led to improvements in 
specific situations, such as cancer therapy, but it still follows a reductionist path as its basis. 
This trend will certainly continue in the coming years, and we will discuss this in detail 
below. However, to understand the limitations of this process and to reveal the unaddressed 
potential in these cases, we will first examine the diagnosis process in more detail.  
  
A general schematic illustrating patient-provider interactions from a system’s view can serve 
as the basis for understanding a number of important issues (Figure 5). The first step in the 
diagnosis process is recognition by a person that his/her ability to function in daily life is 
limited or challenged. These limitations may include a variety of physical and psychological 
features. In fact, a subjective shift in consciousness has already emerged that something is 
wrong, which is often followed by a feeling of fear that the condition will deteriorate in the 
future. Our thinking patterns often gravitate towards envisioning a future that is different 
from what we think is desired or essential (thinking based on pre-conceived ideas), and this is 
a first step towards becoming unhappy and stressed [24]. The next step is typically an 
appointment with a general practitioner. During the appointment, which is schematically 
depicted in Figure 5, many things happen simultaneously that have distinct influences on the 




Figure 5. Schematic illustration of the interaction between a patient and a health care provider. The quality of 
the connection is of key importance for the diagnostic and therapeutic process. 
 
Figure 5 reflects the essence of the meeting between the patient and physician and the 
importance of the connectivity for exchanging information. Typically, a physician will ask 
questions or invite the patient to explain his or her motivation for visiting. In the mean time, 
body language and intuitive processes are active. The process of anamnesis has begun, and 
the physician collects information that is sometimes combined with a physical examination, 
during which symptoms and signs are gathered. It is important to note that by asking 
questions, the consciousness and the awareness of the patient is already influenced and 
changed. Therefore, therapy and personal awareness has already begun.  
The information collected relates not only to the patient’s status at that point in time in 
isolation, but also to the person’s social network, culture and history. These latter aspects are 
of key importance in the systemic view to fully understanding the patient. In fact, we should 
consider a biosphere that includes both the patient and the physician [25,26]. The physicians’ 
biosphere must have the ability to communicate and the worldview (spirituality) of the 
patient and physician play a major role in this process. Although not the focus of this paper, 
we would like to emphasize here that the diagnostic process will follow different routes 
depending on different worldviews. For instance, when the belief is that a “misfortune” 
happened to the patient, this then leads to an intervention (physician-driven, corrective 
action). In contrast, if the situation is viewed as an “exploration” where decisions are made 
together about what the next step should be in the emerging future, then the patient accepts 
responsibility for his consciousness ( reflective and process orientated) . Here the interaction 
is reflective and process-orientated, and the physician acts more like a coach.  
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In the anamnesis process in Western medicine, the physician provides direct advice to the 
patient or refers the patient to a medical specialist for a more detailed investigation. This 
process leads towards more reductionism in many cases. Additionally, the physician may 
prescribe or suggest an intervention with medicine. A clear shift has taken place in recent 
years, and medical advice has begun to comprise medicine along with suggestions for 
lifestyle changes, such as fitness, mental training and nutrition.  This reflects a shift towards a 
more systemic approach, recalling the original Greek definition of the word “anamnesis,” 
which means “remembering who you are” (in context of the whole). 
 
Let us now examine how a broader diagnostic view can cause shifts in the development of 
modern medicine. Modern Western medicine is based on a reductionist view. It involves 
studying aspects or portions of physiology, while ignoring most of the influences of 
psychology or spirituality, with the exception of psychiatry.  
In recent decades, this way of thinking has become more balanced. Much of this change in 
perception is due to placebo research. The placebo effect has been heavily debated for many 
years. The effect is typically considered as an annoyance in scientific medical research, since 
it hampers the ability to analyze the “pure” pharmacodynamic effects of a drug under 
development. The expression, “placebo effect,” reflects the feeling that it is something 
unscientific and without value.  
Even in surgical studies, placebo effects have been reported.  Pain reduction experiments with 
“hidden treatments,” demonstrated that the placebo effect is much smaller when patients were 
unaware that they are receiving medication. In depression research, placebo effects can 
account for at least 75% of the observed positive effects of medications [27,28]. According to 
Wayne Jonas (Placebo Symposium, Nov. 27-28 2009, Starnberg), placebo effects are 
influenced by: (1) pill colour, (2) number of pills or treatments, (3) compliance with 
treatment, (4) packet label, (5) form of treatment (pill, needle, heat, injection, laser), (6) 
location of the treatment (home, hospital or optimal healing environment (OHE)), (7) order or 
administration of treatments, (8) tone of treatment delivery and the authority of the physician, 
(9) information provided with delivery, (10) inherent social and cultural factors, (11) 
effectiveness of the drug, (12) effectiveness of other drugs with similar uses, and (13) 
combinations of the above factors. 
In summary, placebo responses are observed frequently in clinical trials, and they vary 
considerably [29,30]. Therefore, it can be difficult to prove that the effectiveness of a drug is 
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superior to a placebo. When a cause or variable has such a strong effect on the clinical trials 
for developing medicines, the factor should be extensively studied. For the placebo effect, 
this is especially important, since the effect significantly affects both diagnostic and 
therapeutic medical practices. Additionally, a reverse placebo effect called the “nocebo 
effect” (Latin for "I will harm," and named by Walter Kennedy in 1961) has also been 
reported. The nocebo effect indicates a pessimistic view of a medicine under investigation.  
In a recent placebo workshop (Starnberg 2009, Nov. 27-28 2009), Jonas argued  that “for a 
better understanding we need to disentangle the “placebo effect” as the physiological, 
psychological and clinical effects of meaning and context (MAC) and learning” [31]. This is 
mandatory before taking the next step towards a systemic approach in health care.   
To understand the placebo effect, scientists must separately study the effect of the placebo 
substance (ex. sugar) and the effect of administering the placebo (psychological responses 
induced by the health care environment). Often the natural cause of a disease is also taken 
into account. From a systemic perspective, this encompasses the movement of the whole, 
including psychological and spiritual factors.  At this point, it is important to recall the split 
between body and mind in Western sciences, which was introduced by Descartes. This split 
led to the design of scientific experiments to reveal “pure” medication effects, which 
excluded the possible effect of the observer. This concept is now changing as the systemic 
view has emerged.  
It is beyond the scope of this paper to go into further detail on placebo effects. We 
recommend that the interested reader consult the following authors as an entry to the placebo 
field: Fabrizio, Wallach, Kolls and Jonas. Additionally, we recommend exploring the 
references cited in the following papers: [32,33,34,35,36,37,29,38].  
Following diagnosis, the relationship between the patient and the physician is crucial. The 
person’s worldview, including their family, social network, culture, and history, are necessary 
for context, as shown in Figure 5. Furthermore, the physiological network depicted in the 
figure is a reflection of the system response to all of these effects. In systems biology studies, 
this network is not always appreciated, and sources of unknown variation are not linked to 
other important effects. The abilities of a physician to connect to the world of the patient and 
use intuition and authority are extremely important. Despite the efficiency and cost-control 
pressures on medical health care systems today, excellent physicians are still able to use these 
skills. In modern medical education systems, relatively little, if any, attention is aimed at 





Figure 6. The steps from the current Western “one-drug-fits-all” concept to targeted care and eventually to a 
personalized health care system. 
 
What does this mean for diagnostic strategies? From Figure 5, it is clear that from a systems 
view it is essential to consider the interactions of the person with his environment as a whole. 
The diagnosis is a description of a person at a given point in time, knowing the person’s 
history and addressing his current condition, which is expressed as a disease. People with 
different cultural backgrounds will have different views, and consequently have different 
needs. The aim of the diagnosis is to find a way to support a person by relieving him from 
disabling factors or making him aware of necessary lifestyle changes, including changes in 
psychological thinking patterns.  
 
In Chinese medicine, diagnosis is highly related to the above contextual description. A person 
is seen as unique, but also as part of a whole. Both the patient and the doctor grow during 
their interaction in their knowledge of life and its purpose. The modern technologies 
developed in Western medicine have become valuable for obtaining a deep insight into the 
physiological mechanisms of disease. Chinese medicine can be enriched enormously by 
adding this wealth of new diagnostic aspects. The systems biology technology has allowed 
for an additional bridge between the “seen and the unseen.” In fact, the current situation is 
rich in opportunities. Descriptive diagnosis can be linked to a systems-based medical system. 
Additionally, technological capabilities have opened up new insights into biology. The next 





Taking this step requires that health care systems offer solutions that include patient 
participation. Whenever possible, the patient should remain responsible for his own health, 
and the health care process should follow a counselling trajectory. In a way, it can be 
compared to the modern view of how organizational changes can be guided through a deeper 
meaning (identity, soul or source of the organization) and not via a shortcut to a solution. The 
ultimate connection and quality of the relationship between those involved in the process is 
highly relevant, and a deeper understanding arises from reflection upon the whole. This 
approach, called “presencing,” is expressed with other current management insights, such as 
Theory U [39]. These theories link to spiritual literature, such as the Chinese books of 
wisdom, the Tao Te Ching (The Book of the Way and its Virtue). Spiritual books are a source 
of inspiration, and the timelessness of the wisdom serves to help us discover ourselves and 
the purpose and meaning of our life. For instance, Lao Tzu (604 BC - 531 BC) said “If you 
do not change direction, you may end up where you are heading.” This expression can be 
applied to health care as a reason to investigate current practice and envision the future. This 
will allow practical steps to be designed in a direction originating from current health care 
systems. 
From a Western perspective, systems biology research can improve the “one-drug-fits-all” 
interventions based on reductionist diagnoses. In Figure 6, this is shown as the first step 
towards a more targeted approach in which subtype classes are recognized. Still the basis for 
this approach is disease-orientated; however, current medicines can be optimized for a better 
efficacy/safety ratio for a given subtype. The last and largest step towards personalized health 
care is diagnosis support to provide a patient-centred wellness approach. The health care 
ecosystem must fully utilize this potential for personalized medicine. To do so, a major 
driving force could be the combination therapy strategy outlined previously [40]. Chinese 
medicine is already based on a personalized approach, so improvements to this system must 
come from refining and expanding the current Western medicine options, focusing on quality 
control and providing scientific evidence to create a global acceptance of its practices outside 
Chinese culture.  
In Western medicine, the step to improved subtyping (targeted care) can be strongly enhanced 
using knowledge from Chinese medicine. Currently, many studies are underway to detect 
subtypes by profiling cohorts with –omics technologies and systems biology platforms [14], 
 
35 
but these evaluations must be based on non-supervised procedures or drug response profiling 
for specific drugs. Gathering data from these methods is limited, since individual variation is 
high, as outlined above. Consequently, Chinese medicine is an attractive alternative to 
subtype cohorts diagnosed using Western diagnosis methods. For instance, rheumatoid 
arthritis (RA) or type 2 diabetes cohorts could be subtyped using pattern recognition 
techniques based on systems biology. This allows a subset of variables to be obtained and 
validated, which can serve as a new diagnostic principle when developing interventions. This 
strategy is the basis of the Sino-Dutch Centre for Preventive and Personalized Medicine. In 
the following example of subtyping in RA, we will demonstrate the strategy and describe the 
challenges in incorporating this method in practice. 
 
Towards personalized medicine for rheumatoid arthritis 
RA is the most common chronic, inflammatory joint disease, affecting approximately 0.5 -1% 
of the population worldwide [41,42]. The currently favoured treatment strategy focuses on 
reducing inflammation, and pain is generally believed to have a favourable effect on the 
disease course. However, assessments of disease activity and functional disability in patients 
do not always support this treatment strategy [43]. In addition, there is a high variability in 
treatment responses [44] For instance, nearly 30% of patients fail to respond positively to 
anti-TNF therapy, which is currently the most effective therapy for RA [45,46]. 
Predicting a patient’s response to a treatment can help ensure that he receives the right 
treatment and minimizes the risk of side effects. Over the years, several clinical features and 
molecular markers have been identified that allow RA patients to be divided into subgroups 
that may respond differently to treatments [47,48].For example, van der Helm-van Mil and 
colleagues demonstrated that patients who were positive or negative for anti-citrullinated 
protein antibodies (ACPA) had distinctive RA risk profiles [49]. ACPA-positive RA patients 
had more inflamed joints and a higher level of joint destruction [50]. Van der Pouw Kraan 
and colleagues observed a large heterogeneity between the high and low INF-1 subtypes of 
RA patients in their gene expression profiles, but there was no clear difference between 
groups in terms of clinical features [51]. Unfortunately, the knowledge gained from these 
studies has not yet led to personalized health care strategies in clinical practice. 
Since routine molecular markers and disease activity measurements have failed to predict 
treatment responses, patient phenotypes should be measured in more comprehensively. 
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Glocker and others advocate use of a systems biology approach to develop personalized 
medicine for RA [52,44]. This type of approach would simultaneously measure the 
interactions between genes, proteins, metabolites and symptoms [40,22,23]. The resulting 
patient profiles can then be used to diagnose and classify patients. 
Interestingly, there are several health and medical traditions that use a systems approach, 
including Chinese medicine. A key aspect of Chinese medical diagnosis is that symptoms are 
collected from the patient by the practitioner through inquiry. The symptoms and signs 
deigned important for determining the correct treatment vary widely from the Western 
perspective. To diagnose RA, rheumatologists use seven criteria established by the American 
College of Rheumatology [53]. These criteria involve morning stiffness, arthritis of three or 
more joints, arthritis of hand joints, symmetric arthritis, rheumatoid nodules, serum 
rheumatoid factor and radiographic changes of the joints. In contrast, the symptoms involved 
in the Chinese diagnosis include climate factors, emotional states, joint problems, types of 
pain, fever, swellings, digestive problems, and many others [54,55]. The Chinese diagnosis 
provides a more complete description of the entire body. 
A second advantage in Chinese medicine is that its treatment strategies can be considered a 
systems biology approach. For thousands of years patients in China have been treated with 
personalized herbal formulas based on extensive diagnoses. Herbal formulas contain 
hundreds of compounds of which the function is often unknown. Interestingly, the 
combinations of compounds in herbal formulas work together to improve effectiveness and 
reduce side effects [13]. Additionally, an optimization strategy is often followed in which 
patients receive different or adapted herbal formulas after each consecutive consultation to 
improve the effectiveness or change the treatment target . 
The differences in the health, disease and treatment perspectives between Western doctors 
and Chinese experts makes it difficult to simply transfer herbal treatments to the Western 
medical practice. Several herbal treatments for RA have been studied with ambiguous results 
because important subtype information was ignored. For example Tripterygium wilfordii 
Hook. F. extracts are commonly and successfully used as a Chinese medicine intervention 
strategy for RA, and the extract has been studied extensively [56,57].  Preparations of 
Ganoderma lucidum (Leyss. Ex Fr.) Karst, an extract of multiple herbs called San-Miao-Wan 
[58] Celastrus aculeatus Merr. [59] and Forsythia suspense (Thunb.) Vahl [60] have been 
used as immune modulators in RA patients. In these studies, the benefits of using standard 
Chinese medicine preparations in RA patients were not always clear. We believe that it is 
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necessary to develop tools to determine which subgroups of patients will benefit from 
specific Chinese medicines before they can be effectively introduced in Western clinical 
practice. The key issue here is diagnosis.  
In a study of 396 RA patients, a combination of Tripterygium wilfordii Hook. F. with a 
Yishen Juanbi tablet was effective in patients affected with joint pain and joint tenderness, 
who did not experience increased urination at night and joint stiffness [61]. Additionally a 
Western treatment consisting of diclofenac, methotrexate and sulfasalazine was found to be 
more effective in RA patients displaying joint tenderness and thirst, and less effective in RA 
patients with dizziness [61].These results indicate that a Chinese medical diagnosis can be 
used to identify RA subtypes. Specifically, Chinese medical diagnoses may identify RA 
patient subtypes that have different responses to Western treatments or require different 
Chinese herbal treatments. 
The next section explores the Chinese medical diagnosis of RA patients in further detail. In 
Chinese medicine theory, RA is part of a group of syndromes, called the “Bi-syndromes”. The 
character 'Bi' means blockage or obstruction. In Chinese medicine, this term is used to denote 
'obstruction of Qi and blood in the channels and collaterals' [54]. These obstructions mainly 
lead to pain, numbness and stiffness. The “Bi-syndromes” include other Western diseases, 
such as osteoarthritis, frozen shoulder, repetitive strain injuries (RSI), other rheumatic 
diseases, such as fibromyalgia and systemic lupus erythematosus, as well as conditions like 
bursitisand synovitis [54]. 
“Bi-syndromes” are caused by an attack of three out of four external pathogenic factors called 
“Heat”, “Cold”, “Dampness” and “Wind”. After its first superficial stage, the disease can 
develop into later stages that can be classified according to the affected “Fu organs” or the 
affected “Five Tissues” [7] A Chinese medicinal expert can determine the type of “Bi-
syndrome” a patient is suffering from by employing diagnostic methods, such as inquiry, 
palpation, taking the pulse and looking at the tongue. Symptoms and signs related to the “Bi-





Figure 7. Network visualization of the “Bi-syndromes” based on Vangermeersch [54]. The Cytoscape network 
algorithm was used to calculate a network view where the length of the edges were minimized [62]. The red 
hexagonal nodes represent the “Bi-syndromes”, and the yellow circles represent the symptoms and signs related 
to the “Bi-syndromes”. The green lines (edges) represent the relationships between symptoms and syndromes, 
and thicker lines represent stronger relationships.  
 
We can think about the patterns of symptoms and the relationships between symptoms and 
syndromes in terms of Western network theories and visualization methods. In Figure 7, the 
patterns of symptoms and syndromes that make up the “Bi-syndromes” are visualized using 
Cytoscape [63]. It is immediately clear that the “Bi-syndromes” (red hexagons) are intricately 
related and connected by certain specific symptoms (yellow circles). In fact, the syndromes 
act as nodes within the dynamic network of symptoms. While a single symptom, such as dry 
mouth, does not point toward a syndrome, a combination of symptoms, such as dry mouth, a 
warm feeling and an aversion to heat, suggest that the patient has a “Heat syndrome”. Some 
symptoms are related to multiple “Bi-syndromes” and can indicate a change in the disease 
from one state to another. These symptoms can be referred to as bridge symptoms or 
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bifurcation points. For example, a patient with side pain, thirst, headache and cold feet over 
time could develop a new symptom like lower back pain. This indicates that the disease 
might suddenly shift from one stable state to another. In this case, the shift is from a liver 
disorder to a kidney problem, which reflects a more chronic stage of the disease. 
Although the Western concept of RA is very different from the “Bi-syndromes”, there are 
some connections between the two disease classifications. We compared the symptoms and 
signs of RA described in the Merck manual with those related to the “Bi-syndromes” [64]. 
Only four symptoms were shared in both classifications: stiff joints, swollen joints, fever and 
pain with redness and swelling. Additionally, we compared the symptoms and signs of other 
rheumatic diseases with the “Bi-syndrome” symptoms. Again, there were few overlapping 
symptoms. Figure 8 shows the symptoms and signs that connect the “Bi-syndromes” (red 
hexagons) with RA and osteoarthritis (OA) (blue hexagons). Additionally, the symptoms 
connecting the various “Bi-syndromes” are drawn, and the symptoms connecting RA with 
OA are depicted. For simplicity, the symptoms unique to single diseases were left out of the 
network. In Chinese medical theory, all the symptoms that are related to the “Bi-syndromes” 
can occur in RA patients and in patients with other rheumatic diseases. However, it proves to 
be difficult to match the symptoms and signs used in Chinese and Western medicine. For 
instance, only a few of the symptoms and signs described in Chinese medicine as being 
related to arthritis were listed in the Merck manual [64]. The additional symptoms and signs 




Figure 8. Network visualization of the connections between the “Bi-syndromes” (red hexagons) and RA and 
OA (blue hexagons). Only the symptoms (yellow nodes) that connect a “Bi-syndrome” with a Western 
rheumatic disease are labelled. For simplicity, the symptoms unique to single “Bi-syndromes” or diseases were 
left out of the network.  Although in Chinese medical theory RA and OA are connected to all the symptoms of 
the “Bi-syndromes”, only a few of these symptoms are recognized in Western medicine. 
 
To test our hypothesis that a Chinese medicine diagnosis could point towards RA patient 
subtypes that can be interpreted with modern Western systems biology techniques, we 
designed a study that included 33 RA patients and 16 healthy volunteers. The patients were 
classified into “Cold” or “Heat” groups by a Chinese medicine expert, according to Chinese 
medical diagnosis. All patients had swollen and painful joints at the time of diagnosis and 
during collection of the blood samples. The blood samples were used to perform a gene 
expression analysis in CD4+ T-cells and for a broad-spectrum gas chromatography-mass 
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spectrometry (GC-MS) metabolomics analysis [65]. 
“Cold” and “Heat” were specifically chosen because these Chinese medical classifications 
are commonly used in Chinese medical schools. Therefore, there is little controversy over 
how to classify patients into the two categories although patients can express both “Cold” and 
“Heat” symptoms at the same time. According to Zhang and colleagues, approximately half 
of the RA patients in the general population fall into the “Cold” type while approximately 
16% are classified as the “Heat” type [66]. We also selected these two groups because there 
are different Chinese herbal formulas for curing RA Cold and RA Heat patients. In this study, 
clearly defined “Cold” and “Heat” RA patients were asked to participate.  
The “Cold” pattern can be described by severe pain in a joint or muscle that limits the range 
of comfortable movement with pain that does not move to other locations. The pain is 
relieved by applying warmth to the affected area, but increases with exposure to the cold. 
Loose stools are characteristic of this pattern, as well as clear profuse urine and an absence of 
thirst. A thin, white tongue coating is observable, combined with a wiry and tight pulse. In 
contrast, the “Heat” pattern is characterized by severe pain with hot, red, swollen and 
inflamed joints. Pain is generally relieved by applying cold to the joints. Other symptoms 
include fever, thirst, a flushed face, irritability, restlessness, constipation and deep-coloured 




Figure 9. The centre panel shows a partial least square-discriminant analysis (PLS-DA) score plot in which all 
the RA patients  are represented by a dot. The blue dots represent RA Cold patients, and the red dots represent 
RA Heat patients. The RA Cold patients and RA Heat patients are clearly separated. The PLS-DA model was 
validated using cross validation and permutation testing. Above and below the score plot are network views of 
correlations between blood plasma metabolites measured using GC-MS in the RA patients. The top network 
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shows correlations between metabolites >50% for RA Heat patients, and the bottom network shows correlations 
between metabolites >50% in the RA Cold patients. The  nodes in both networks are the same and are composed 
of > 80% correlations in the RA Heat patients and > 80% correlations in the RA Cold patients. The topology of 
the network was generated using the Kamada algorithm, which was unweighed. The position of the nodes is 
equal in both networks, which means that the same metabolites (nodes) are represented in both networks, only 
the strength of the correlations are different.   
 
This study revealed differences in gene expression profiles and metabolomics profiles 
between RA Cold and Heat patients (Figure 9 shows the metabolomics results). These 
differences involved apoptosis genes, and the RA Heat group showed more activity in 
apoptosis-stimulating genes than the RA Cold group. In contrast, several genes related to 
apoptosis resistance were more active in the RA Cold group than in the RA Heat group [65]. 
Thus, besides finding molecular differences between the two subgroups, there is also a 
biological explanation using Western chemical concepts that can explain the difference in 
subtypes that were distinguished through Chinese medical approaches.  
Apparently, the Chinese concepts of “Heat” and “Cold” are relevant in understanding RA. A 
more general relationship between “Cold” and “Heat” and Western medicine was well 
described by Li and colleagues [68]. Using a database built from PubMed articles related to 
keywords Heat and Cold, the researchers calculated the co-citations of these keywords with 
hormones, cytokines and neurotransmitters. “Heat” symptoms were related more strongly 
with immune factors, while “Cold” symptoms were more strongly related to hormones. 
Neurotransmitters were equally related to “Cold” and “Heat” symptoms [68].  
It is well known that patients with autoimmune diseases, including diabetes, RA and lupus, 
have autonomic nervous system dysfunctions [69].The autonomic nervous system – the 
sympathicus and parasympathicus – regulate basic physiologic processes, such as heart rate, 
blood pressure, respiratory rate, gastrointestinal motility and body temperature. Czura 
hypothesized that dysfunction of the cholinergic anti-inflammatory pathway may predispose 
some individuals to excessive inflammatory responses [70]. The cholinergic anti-
inflammatory pathway normally provides a brake on the immune system that restrains 
cytokine production. If the brake becomes insufficient, due either to insensitivity to 
acetylcholine released by the pathway or to diminished signals in the pathway, cytokine 
responses can become excessive [70] Therefore, in RA, it is possible that there is both a 
disregulation of the autonomic nervous system and a disbalance in the immune system. 
Additionally, the extent to which each system is out of balance has relevance, which may be 
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understood by studying Chinese medicine diagnosis. 
Li's study suggests that RA Cold patients suffer more from a hormone disbalance, and RA 
Heat patients suffer more from an immune system disbalance, although the two systems are 
closely related. Moreover, this suggests that RA Cold patients may respond better to a 
hormone treatment, such as corticosteroids, while RA Heat patients may benefit more from 
an immune related treatment, such as one of the new biologicals. Although this hypothesis 
has not yet been tested, this could be an excellent example of subtyping RA patients using 
Chinese medical diagnosis to personalize and improve the Western treatments for RA 
patients. 
 
Conclusion and perspectives 
During the last 10 years, systems thinking has been emerging in pharmaceutical and 
biomedical sciences. Consequently, a natural bridge can now be formed between holistic- and 
reductionist-focused philosophies. There are vast opportunities available through merging the 
Chinese and Western medical perspectives, since both are complementary to one another and 
each has its own merits. For example, reductionist strategies are favorable in acute (disease 
management) situations, while holistic approaches offer more opportunities for preventive 
(health promotion) and chronic conditions.  
 
Figure 10. A composite photo made by merging two photographs [22] taken sequentially with different focal 
settings. The composite photo illustrates the wish to see both the whole and the details sharply in one glance 
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(holistic-systemic) in modern medicine. 
 
In Figure 10, an analogy of the desired situation of combining holistic and reductionist 
perspectives is shown as a composite photo that displays a sharp view on the whole (moon) 
and the details (migrating cormorants). This view reflects the desire to merge the holistic and 
reductionist perspectives in health care. However, to create this image, two pictures were 
taken in sequence, each under different focal conditions, and then the two photos were 
merged. Today, such an image is impossible to obtain in a single shot even with advanced 
cameras, but the future may reveal new options in due time. 
Diagnosis will play a major role in future developments, since it will serve as bridge between 
the different medical perspectives, and interventions can only be designed and exchanged 
based on a common diagnosis. The future points to an advanced personalized health care 
system in which personalized medicine is one of the key pillars. In Western medicine, the 
driving force is to improve the quality of life for patients as 90% of drugs work for only a 
limited number of patients. For instance, oncology medications have only a 35% response 
rate and the side effects are significant [71]. The economic resistance in leaving the 
blockbuster strategy has decreased, since the “one-drug-fits-all concept” is no longer a viable 
option. Combining subtyping and personalized medicine could bring more drugs into orphan 
drug status, which could be advantageous for drug development. When the efficacy/safety 
ratio improves, a higher return could be obtained for newly developed drugs within a smaller 
market. It is clear that combination therapy, the basic strategy in Chinese medicines [13] will 
create an important opportunity to generate the diversity needed for more personalized 
approaches. 
Future trends in research and development will be more patient-centered, and the patient-
physician relationship will be recognized more and more as a key element for providing the 
health care in the future. Health promotion and preventive approaches must be revised in 
Western medicine, since the development process is not geared towards health challenges 
where strengthening homeostasis is the key approach and subtle subtyping is the basis. 
Chinese medicine is likely to provide a variety of options based on the available diagnostic 
opportunities. In line with systems theory, the scale and complexity of a solution should 
match that of the problem. This theory indicates that combination therapy is an option, and 
diagnostic principles should utilize a personalized approach. Additionally, Chinese medicine 
can be used to strengthen the biological system, maintain a better basic health and reduce side 
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effects. These approaches can be developed further when Chinese-based diagnostic principles 
are scientifically proven and translated into biochemical fingerprints. 
Systems biology-based diagnostics and particularly metabolomics will be essential in this 
merging process, since it captures relevant phenotype information. Studying the dynamics of 
systems might become mandatory to provide early, more preventive diagnoses. Health care is 
expected to change fundamentally in the next 25 years based on these new insights and the 
driving force from both the quality of life and health care cost perspectives. The Sino-Dutch 
Centre for Personalized and Preventive Medicine is contributing to these developments by 
stimulating education and through scientific research that applies metabolomics-based 
systems biology that is guided by the principles of Chinese medicine-based diagnostics. 
Disease subtyping is believed to improve the understanding of responder and non-responder 
challenges in Western medicine, to optimize cohort selection in clinical trials, and to underpin 
the current understanding of the combined use of Chinese and Western medicine in China. 
Most importantly, subtyping will provide a scientific basis to understand and globally 
integrate the complementary Chinese and Western medical systems. 
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Metabolites have played an essential role in our understanding of life, health, and disease for 
thousands of years. This domain became much more important after the concept of 
metabolism was discovered. In the 1950s, mass spectrometry was coupled to chromatography 
and made the technique more application-oriented and allowed the development of new 
profiling technologies. Since 1980, TNO has performed system-based metabolic profiling of 
body fluids, and combined with pattern recognition has led to many discoveries and 
contributed to the field known as metabolomics and systems biology. This review describes 
the development of related concepts and applications at TNO in the biomedical, 
pharmaceutical, nutritional, and microbiological fields, and provides an outlook for the 
future. 
 
Based on: van der Greef J, van Wietmarschen HA, van Ommen B, Verheij E (2012) Looking back into the 
future: 30 years of metabolomics at TNO. Mass Spectrometry reviews, submitted 
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Introduction to Metabolomics 
Metabolites in ancient history  
The word metabolism originates from the Greek “μεταβολισμός”, which means “change”. 
The concept of metabolism was mentioned by Ibn al-Nafis (1213-1288), who stated that “the 
body and its parts are in a continuous state of dissolution and nourishment, so they are 
inevitably undergoing permanent change.” Studies on individual changes during different 
daily activities were performed by Santorio in 1614 and were mentioned in his book Ars de 
Statica Medecina (Bing, 1971).  
The measurement of single metabolites as a source of information related to health and 
disease has a long history that precedes the introduction of metabolomics and acronyms such 
as metabolomics, body fluid profiling, metanomics, metabonomics, metabolic profiling, etc. 
(Oliver et al., 1998; Lindon, Holmes, & Nicholson, 2003; Raamsdonk et al., 2001; Ramsden, 
2009). The terminology is not relevant for the content. As stated by Juliet in Shakespeare’s 
Romeo and Juliet, "What's in a name? That which we call a rose by any other name would 
smell as sweet" (Shakespeare, 1594). From another perspective, metabolites have a long 
association with sweet flavors that extends to ancient times and predate the development of 
metabolic nomenclature. Ancient Chinese cultures (1500–2000 BC) recognized urine as an 
important source of health-related information and sweet-tasting urine as indicative of a 
disease (now known as diabetes). At that time, “clinical testing” involved actual urine tasting. 
Advanced “biosensor” ants could also be used to test differences between sample and 
reference urines. The association between sweet urine and disease was contemporaneously 
made in India by Ayurveda Hindus.  
Diabetes as a disease state was described on 3rd Dynasty Egyptian papyri by the physician 
Hesy-Ra, who mentioned an additional symptom, frequent urination or polyuria. 
Approximately 1000 years ago, the Arabian physician Avicenna observed that an individual's 
urine changes during illness. In modern times, changes in the smell or color of urine are 
known to be related to changes in the concentration of chemical components and 
dysregulation of biochemical pathways that indicate certain metabolic diseases. For instance, 
blue urine can indicate Blue Diaper syndrome, caused by a defect in tryptophan absorption. 
Urine with a musty/mousey odor is suggestive of classical phenylketonuria (PKU), an 




Metabolites in modern history (1900–present) 
The discovery of enzymes by German chemist Eduard Buchner (1860–1917) at the beginning 
of the 20th century led to a focus on intracellular chemical reactions and inspired 
development of the field of biochemistry. The biochemical understanding of metabolism 
developed rapidly due to new insights into enzymatic reactions and intracellular biochemical 
pathways.  
New technological developments in the early 20th century in the domain of mass 
spectrometry (MS) enabled researchers to measure the molecules involved in biochemical 
pathways, and to investigate their roles in disease states. As early as 1948, Williams and his 
associates identified important concepts of normality based on MS profiling of body fluids, 
and examined individual differences and pathologies in patients with alcoholism and 
schizophrenia. The correlation of emotional stress and physical exertions with urinary 
metabolite profiles were already emphasized by Ludwig et al. (Ludwig 1977). Gates and 
Sweeley performed a review of these early thoughts and experimental approaches (Gates & 
Sweeley, 1978). In their review, they mentioned some important hallmarks related to 
quantitative metabolic profiling. In particular, they referenced the works of Horning & 
Horning, who first introduced the concept of metabolic profiling by MS (Horning & Horning, 
1971), and Pauling et al., who reported urine vapor and breath analyses with gas-liquid 
partition chromatography related to the effects of defined diet (Pauling et al., 1971).   
To enable the routine measurement of molecules in biological matrices, researchers in the 
1950s coupled gas chromatography (GC) with MS. Early commercial GC/MS instruments 
enabled practical clinical investigations and the measurement of profiles of urine and blood 
samples. Such profiles were typically limited to a specific class of compounds, such as 
organic acids, because the available technology required volatile components or compounds 
made volatile by chemical derivatization.  
Opportunities for the direct application of GC/MS techniques came in the early 20
th
 century. 
The British physician Sir Archibald Garrod (1857–1936) proposed the detection of changes in 
metabolic pathways caused by a single inherited gene defect. This concept became the basis 
for the field of inborn errors of metabolism. In clinical chemistry, body fluid profiles led to 
the discovery of numerous diseases related to single-gene defects (for more information, see 
reviews by Politzer, Dowty & Laseter, 1976, and Jellum, 1977). However, these types of 
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profiles were very limited from a systems perspective. Concentration changes in such genetic 
diseases are typically very large and more easily detected than changes in chronic diseases, in 
which time-dependent changes of regulatory processes must be observed. Consequently, there 
was a need for a broader characterization of systems and for sophisticated pattern-recognition 
tools to evaluate complex patterns. 
In the 1970s, several developments occurred in The Netherlands that influenced research at 
TNO. Meuzelaar and Kistemaker developed an impressive pyrolysis-MS (PyMS) 
characterization methodology that allowed the pyrolyzation of bacteria and many other 
nonvolatile biomaterials (Meuzelaar & Kistemaker, 1973) . The resulting constituents were 
recorded as fingerprints and analyzed with multivariate statistical methods, such as nonlinear 
mapping and factor analysis (Windig, Kistemaker & Haverkamp, 1980). New multivariate 
tools became available in the field of GC profiling (Blomquist et al., 1979; McConnell et al., 
1979; Rhodes et al., 1981). Although PyMS was a novel systems profiling method, it had 
some limitations: typically, only nonvolatile materials could be investigated, and thermal 
degradation products were not easily related to their precursor macromolecules. Despite these 
challenges, many successful investigations were achieved with PyMS in subsequent decades.  
In the 1970s, the MS field expanded with the development of soft-ionization methods, such 
as field desorption and laser desorption (Schulten & Beckey, 1975) that enabled the analysis 
of low-volatile components. As part of his PhD project, under the guidance of Nico Nibbering 
at the University of Amsterdam, new electronics were developed to enable controlled 
desorption and reproducible biofluid profiling through field ionization kinetics/ field 
desorption (van der Greef, 1980). At the same time, new multivariate statistical tools became 
available in commercial packages such as Arthur (CPC, Seattle, WA, USA). However, 
interpretation of outputs from these tools was not straightforward; this time-period marked 
the beginning of the analysis of datasets with many more variables than objects. To illustrate 
this perspective, after a night of intense calculations, the Arthur program was known to return 
the following famous output: “In controversial matters, my perception is rather fine. I always 




Metabolomics at TNO  
The body fluid profiling and pattern recognition project (early 1980s) 
The developments of field desorption (FD) and the so-called emission-control device (van der 
Greef, 1980) overcame a major bottleneck in reproducible profiling of biofluid samples under 
controlled desorption conditions and presented a unique opportunity for researchers. In 
August 1980, the “body fluid profiling and pattern recognition” project was initiated at TNO, 
led by Jan van der Greef in the Instrumental Analysis group. Headed by Michael ten Noever 
de Brauw, these facilities held some of the most advanced MS capabilities worldwide at that 
time. The initial phase of the project involved construction of an ion source and an electronic 
control unit, equipped with photographic and electric detection, for the Varian 731 MS 
instrument. The design of the control unit was based on the original electronic design of Jim 
Dawson (University of Amsterdam).  
The initial phase involved implementation of earlier designs, as well as production and 
successful operation of an automatic field-desorption emitter-production unit. The most 
complicated step was to interface the MS system with the PDP-8 computer because the high-
voltage field-desorption ion source generated frequent sparking events. Software was 
developed to acquire, normalize, and import data to the Arthur software package for 
multivariate analysis. The multidisciplinary core team for this project included Jan van der 
Greef, Leo Bergman (electronics), Jaap Bouwman (computer hardware and software), Albert 
Tas (pattern recognition), and Michael ten Noever de Brauw (MS). An MS machine equipped 
with a field desorption source and emission-control electronics (van der Greef & Nibbering, 
1977) coupled to computer data acquisition (Varian 620i, SS100 datasystem) with the Arthur 
package became operational in mid-1981 (Figure 1). This setup would be the basis for further 





Figure 1. The first “body fluid & profiling” (metabolomics) instrument constructed at TNO in 1981. The 
instrument consisted of a Varian MAT 731 mass spectrometer equipped with a field desorption source and 
coupled to a 12-bit PDP-8 DEC computer, operated by Jan van der Greef (photo taken by M.C. ten Noever de 
Brauw). 
 
The first important experiment performed with this system was measurement of human 
gender differences (van der Greef et al., 1983) with the unsupervised multivariate analysis of 
urine profiles in late 1981 (Figure 2). Clear differences between urine samples from different 
genders were observed. These differences were related, in part, to steroid conjugates. This 
result was later confirmed with high-resolution measurements with multichannel-analyzer 
methodology.   
A major challenge presented by this system was desalting of body fluids and removal of 
abundant components (urea, etc.) while capturing as many components as possible. After 
investigating various options, it was decided that it was not feasible to use a single method to 
profile small molecules in body fluids. Thus, a multiplatform approach was developed. An 
additional challenge in analysis was normalization, and an inclusion/ exclusion approach 
(Fischer weighting) for MS peaks was chosen. Researchers recognized the complexity of 
datasets with many more variables (300-500) than objects (12-40), and the danger of using 
Fisher weighting (i.e., class information as the preselection filter). Validation procedures also 
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needed to be implemented. A practical solution to validate findings of this, and later, 
discriminant approaches, such as principal components discriminant analysis (PC-DA), was 
to classify unknowns or to use cross-validation to obtain a step towards validation. Soft 
independent modelling of class analogy (SIMCA) was evaluated for building models (Droge 
et al., 1987); however, at that time, the program was limited to the developmental stage.  
 
Figure 2. The first “metabolomics” outcome of an experiment performed in 1981. This experiment detected 
gender differences due, in part, to steroid conjugate profiles in human urine as analyzed with field desorption 
mass spectrometry combined with principal component analysis. 
 
The fast atom bombardment (FAB) soft-ionization technique (Morris 1981) became available 
in the early 1980s. Although faster and easier than other methods, the routine application of 
FAB was limited because the robustness of FAB profiles was low due to background 
desorption matrices. FD and FAB were compared for metabolomics analysis with pattern 
recognition. The results were presented during the first International Chemometrics meeting 
in 1982 in Petten, The Netherlands, and published in Analytica Acta in 1983 (van der Greef et 
al., 1983).  
 
58 
Interestingly, the 1982 Chemometrics meeting focused on discussion of significant within-
group variations, so-called interindividual differences. The discussion highlighted one of the 
strongest aspects of metabolomics as a phenotyping methodology, the potential for 
personalized medicine/ health approaches.  
In 1991, Albert Tas developed direct chemical ionization (DCI)/MS as part of his PhD 
research (Tas, 1991). This robust method combined the soft ionization of volatile and low-
volatility/ nonvolatile components (metabolomics part) with pyrolysis of biopolymer 
structures. This method became a routine methodology used in parallel with field desorption 
MS, and in the late 1980s it became the first method of choice until GC, GC/MS, and liquid 
chromatography (LC)/MS technologies were developed. 
 
Technology-driven metabolomics research at TNO (1980–2000) 
Figure 3 describes major metabolomics developments at TNO in the period 1980–2000. 
Research in this time frame was driven by technological development, combined with 
exploration of potential applications for these technologies.  
Despite the experimental challenges of metabolomics profiling with field desorption MS, 
some intriguing concepts were developed in the early 1980s. Fast drug-metabolite detection 
was developed with the quotient spectra to correct for individual differences in backgrounds 
(van der Greef et al., 1984). The ratio of the metabolomic profiles before and after drug 
administration to rats was calculated, and the quotient spectra were statistically evaluated to 
improve drug-metabolite detection. 
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Figure 3. Metabolomics events with an impact on technology and applications from 1980 to 2000. 
 
Interestingly, the approach revealed that levels of non drug-related compounds changed 
significantly. This concept underlies the contemporary use of biomarkers to assess system 
response. The system-response approach corrects for individual differences in homeostasis 
and focuses on changes, for instance in challenge tests. However, at that time of its 
development, this approach was not of major interest to the pharmaceutical industry because 
it revealed nontargeted mechanisms that were considered irrelevant. Investigations into new 
phenomena were believed to slow down the drug-development process. In hindsight, this 
approach provides a very relevant source of important information, not only for the discovery 
of drug mechanisms and off-target effects, but especially for recently very important systems 
toxicology effects. COMET I and II were important recent metabolomics projects in the area 
of drug safety as well as the US Critical Path Initiative and MetaMap Tox project run by 
BASF. 
Interesting applications of TNO projects from 1980 to 2000 covered a wide range of topics, 
including microbiology related to food safety (bacteria, fungi, and algae), food production 
(barley, juice adulteration), feed, fermentation, doping, forensic toxicology, chemical 
industry, and pharmaceutical/ biomedical research. Microbiology was the first important field 
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that used Py-DCI/MS, and achievements of this research are summarized in a review (Tas, 
1995). Other relevant reviews are indicated in Figure 3.  
The concept of reversed pharmacology/ discovery was first described in 1989, based on a 
study that revealed the working mechanism of Lombazole inhibition of the yeast-hyphal 
conversion of the dimorphic fungus Candida albicans (Tas et al., 1989a). Profiling combined 
with pathway analysis allowed the targeted identification of the drug, as described in detail in 
a later review (van der Greef et al., 2003). This is a remarkable approach that, in the last 10 
years, has formed the strategy of metabolomics-driven system research to identify multitarget 
pharmacology of complex herbal medicines. Metabolic foot printing, identification of 
biomarkers in supernatants of virus-infected cells, was another noteworthy tool developed at 
TNO (Tas et al., 1989b; Kell et al., 2005). 
The use of nuclear magnetic resonance (NMR) technology for metabolomics became an 
option after an internal reorganization at TNO in 1990, when the NMR group was moved into 
the MS department. The first NMR-profiling results combined with pattern recognition were 
published in 1989 by Jeremy Nicholson’s group (Bell, Brown & Sadler, 1989; Nicholson & 
Wilson, 1989). Since then, Nicholson’s work has inspired the field of NMR-based metabolic 
profiling combined with pattern recognition globally in many application domains. At the 
turn of the century, Jack Vogels developed a new partial-linear fit algorithm for NMR data 
preprocessing to avoid unnecessary resolution loss due to the binning process. The NMR 
applications described by Vogels included characterization of wine, coffee, illegal use of 
growth promoters, biomarkers in multiple sclerosis, and hop suspension culture results, 
among others (Vogels, 2002). The NMR field at TNO remained important until about the year 
2000, due to the high reproducibility and quantitative aspects of NMR. However, interest in 
this method dropped with the development of systems biology and the limited dynamic range 
of detected compounds with NMR. Although the concentration sensitivity limits of NMR 
result in a limited number of metabolites that can be monitored, the high concentration 
metabolites, including  house keeping related molecules, may give an important view on high 
level system organization and might be very relevant especially when applied to prevention 
or early onset processes (Nicholson 2008). The focus in these areas is more on the balance 
between various regulatory processes than on detailed underlying metabolic processes. 
After the appointment of Jan van der Greef as a professor at Leiden University in 1986, 
several new collaborations were initiated between TNO and Leiden University, specifically in 
the field of separation sciences and the domain of novel analytical MS techniques. A 
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landmark was development of single-cell metabolomics, which used peptide profiling by the 
matrix-assisted laser desorption/ionization (MALDI)-MS of single neurons in Lymnaea 
stagnalis (Jiménez 1994). This approach was used to identify proopiomelanocortin-
processing products in melanotrope cells of the pituitary intermediate lobe of Xenopus laevis 
(Vázquez-Martínez 1999, Jespersen 1999, van Strien 1996). 
An important project in the development of metabolomics field was the PhD project of Elwin 
Verheij (Verheij, 1993), the results of which formed a sound basis for unique LC/MS 
expertise. The combined use of LC/MS with field desorption was explored in the plant 
metabolomics profiling of the purgent principles of capsicum (van der Greef et al., 1985). 
Because TNO functioned as a testing location for new MS instruments produced by Varian 
MAT, many new technologies passed through the TNO MS group. In particular, field 
desorption MS was combined with LC/MS as early as 1984 with the moving-belt interface 
technology (van der Greef et al., 1984). The moving-belt interface LC/MS required 
substantial improvement for bioanalytical applications, and it was too limited for routine 
analysis and metabolomics-like applications.  
The LC/MS technique became more applicable to metabolomics after introduction of 
thermospray (Heeremans, 1990), continuous-flow FAB LC/MS (Kokkonen, 1991), and 
electrospray combined with LC or capillary electrophoresis (Mazereeuw, 2000). 
Electromigration techniques such as micellar and chiral capillary electrophoresis and 
isotachophoresis were explored as separation and sample (stacking) pretreatment 
technologies (Storms et al., 2004). However, in spite of the attractiveness of electromigration 
methodologies, few metabolomics applications resulted from them so far, because of their 
limited sensitivity and lack of robustness in bioanalysis. A recent exception is Human 
Metabolome Technologies Japan which started to offer a CE-MS metabolomics service. 
From 1980 onwards, many technological variations of GC/MS became available at TNO. The 
main limitation to the use of GC/MS and GCxGC/MS was (and continues to be) data 
handling. The reader is referred to a 2005 review that discusses the challenges involved in the 
symbiosis of mass metabolomics and chemometrics (van der Greef & Smilde, 2005). Of note, 
the step from direct profiling with field desorption and DCI/MS to separation techniques 
coupled with mass spectrometry (LC/MS and GC/MS) introduces the need for automatic 
corrections for peak shifts in the chromatography, baseline drifts, etc. The real application of 
chromatography-MS in metabolomics only became possible after software was developed 
that allowed automatic corrections for the above-mentioned issues. Solutions for these issues 
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were first developed in the late 1990s (Gaspari et al., 2001).   
Biology-driven metabolomics research at TNO (2000–present) 
Figure 4 describes major events in metabolomics development at TNO in the period 2000–
present. From about 2000 forward, the major driver of metabolomics research at TNO has 
been biology, although technological developments have remained of major importance. 
 
Figure 4. Metabolomics events from 2000 onwards. Reviews are divided into food (F), pharma (P), 
microbiology (M), Chinese medicine (C), and data analysis (D). 
Systems biology at TNO  
A working definition of systems biology in the year 2000 was “the study of biology as an 
integrated system of genetic, protein, metabolite, cellular, and pathway events that are in flux 
and interdependent” (Davidov et al., 2003). The concepts of systems diagnosis and systems 
intervention had been present at TNO from its inception.    
The major drive for improvement of metabolomics research at TNO found its basis in a 
November 1999 discussion between Fred Regnier and Jan van der Greef on the future of 
biological and pharmaceutical research. Inspired by the development of first-generation 
proteomics tools at Purdue University, Regnier and van der Greef envisioned the integration 
of data at the transcript, protein, and metabolite levels. They shared this idea with Noubar 
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Afeyan of Flagship Ventures, and a business plan for integrative omics research  was 
developed . In 2000, the first systems biology company in the world, Beyond Genomics 
[known later as BG Medicine (BGMD)], was born. In the year 2000, the famous Systems 
Biology Institute was founded  by Leroy Hood. Research at this institute focused on systems 
modeling, but modeling at the metabolite level was not included in its analytical capabilities. 
TNO served as the metabolomics research and development component of BGMD. Through 
this company, TNO collaborated in systems-biology projects with the pharmaceutical 
industry. In particular, the apolipoprotein E 3 (APOE3) Leiden transgenic mouse model was 
developed for studying atherosclerosis and as an initial proof-of-principle experimental 
model for systems biology. The results of the combined transcriptomics, proteomics, and 
metabolomics analyses of this transgenic model, which were based on and integrated with 
correlation networks, became available as early as 2001. This project was the first integrated 
in vivo systems biology experiment in the world of its kind.  
To date, few published studies are available that measure all three biological levels in a single 
model with integration by a de novo correlation network. Most systems-biology studies are 
based on measurement of one or (at most) two levels (i.e., gene, transcript, or metabolite 
level), and literature data that concerns pathways are added to these findings. The results of 
the APOE3 Leiden transgenic mouse model study required substantial effort to publish 
because reviewers were very reluctant to accept this new approach. However, two related 
papers were finally published in 2004 (Clish et al., 2004; Oresic et al., 2004). In the 
meantime, various projects with the pharmaceutical industry delivered unique data, although 
most of these results had to remain confidential.  
A 2005 review in Nature Reviews Drug Discovery (van der Greef & McBurney, 2005) 
explained the concept and thinking behind systems pathology and pharmacology. Several 
other reviews and opinion papers described the general concept of systems thinking (Morel et 
al., 2004; van der Greef, Stroobant & van der Heijden, 2004), (reversed)-translational 
research (van der Greef, 2005; van der Greef et al., 2006), systems toxicology (Heijne et al., 
2005b), and connecting multicompartment omics (van der Greef, Hankemeier & McBurney, 
2006; van der Greef et al., 2007). 
The potential for systems biology in nutrition was recognized very early, as shown by the 
extensive literature describing this view from 2001 onwards (van der Werf et al., 2001; van 
Ommen & Stierum, 2002; van Ommen, 2004; Gibney et al., 2005; Corthésy-Theulaz et al., 
2005; Joost et al., 2007; van Ommen, 2007; van Ommen et al., 2009). Ben van Ommen has 
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been the nutritional systems biology leader at TNO since 2001. In 2004, TNO coestablished 
and coordinated the European Nutrigenomics organization (NuGO), which has been 
instrumental to develop nutritional metabolomics technology (Kaput et al., 2005, 2006; 
Scalbert et al., 2009), concepts (Daniel et al., 2008; van Ommen et al., 2008a, 2008c, 2010a) 
and proof-of-principle studies (Cavalieri et al., 2009). This work became the basis of the 
nutrigenomics-based NuGO consortium (Baccini et al., 2008; Harttig et al., 2009). A key 
feature of nutritional metabolomics is the concept of the “biomarker of health,” which is 
based on quantification of the stress-response curve after perturbation of homeostasis (van 
Ommen et al., 2009; Wopereis et al., 2009). 
Metabolomics applications within Chinese medicine 
Because systems biology encompasses a holistic perspective, the idea to use traditional 
Chinese medicine (TCM) as an entry to systems knowledge was born in 2002. With his 
background in natural product bioactive component detection in the spin-off company 
Screentec (now Kiadis) from his Leiden University group, Jan van der Greef arranged to 
meet with Mei Wang, a molecular biologist with knowledge of TCM and a strong network in 
China. In 2003, a lecture tour was organized to explain the new systems biology tools at TNO 
within the context of TCM. This collaboration created a strong link with the Chinese 
Academy of Sciences. Research was initiated at TNO to identify and elucidate the actions of 
synergetic active compounds (multidimensional or multitarget pharmacologic agents) within 
TCM (Wang et al., 2005). Through this research, many new insights were gained that 
complemented the Western disease-management approach with health-promoting knowledge. 
These discoveries led to the formation of the company SU (“Bridging the Seen and Unseen”) 
Biomedicine in 2004.  
A new research program was started between China and The Netherlands, known as the Sino-
Dutch Center for Personalized and Preventive Medicine (SDPPM). The video message at the 
official opening of the SDPPM was delivered by the Chinese Minister of Health, Prof. Chen 
Zhu (see www.sinodutchcentre.nl). Zhu originally trained as a barefoot doctor, is a renowned 
scientist in the leukemia field. He understood the potential of systems biology, published with 
Lee Hood (Auffray, Chen & Hood, 2009), and his speeches always focus on the enormous 
complementarity of the two perspectives (systems biology and TCM).  
The background ideas  that unify systems biology and TCM areoutlined in a diagnosis-
focused paper (van der Greef et al., 2010). This complementarity also holds promise for the 
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concept of personalized health/ medicine (van der Greef, 2011).  
The first activities in the field of TCM at TNO were related to the systems biology of herbal 
medicine (Wang et al., 2005). With metabolite profile measurements, Boelsma et al. showed 
that the skin blood flow-regulating properties of Ginkgo biloba depended on the baseline skin 
blood flow (Boelsma et al., 2004). Chang et al. used GC-MS to study the effects of different 
growth conditions of Rehmannia glutinosa on its constituents (Chang et al., 2006, 2011). 
Wang et al. developed LC-MS and MALDI-MS methods to study systems toxiclogy (Wang et 
al., 2009a) and alkaloid concentrations in Aconitum carmichaeli, which are important to 
control toxicity in this plant (Wang et al., 2009b). Bioconversion of ginsenosides was studied 
in an in vitro gastrointestinal tract model (Kong et al., 2009). Effects of various ages of 
Ginseng root extracts were compared in a diabetic rat model (Hu et al., 2011b). The APOE3 
Leiden mouse model was used to test effects of Rimonabant and a Chinese herbal formula on 
lipid profiles (Hu et al., 2011c; Wei et al., 2012a). The Chinese formula was shown to reduce 
plasma cholesterol, cholesteryl ester transfer protein (CETP) levels, and CETP activity, and to 
increase high-density lipoprotein (HDL) cholesterol. Such studies are crucial for the quality 
control of herbal medicine -  an important prerequisite for the introduction of Chinese herbal 
products to the European market and to modernize TCM. 
An important recent activity of the SDPPM is the subtyping of patient groups based on TCM 
diagnosis. Focusing on rheumatoid arthritis (RA) and diabetes type 2, the aim is to discover 
subgroups of patients for whom treatment can be optimized. One step in the direction of 
personalized medicine was taken in a study that showed distinct gene expression and 
metabolomics profiles between Cold and Hot types of RA patients (van Wietmarschen et al., 
2009). Different urine metabolite profiles were measured in two subgroups of prediabetes 
patients based on TCM diagnosis (Wei et al., 2012b). Further focus on standardization of 
TCM diagnosis revealed symptom clusters related to Cold and Heat in arthritis patients (van 
Wietmarschen et al., 2011). The principles of TCM will continue to contribute strongly to 
developments in systems thinking, health promotion, prevention, subtyping of disease, 
multifactorial therapeutics, and integrated medicine. 
 
Metabolomics platforms at TNO and applications to improve human health  
In the 21st century, metabolomics technology at TNO has increasingly been used. Figure 5 
presents an overview of the metabolomics platforms developed over time and currently in use 
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(as of 2012) at TNO. A distinction is made among four types of platforms, which are used in 
combination and depend on the application type. Global platforms consist of unbiased 
methods especially useful for broad profiling and to discover new compounds and regulatory 
motifs. Metabolite class profiling methods typically use Fourier transform (FT) or orbitrap to 
measure classes of compounds, with the option to detect novel compounds in those classes. 
Targeted methods are specifically designed to measure a selection of known compounds of 
interest. Biomarker assays include accepted and validated assays that generally measure a 
single component per method. 
Figure 5. Overview of the currently used TNO metabolomics platforms. 
 
The desire to measure complex changes in system organization required development of 
robust and sensitive measurement technologies, and extension of the types of body fluids and 
classes of metabolites that could be measured. Over the years a wide variety of instruments 
have been used. In the early days of LC-MS metabolomics quadrupole instruments were 
used, but quadrupole technology suffers from poor sensitivity in full scan data acquisition 
mode (duty cycle) and because of unit mass resolution (selectivity). The introduction of ion-
trap systems improved the performance of many methods dramatically, resulting in improved 
 
67 
coverage of the metabolome despite the fact that selectivity is still poor on these insturments. 
A major step forward was obtained by applying high resolution mass spectrometers, e.g. ToF, 
FT-MS and Orbitrap MS as with these instruments metabolites at low concentration are 
typically resolved from intense background signals in LC-MS.   A 2004 study found LC/MS 
lipidomics analysis to be the fastest method to categorize anti-inflammatory compounds 
(Verhoeckx et al., 2004b). In collaboration with Thomas Hankemeier at Leiden University, 
Hu et al. developed an extensive RPLC-ion trap-FTMS method for lipid profiling, which they 
used to measure over 160 lipids of eight different classes (Hu et al., 2008). In 2006, an effort 
was made to use capillary electrophoresis for urine sample profiling (Benavente et al., 2006). 
At the same time, a novel ion-pair LC-electrospray ionization-MS method was developed to 
measure several key classes of polar metabolites, such as nucleotides, coenzyme A esters, 
sugar nucleotides, and sugar biphosphates in microbes (Coulier et al., 2006).  
Differences in bile-acid levels were detected in serum and liver samples of APOE3 mice on a 
high versus low cholesterol diet with a novel linear ion trap-Fourier transform-MS method 
(Bobeldijk et al., 2008). A 1H NMR method was developed to improve sensitivity in 
toxicology studies (Schoonen et al., 2007a, 2007b). An advanced GC × GC method was 
developed to improve the number of compounds that could be measured in a single analysis 
(Koek et al., 2011). This development was headed by Thomas Hankemeier in close 
collaboration with Mariet van der Werf, project leader for metabolomics-microbiology 
research at TNO. A comprehensive GC/MS method, which allowed detection of nearly 400 
compounds, was developed to study microbial metabolomes (Koek et al., 2006; van der Werf 
et al., 2007). Host selection and target identification became an important analytical method 
(van der Werf, 2005; van der Werf, Jellema & Hankemeier, 2005). Other GC-MS and GC x 
GC-MS methods for metabolomics analysis have been reported (eg. Fiehn 2000, Jonsson 
2004, O’Hagan 2007, Pierce 2006). 
To measure synovial and cerebrospinal fluid (CSF), methods that could handle very small 
sample volumes needed to be developed. A nano-LC method was developed and applied to 
measure peptides in synovial fluid of osteoarthritis patients (Kamphorst et al., 2007). The first 
GC/MS method to profile mouse CSF was developed at TNO (Koek et al., 2010), which was 
followed by measurements of human CSF (Stoop et al., 2010). A set of stability studies 
showed changes in CSF compounds, such as transthyretin, after freeze/thaw cycles and in 
prostaglandin D synthase-derived peptides and certain amino acids after longer sample 
storage (Rosenling et al., 2009, 2011). 
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Disease biomarker discovery has become a hot topic globally in the last decade (Kussmann 
2006, Schlotterbeck 2006). Research at TNO has led to identification of biomarkers in guinea 
pig urine (Lamers et al., 2003), patients and primates with multiple sclerosis ('t Hart et al., 
2003, 2004), and patients with osteoarthritis (Lamers et al., 2005).  
 
Metabolite profiles have been used to evaluate pharmacological effects of drugs. Early-
responding biomarkers were found for the effects of thiazolidinediones in urine and blood 
samples of patients with type 2 diabetes (van Doorn et al., 2006). Early biomarkers for 
diabetic kidney disease were discovered (van der Kloet et al., 2011). When patients in two 
groups were treated with different statins, changes in the lipid profiles between groups were 
detected with metabolomics technology that could not be detected by classical clinical 
measurements (Bergheanu et al., 2008). Another study examined changes in the low-grade 
inflammatory status of obese subjects, with extensive metabolomics, proteomics, and 
genomics profiling to reveal a network of markers (van Erk et al., 2010). Metabolite profiles 
associated with drug-induced hepatotoxicity in rats were discovered with a novel NMR urine 
analysis approach (Heijne et al., 2003, 2004, 2005a, 2005b, 2005c, 2005d; Schoonen et al., 
2007a, 2007b). The combination of metabolomics, proteomics, and genomics also revealed 
anti-inflammatory markers in macrophage cells stimulated with LPS and treated with beta-
agonists (Verhoeckx et al., 2004a). Metabolomics has become a standard tool in research with 
mouse models in the area of metabolic and inflammatory disorders (Kleemann et al., 2007, 
2010; Wopereis et al., 2012). 
Nutrition is a major research topic at TNO. Of particular interest is the relationship between 
nutrition and metabolic syndrome, characterized by low-grade inflammation, excessive body 
weight, reduced insulin sensitivity, and other markers. Metabolomics integrated with other -
omics technologies is a promising approach to study such early and subtle changes in the 
body (de Graaf et al., 2009). Altered lipid metabolism and markers of inflammation and 
tissue development were found in the APOE3 Leiden transgenic mouse model of 
atherosclerosis (Oresic et al. 2004). A high-cholesterol diet in these mice switched the liver 
from a resilient to a mainly inflammatory state (Kleemann et al., 2007; Radonjic et al., 2009a, 
2009b).  Another mouse model was used to study effects of starvation on lipid profiles (van 
Ginneken et al., 2007). Data from these and other studies led to the development a metabolite 
profile-based “health space” that spanned the dimensions of oxidative stress, inflammatory 
stress, metabolic disorders, and cell-cycle disorders (van Ommen et al., 2008b). This model 
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was used to visualize effects of an anti-inflammatory diet intervention in overweight subjects 
(Bouwman et al., 2012). 
With the shift towards detection of early deviations from health, it is necessary to challenge 
the system and measure its resilience. Subtle metabolic changes in overweight subjects 
induced by a mild anti-inflammatory drug could be detected after administration of an oral 
glucose tolerance test (Wopereis et al., 2009) or a prostprandial challenge test that consisted 
of a high lipid, carbohydrate, and protein shake (Pellis et al., 2011). Baseline effects of the 
drug were also examined (Bakker et al., 2010). Dynamic-system measurement proved to be 
another approach to detect more subtle system changes (Kleemann et al., 2010). 
Although TNO introduced metabolomics to improve food quality control in the 1980s, a 
more advanced multiplatform strategy was recently developed to measure sensory properties 
of tomatoes (Thissen et al., 2011). Metabolomics was used to show the enhanced immune 
reactivity of chickens fed with organic feed as compared to those fed normal feed (Huber et 
al., 2010). Metabolomics is a key technology for advanced microbial host selection. A 
substrate-oriented host-selection approach was shown to be superior to a product-oriented 
approach (van der Werf et al., 2008, Rumbold et al., 2009). Metabolomics has also been used 
to improve characterization of strain phenotypes, crucial in microbial production (Braaksma 
et al., 2009, Braaksma et al., 2011). 
Plant metabolomics has played a minor role at TNO; therefore, this topic is hardly mentioned 
in this review. We refer the interested reader to a recent book (Hardy & Hall, 2012) that 
covers majors aspects of the application of metabolomics technology to plant biology. 
Challenges of metabolomics data analysis 
Datasets in the metabolomics field are characterized by a large number of variables compared 
to a relatively small numbers of objects. This feature greatly enhances the chance of 
overfitting the data, especially when supervised methods, such as discriminant analysis (DA), 
are used (Westerhuis et al., 2008). Several authors (Bijlsma et al., 2006; Hendriks et al., 
2007) proposed the use of double cross-validation with permutation testing as a standard 
technique to validate supervised multivariate data analysis. This procedure was extensively 
tested for megavariate datasets, in which the number of variables was more than 10 times the 
number of objects (Rubingh et al., 2006). 
Before data analysis can actually start, the quality of the data must be assured. Data quality 
can be compromised by various sources of analytical error, such as instrumental drift, ion 
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suppression, and metabolite concentration. A workflow was proposed that included the 
regular injection of pooled quality control samples and the use of multiple internal standards. 
Statistical techniques were developed to correct data with calibration samples and standards 
(van der Kloet et al., 2009). Extensive research has been done at TNO to develop 
comprehensive figures of merit that can give a reliable idea of the performance of a 
metabolomics platform (Smilde et al., 2009; Case et al., 2011). The next important step in the 
process of turning data into knowledge is the data scaling or transforming. Data 
transformation is used to reduce effects of noise, and can be employed in various ways, 
depending on the biological question (van den Berg et al., 2006). A discussion of the 
implications and applications of multivariate data analysis techniques on various types of GC 
× GC experiments was published (van Mispelaar et al., 2005). 
Over time, metabolomics experiments have become increasingly complex. Particular 
experimental designs (Thissen et al., 2009), such as those that include different dosage groups 
or various time points per subject, require data analysis strategies that incorporate the study-
design information. For example, batches of samples from a single study measured at 
different time-points cannot readily be compared; that fact has led to the development of 
data-fusion techniques (Draisma et al., 2008). In 2005, the first papers on analysis of variance 
(ANOVA)-simultaneous component analysis (ASCA) were published. This method combined 
ANOVA with principal component analysis (PCA) (Jansen et al., 2005b; Smilde et al., 2005a; 
Vis et al., 2007). Consensus PCA and canonical correlation analysis were developed to 
analyze relationships between a specific set of variables and the remainder of the data (van 
den Berg et al., 2009). Other methods that consider prior knowledge or experimental design 
are multiway partial least squares discriminant analysis (PLS-DA) (Rubingh et al., 2011), 
simplivariate models (Saccenti et al., 2011), two-mode clustering (Hageman et al., 2008), and 
subspace clustering (Damian et al., 2007). Development of analytical comparison methods, 
such as simultaneous component analysis (SCA) methods and quantile equating, allowed a 
comparison of different types of data or samples measured on different systems (van Deun et 
al., 2009; Draisma et al., 2010; Smilde et al., 2005b). Network theory was used to integrate 
data at the level of correlations, to allow visualization of changes in relationships between 
conditions or groups of subjects (Clish et al., 2004; Davidov et al., 2004; Adourian et al., 
2008). 
The introduction of longitudinal metabolomics data required yet another line of data analysis 
(van der Greef, 2005). The behavior of complex systems cannot be properly ascertained from 
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measurements at a single time point (Glass et al., 1988). Rhythms in the intensities of 
metabolites, proteins, and gene transcripts have been extensively measured, as have health 
problems associated with disturbances in these rhythms (Jonsson et al., 2006; Vis et al., 2010; 
Moser et al., 2006). A weighted PCA method was developed to tackle longitudinal data 
(Jansen et al., 2004), and multiway PLS was used to analyze longitudinal microbial 
metabolomics data (Rubingh et al., 2009). A multilevel component analysis strategy was 
applied to 29 time points of monkey urine data (Jansen et al., 2005a). A recent review 
discusses the longitudinal metabolomics data analysis strategies (Smilde et al., 2010). 
Finally, as the metabolomics field has matured, there has been an increased need for the 
standardization of study designs and their reporting. Such standardization is essential when 
large multicenter studies are performed. The Human Metabolomie Database was founded to 
concentrate and curate metabolite information and make this information freely accessable 
(Wishart 2007). In 2003, the Standard Metabolomics Reporting Structures was founded, 
followed up by the Metabolomics Standards Initiative in 2005 (Lindon et al., 2005; MSI 
Board Members et al., 2007; Fiehn et al., 2007). Standardization was also followed through 
in the area of environmental metabolomics (Morrison 2007). Researchers at TNO specifically 
addressed the issue of standardization in the area of metabolomics (Fiehn et al., 2006; van der 
Werf et al., 2007). 
 
Metabolomics in the Future  
The changing landscape of health care 
The definition of “health” was recently readdressed and emphasizes a person’s ability to 
adapt and cope in the face of social, physical, and emotional challenges (Huber et al., 2011). 
The utopian definition of health provided by the World Health Organization (Callahan, 1973) 
as complete physical, mental, and social well-being is no longer useful in the face of a health 
care system that moves towards personalized medicine and health promotion. Health is no 
longer only a goal, but it is also a means to attain a good life as a well-functioning being in 
harmony with one’s surroundings (Mordacci & Sobel, 1998). This shift away from health as a 
state and towards health as a process has important implications for research into wellness 
and health promotion. 
The development of personalized prevention strategies based on health promotion requires 
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methods to measure health. Developing these methods is an enormous challenge because 
most biological knowledge is obtained from disease models and patient populations. Looking 
at healthy people raises questions about the variability of biological processes within the 
individual over time, between healthy individuals, and the subjectivity of experiencing health. 
Currently, few (if any) studies have assessed the variability of metabolomics profiles between 
and within healthy individuals. 
In the 19th century, French physiologist Claud Bernard (1813–1878) proposed homeostasis as 
the regulatory model of the body. Homeostasis is characterized by the body’s maintenance of 
stable conditions with feedback mechanisms. However, the body is a nonlinear dynamic 
system that must continuously adapt to new situations. Allostasis is the regulatory model in 
which the brain integrates prior knowledge with sensory data to optimize the resources 
distribution (Sterling, 2011). Figure 6 illustrates the dynamic processes of regulation. As long 
as the system is able to respond effectively to a challenge (i.e., the stress level goes up), the 
system can be called “healthy”. However, when the system is no longer able to respond 
sufficiently to stress, a disease state occurs. 
Figure 6. Illustration of dynamic system regulation. A system that is able to respond effectively to a challenge 
(“allostasis” area in the figure) can be called “healthy”. When the system is no longer able to respond 




Systems science, complexity theories, and nonlinear dynamic system theories are specially 
designed to account for system properties, such as connectivity, emergence, self-organization, 
stability, and flexibility (Prigogine, 1980; Capra, 1997). Systems science will allow a proper 
investigation of many healing arts that are based on holistic concepts of health, such as mind-
body interventions, herbal medicine, etc. Processes of healing can be elucidated and the right 
treatment options can be found for the right situations.  
For additional insight, we can look to other health traditions, such as Asian medicine, which 
are founded on systems thinking. These traditions incorporate, for example, organization of 
symptoms into clusters, sudden changes of symptom patterns, irregular healing processes, 
and multitarget herbal medicine, among others (Wang et al., 2005; van der Greef et al., 2010).  
The integration of these medicine approaches will complement the Western model of 
reductionist science and disease management strategies. A recent study in the Annals of 
Internal Medicine found that RA patients treated with standard therapy complemented with 
Trypterigium wilfordii Hook F had a significantly higher response rate than the group 
complemented with sulfasalazine (Goldbach-Mansky et al., 2009). As a simpler example, a 
patient’s good physical condition before cardiac surgery greatly improves how well the 
person recovers from surgery (Jack, West & Grocott, 2011).  
A movement towards health promotion invites the question of who is responsible for which 
part of health care. A shift towards a more equal patient–practitioner relationship, which is 
already occurring, will place the doctor in the relative role of health coach. Health promotion 
strategies will be much more integrated in daily life by, for example, health “apps” on mobile 
phones, courses in stress-reduction techniques, personalized nutrition advice, etc. 
As health care becomes more patient-centered, integrated, preventive, and personalized, the 
role of scientists must change. Science conducted in multidisciplinary teams, including 
patients, consumers, and health care organizations, will allow development of health-care 
products that are actually desired by patients and consumers. The scientist will act as a 
knowledge organizer and integrator. Discoveries will more easily lead to strategies that can 
enter clinical practice and reach the consumer. The future health of the society and its 
members will emerge from the many relationships among the various actors and the 




Role of metabolomics in preventative health care strategies 
Metabolomics will be a major research area to develop dynamic system-monitoring tools that 
lead to diagnosis. Static, single time-point biomarkers will be replaced by dynamic 
biomarkers that can identify whether the system is moving towards or away from health. 
There is ample literature that relates disease to disturbances of the daily, seasonal, yearly, or 
other rhythms in the human body. For example, inflammation and depression seem to be 
related to sleep disturbances and, especially, to perturbations of the body’s activity/ rest 
cycles (Cutolo, 2012). This knowledge has resulted in glucocorticoid chronotherapy with 
optimal medication at 3 am. Shift work has been shown to increase one’s risk to develop 
breast cancer (Moser et al., 2006). Several studies in the area of chronobiology have revealed 
metabolic dynamics and their relationships with disease (Eckel-Mahan et al., 2012; Bass & 
Takahashi, 2010; Froy, 2010). Promotion of “healthy” rhythms and measurement of these 
rhythms in the body will be crucial in the future. 
Figure 7. Contemporary nature photography that emphasizes dynamics and emotion with time-lapse integration. 
This image, obtained with a shutter speed of 1/8 s, is of a herring gull taking off from a Norwegian fjord 
(photograph by Jan van der Greef). The same principle of visualization of dynamic living systems is the key 




The focus on dynamics, movement, and emotion, with less emphasis on structure and form, 
in systems-based metabolomics has its parallel with developments in art history, when 
figurative painting developed into expressionism and impressionism. Figure 7 shows an 
example of this concept in contemporary nature photography. The use of slow shutter speeds 
allows time integration and provides insights into the dynamics and movement of (in this 
case) a herring gull taking off in a Norwegian fjord. The ripples on the water and the 
shimmering stream of water from its legs, illustrating the transition from floating on the water 
to the freedom of movement in the air, creates an ethereal image in which dynamics, emotion, 
rhythm, and direction of movement are captured. 
Another approach to obtain a more dynamic picture of health is to measure the reaction of a 
system to physical, mental, spiritual, and other challenges (van der Greef et al., 2007). A 
classic example is the oral glucose tolerance test, used to detect early changes in the 
regulation of blood glucose levels and other metabolic processes (Shaham et al., 2008). Other 
examples are the high fat-load challenge (Pellis et al., 2011), exercise challenge (Lehmann et 
al., 2010), and stress tests. New challenge tests in the areas of spiritual, mental, physical, 
environmental, and social domains of resilience would be valuable additions. 
Almost all data-analysis techniques used to describe such biological processes utilize linear 
models and specific linear statistical tests. However, many of the nonlinear dynamic features 
of biological systems cannot be captured by such techniques. The future of systems science 
will see a rapid rise of nonlinear techniques, such as nonlinear PCA, network analysis, and 
fractal calculations (Meulman, 2003; Zhou, 2012; van Wijk et al., 2010). With such 
techniques, it will be possible to analyze changes in symptom clusters and to treat these 
clusters. 
Health is related to myriad aspects (e.g., spiritual, psychological, and physical conditions) 
that are reflected over many levels of organization (e.g., molecular, cellular, organ, whole 
body, and societal levels). At each level, new properties emerge that cannot be detected at a 
lower level of organization. Metabolomics can measure several levels of organization, 
although its coverage must increase. Plasma metabolome measurements reflect the system’s 
response to keep certain processes within specific boundaries. Numerous stress and immune 
system components can also be detected (Bouwman, 2012). Urine is informative about what 
is processed by the system, whereas single-cell metabolomics will eventually allow a more 
differentiated view of cellular processes (Svatos, 2011). The metabolomics analysis of breath 
is an interesting development because it is noninvasive (Haviland et al., 2011). Gut 
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microflora metabolomics adds a very important dimension to this field because the gut is one 
region where the inside and outside of the body connect (Nicholson et al., 2012; Wikoff et al., 
2009).  
It is clear that the human body is an open system which continuously needs input of food, 
oxygen and water. Without this input the system would certainly fall apart in a certain amount 
of time. Such a system is called an autopoetic system, an open system far from equilibrium 
(Maturana 1980). The composition and quality of nutrients that enter the body is therefore 
paramount for maintaining optimal health as well as for the capacity of the body to store and 
utilize fuel when it is needed. This dynamic relationship between the self and the 
environment in the area of nutrition is termed metabolic flexibility (Galgani 2008). 
Improving metabolic flexibility is a relatively new target for preventing life style related 
disorders such as metabolic syndrome and diabetes. For instance reducing insulin resistance 
will improve the response to an oral glucose tolerance test. Metabolic flexibility as a measure 
of health can therefore be used to test the effects of nutritional interventions (Suhre 2010). 
However, the large variations in metabolic make-up of people needs to be taken into account 
to optimize nutritional interventions for the individual (Gieger 2008, Illig 2010). 
A challenge in the area of data analysis is the fusion of the data obtained from these 
measurements. A good quality of the quantitative data is essential for the optimal integration 
of information (MSI Board Members et al., 2007). A great step forward in this area is the 
recently developed standard reference plasma available from the National Institute of 
Standards and Technology. 
Metabolomics must be integrated with physiological measurements, such as heart rate 
variability, ECG, EEG, and ultra-weak photon emission, which measure higher levels of 
organization (McCraty et al., 2009; van Wijk, van Wijk & Bosman, 2010). To obtain an 
integrated view of an individual within its environment, information about psychological 
processes and coping mechanisms are needed (Antonovsky, 1987). Psychobiology is a 
growing field of science that aims to integrate physical with psychological measurements 
(Rossi, 2002). The effects of the environment on the immune and central nervous system 
regulation are slowly becoming common knowledge (Irwin & Cole, 2011). The discovery of 
early immediate genes, which are activated within minutes of an environmental stimulus and 
have profound effects on various biological processes, have given new direction to the nature 
versus nurture debate (Pérez-Cadahía, Drobic & Davie, 2011). Medical-imaging techniques 
are currently being employed to study gene expression throughout the living body (Lok, 
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2001). Altogether, measurement techniques allow a more-comprehensive view of processes 
in the body and between the body and its environment.  
 
A better understanding of biology from a systems perspective will be the driving force for the 
next generation of metabolomics technologies, with a focus on low-cost, high-throughput 
capabilities to enable longitudinal studies with improved coverage. Miniaturization and 
electromigration technologies might be instrumental in this development (Lindenburg, 2012). 
Advanced multivariate statistics and nonlinear dynamic modeling are vital to obtain new 
insights into living systems. Metabolomics will provide new opportunities to guide industrial, 
applied, and research activities in the life sciences and to build the future of health care. 
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4. Metabolite space of rheumatoid arthritis 
 
Abstract 
Metabolites play numerous roles in the healthy and diseased body, ranging from regulating 
physiological processes to providing building blocks for the body. Therefore, understanding 
the role of metabolites is important  in elucidating the etiology and pathology of diseases and 
finding targets for new treatment options. Rheumatoid arthritis is a complex chronic disease 
for which new disease management strategies are needed. The aim of this review is to bring 
together and integrate information about the various roles that metabolites have in rheumatoid 
arthritis.  
An extensive PubMed search is conducted to collect the relevant manuscripts. The 
metabolites are discussed in relation to rheumatoid arthritis. Subsequently, the metabolites are 
organized according to levels of system organization. In the last section an integrated 
pathway analysis of the metabolites conducted with  Ingenuity Pathway Analysis software is 
presented.  
Literature search resulted in information about vitamins, eicosanoids, fatty acids, lipids, 
hormones and peptides. The metabolites could be related to metabolic processes, oxidative 
stress processes and inflammatory processes. Cell death, lipid metabolism and small 
molecule biochemistry were found by the pathway analysis to be the top functions, 
characterized by the metabolites arachidonic acid, ascorbic acid, beta-carotene, 
cholecalciferol, hydrocortisone, keratan sulfate, melatonin, palmitic acid and stearic acid. 
These nine metabolites are highly connected to a number of canonical pathways related to 
immune functions, the production of nitric oxygen and reactive oxygen species in 
macrophages and pathways involved in arthritis.  
This review indicates groups of metabolites that could be interesting for metabolomics 
studies related to rheumatoid arthritis. Circadian rhythms of metabolite levels are found to be 
important for understanding and treating rheumatoid arthritis. In addition, some key 
processes and pathways are found by integrating the metabolite data. This might offer new 
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Metabolites, the intermediates and products of metabolism, play numerous roles in the 
healthy and diseased body, ranging from regulating physiological processes to providing 
building blocks for the body. Together with genomics, transcriptomics and proteomics, 
metabolomics provides the biochemical building blocks for understanding the body as a 
complex and dynamic system of interactions (Wishart et al. 2007). Metabolites occupy a 
special place in this systems biology approach in that they are usually close to the phenotype 
(vd Greef et al. 2007). Therefore understanding the role of metabolites is very important in 
elucidating the etiology and pathology of diseases and finding targets for new treatment 
options. Metabolic profiles of cells, tissues or body fluids can provide snap-shot information 
about the current condition of (part of) the system. However, the future will be more 
determined by dynamic metabolic profiling. Measuring changes in metabolism over time and 
in response to challenges to the system provides a more profound insight not only in the 
status of the living system but also in it's capacity to regulate and adapt. 
Especially for chronic diseases such as Rheumatoid Arthritis (RA) of which the etiology is 
unclear but with both genetic and environmental factors playing a role, it is interesting to 
study the metabolome (Glocker et al. 2006). RA is a chronic systemic autoimmune disease 
characterized by inflammatory polyarthritis which affects approximately 0.5 -1% of the 
population worldwide (Hochberg et al. 2007). Although the currently favored treatment 
regime using disease-modifying anti-rheumatic drugs (DMARD's) in an early stage of RA is 
believed to have a favorable result on disease course by influencing inflammation, patients 
assessment of disease activity and functional disability do not always support this result 
(Welsing et al. 2005). Even 30% of the RA patients initiating the most effective treatment 
option available, anti-TNFα therapy, fail to respond (Smolen 2005). New disease 
management strategies are therefore needed. 
In this review the focus is on metabolites involved in RA. Various hypotheses about the role 
of certain metabolites in the etiology and progression of RA are reviewed. Secondly, an 
attempt is made to elucidate relevant interactions between the metabolites identified in the 
RA literature making use of pathway analysis tools. Finally we show the relevance of 





Metabolites and metabolic processes involved in RA 
An extensive literature search of the PubMed database was performed using several key 
words related to metabolites in combination with the keyword 'rheumatoid arthritis'. The 
results were screened and categorized, leading to a number of topics with sufficient material 
to be discussed for this review. In this section research is discussed concerning vitamins, 
eicosanoids, fatty acids, lipids, hormones and cartilage breakdown products. Although trace 
elements are not considered metabolites, information about this particular group of 
micronutrients is included because of the importance for RA. 
 
Vitamines 
Vitamin D deficiency is related to several autoimmune diseases including type 1 diabetes, 
multiple sclerosis, SLE and rheumatoid arthritis (Arnson et al. 2007). Vitamin D (a 
secosteroid) is transformed in the liver and kidney into the hormone 1,25 dihydroxyvitamin D 
(1,25(OH)2D3), the active form that stimulates the intestinal absorption of calcium and 
phosphor. Vit D receptor is expressed on mononuclear cells, dendritic cells, activated T and B 
cells, antigen presenting cells. Dendritic cells produce vit D hormone which inhibits T-cell 
proliferation, maturation of dendritic cells, secretion of IL-2 and INF-y by CD4+ T-cells, 
secretion of cytokines by macrophages and B-cell antibody production  (Arnson et al. 2007). 
Low blood levels of vit D hormone also result in increased blood levels of insulin-like growth 
factor (IGF-1), a potent stimulator of cell growth and inhibitor of apoptosis (Huynh et al. 
1998, O'Connor et al. 2008). In short, Vit D hormone stimulates an anti-inflammatory 
environment and particularly affects Th1 driven autoimmunity (Cutolo et al. 2007). 
There is some controversy concerning the association of vit D intake with RA risk. However, 
Cutolo et al. suggest that these differences in results arise from the various ways of measuring 
vit D intake. Vitamine D intake should be measured in serum and not by dietary 
questionnaires (Cutolo et al. 2011).  When this is taken into account, low levels of vitamin D 
can be associated with an increased disease risk as well as increased disease activity (Merlino 
et al. 2004, Oelzner et al. 1998). Several factors can result in lower blood vit D hormone 
levels. Animal protein has been shown to block the kidney enzyme responsible for converting 
vit D to the active vit D hormone by promoting blood acidity (Breslau et al. 1988, Langman 
1989). Secondly, high blood calcium levels decreases vit D hormone which regulates blood 
calcium levels (Chan et al. 1998). 
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Interestingly a circannual rhythm in Vit D levels was found which correlates inversely with 
DAS28 scores of RA patients, which could also provide difficulties in interpreting 
measurements (Cutolo et al. 2006). Taking this into account lower serum levels of vit D seem 
to be associated with higher disease activity. This suggests that vit D might play a role in the 
differences in RA prevalence between northern and southern countries (Cutolo et al. 2006).  
Other vitamins with antioxidant activity such as vitamin C, vitamin E and β-carotene have 
also been implicated in RA. Pattison et al. found a threefold increased risk of developing 
inflammatory polyarthritis when vitamin C intake was very low (Pattison et al. 2005). Low 
serum levels of β-carotene have been detected in blood bank samples of people who later on 
developed RA (Comstock et al. 1997). Low levels of plasma pyridoxal-5-phosphate (PLP) the 
active form of vitamine B6 have been found in RA patients (Roubenoff et al. 1995). In 
general, a low antioxidant status increases the risk of developing RA (Heliovaara et al. 1994). 
No relationships have been found between the progression of RA and plasma vitamin D, 
vitamin C, vitamin E and β-carotene levels. 
 
Eicosanoids and fatty acids 
RA patients have been shown to improve on a diet low in arachidonic acid (AA) and 
supplemented with N-3 fatty acids (Adam et al. 2003). Arachidonic acid and other fatty acids 
are precursors for eicosanoids which are important mediators of inflammation. Interestingly 
N-6 and N-3 fatty acids are competitively metabolized into N-6 and N-3 eicosanoid families 
with different functions. An N-6 dominant diet is implicated in increased prevalence of 
thrombotic vascular events and inflammatory diseases. The modern diet contains over 50 
times the required amount of N-6 fatty acids which markedly shifts the n-6/n-3 ratio (Cleland 
and James 1997). N-3 fatty acids are less pro-inflammatory and have been shown to reduce 
TNF-α and IL-1β levels in RA patients, by competitively inhibiting the production of 
leucotriene B4 (LTB4) from arachidonic acid  (Kremer et al. 1990).  
Arachidonic acid is metabolised in several classes of compounds denoted as eicosanoids 
including prostaglandins, thromboxanes, leukotrienes, hydroxy- and epoxy-fatty acids, 
lipoxins and isoprostanes (Funk 2001). Leukotriene B4 and 5-hydroxy-eicosatetraenoic acid 
(5-HETE) are two strong chemotactic eicosanoids found in synovial fluid of RA patients 
(Klickstein et al. 1980). Dietary AA is exclusively derived from animal based foods of which 
80% is metabolized into eicosanoids. Endogenous AA synthesis from linoleic acid also 
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occurs in the body, which is inhibited by poly-unsaturated fatty acid (Adam et al. 2003). 
These prostaglandin synthesis pathways are the basis of NSAID's and are therefore essential 
in current RA management strategies (ACR 2002). 
 
Lipids 
An atherogenic blood lipid profile has been reported in persons who more than 10 years later 
developed RA, characterized by higher total cholesterol, triglyceride and apolipoprotein B 
levels and lower high-density lipoprotein (HDL) cholesterol levels (van Halm et al. 2007). 
Contradictory observations have been reported concerning changed lipid profiles in RA. 
Dursunogh reported higher levels of Lp(a) lipoprotein, triglyceride (TG), lower levels of  
HDL cholesterol and no changes in total cholesterol and low-density lipoprotein (LDL) 
cholesterol (Drusunoglu et al. 2005). Lazarevic also reported increased TG and decreased 
HDL-c levels, but found lower total cholesterol (TC) and LDL-c levels (Lazarevic et al. 
1993). Lakatos in contrary reported lower TG and higher TC and LDL-c levels, but also 
reported lower HDL-c levels (Lakatos and Hárságyi 1988). Only higher lipoprotein Lp(a) and 
lower HDL-c levels are consistently reported.  
Ethnic, racial and geographic differences are suggested as possible causes for these 
differences in lipid profiles. Both genetic and dietary factors may contribute to higher Lp(a) 
levels, especially increased fat and cholesterol consumption (Cesur et al. 2007). Blood 
cholesterol levels increase most effectively by consuming animal protein, and to a lesser 
extend by consuming saturated fat and cholesterol. In contrast, plant based foods contain no 
cholesterol and decrease blood cholesterol levels (Kritchevsky et al. 1982). 
A high LDL/HDL ratio, which indicates a less favorable lipid profile, has been associated 
with the pro-inflammatory molecules CRP, IL-6 and TNF-α (Hulthe and Fagerberg 2002). In 
contrast HDL cholesterol associated with apolipoprotein A-1 has anti-inflammatory effects. 
Apo A-1 is reported to inhibit IL-1, TNF-α and interactions between T-cells and monocytes 
(Burger and Dayer 2002, Hyka et al. 2001). This suggests that a less favorable lipid profile 






Cortisol is the strongest endogenous anti-inflammatory substance in the human body. 
Inflammation activates the immune system and the hypothalamic-pituitary-adrenal (HPA) 
axis, leading to the secretion of cortisol. However, in RA patients cortisol levels are not 
sufficiently increasing in response to inflammation (Neeck et al. 1990). Even in the presence 
of high serum levels of circulating cytokines, plasma cortisol levels in RA patients are similar 
to that of control subjects. A result of the relatively low plasma cortisol levels and presence of 
vasodilatory cytokines such as TNF-α is an increase in sympathetic activity. This is needed to 
stabilize blood pressure, systemic circulation and glucose homeostasis. However, the higher 
sympathetic tonus does not lead to an increase of noradrenaline, which has an anti-
inflammatory effect, and therefore doesn't compensate the relatively low cortisol levels 
(Capellino and Straub 2008).  
Inflammatory cytokines stimulate the conversion of anti-inflammatory adrenal androgens into 
estrogens. Elevated estrogen and estrone levels in the synovium of RA patients sustains a pro-
inflammatory state. This is thought to be related to the increased prevalence of RA in women 
(Capellino and Straub 2008).  
It is well known that RA symptoms such as stiffness and pain can differ greatly during the 
day and even during the year (Labreque at al. 1995). Cutolo extensively studied metabolic 
processes underlying such circadian, circamensual and circannual rhythms in RA (Cutolo et 
al. 2005). Cortisol, melatonin and prolactin show a marked daily rhythm. Melatonin 
stimulates Th1 type cytokines while cortisol stimulates Th2 type cytokines with a diurnal 
rhythmicity (Cutolo 2008). In patients with a high disease activity cortisol is downregulated 
during the evening and night, leading to an increase of inflammation in the morning. Low 
cortisol levels reduces its IL-6 and TNF inhibitory effects and consequently drives an 
increase in TNF, IFN-γ, IL-2, IL-12 and IL-6 levels. In RA patients, a melatonin plateau of 2-
3 hours is observed and prolactin levels are significantly higher during the night. As a result, 
a Th1 response is induced during the night (Cutolo and Straub 2008). Rhythms in 
concentrations of inflammatory metabolites have to be considered when time-points for 




Cartilage breakdown products 
RA is characterized by extensive degradation and synthesis of joint cartilage which consists 
for a large part of type II collagen fibers, other types of collagen and proteoglycans. 
Consequently, cartilage breakdown products of type II collagen have been extensively studied 
in the synovium, serum and urine of RA patients (Charni et al. 2005). An immunoassay is 
described that detects C-terminal crosslinking telopeptide of type II collagen (CTX-II) 
(Christgau et al. 2001). Elevated urine CTX-II levels have been associated with more rapid 
disease progression in OA and RA patients. Another urine marker for early RA and 
progression of RA is HELIX-II, a sequence arising from degradation of the helical region of 
type II collagen (Charni et al. 2005). 
Another collagen breakdown product that has been used as a biomarker in synovial fluid and 
serum is cross linked carboxyterminal telopeptide of type I collagen (ICTP). Markers for 
collagen synthesis that have been used are the aminoterminal propeptides of type I 
procollagen (PINP) and of type III collagen (PIIINP) (Aman et al. 1999). One study reported 
an increase of serum PIIINP and ICTP levels in 50% of the RA patients. Additionally PINP 
and PIIINP were both increased in synovial fluid indicating collagen synthesis (Hakala et al. 
1995). A disturbed balance of collagen breakdown and synthesis seems to be evident in 
inflamed joints. 
Apart from various types of collagen, cartilage also contains large proteoglycans including 
the glycosaminoglycans keratan sulfate (KS) and chondroitin sulfate (CS). KS and CS 
containing fragments have been measured in synovial fluid as biomarkers of cartilage 
metabolism. In RA patients, the level of 846 fragment of CS is reported to be increased in 
serum and more so in synovial fluid, indicating aggrecan synthesis in the inflamed joint. 
Serum KS levels were reduced in RA (Poole 1994). It is important to note that metabolite 
concentrations and changes can differ markedly between synovium and serum, providing 
multiple sources of information concerning local and systemic aspects of the disease. 
 
Trace elements 
Zinc and copper are two trace elements of which plasma concentrations decrease during acute 
inflammation (Halsted and Smith 1970, Lewis 1984). Plasma zinc levels are found to be 
decreased in RA patients. Especially T-cell function is impaired by reduced zinc availability 
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leading to reduced T-cell numbers and the Th1/Th2 ratio shifting towards Th2 (Honscheid et 
al. 2009). Zinc and copper have antioxidant properties. They are constituents in cytoplasmic 
superoxide dismutase (SOD), a metalloenzyme with anti-inflammatory properties, and copper 
is also found in the serum antioxidant ceruloplasmin (Honkanen et al. 1991). Intracellular 
SOD activity has been shown to be decreased in RA patients (Rister et al. 1978) which 
corresponds with decreased plasma zinc levels. However, the ceruloplasmin levels in serum 
of RA patients is increased. An increase in zinc consumption is correlated with a decrease in 
copper absorption by the intestine (Honkanen et al. 1991). This decrease of copper absorption 
might be a reason for the contradictory results found in studies into the effects of dietary zinc 
supplementation in RA (Rasker and Kardaun 1982, Mattingly and Mowat 1982, Tudor et al. 
2005). 
Selenium (Se) is another trace element that plays a role in regulating ROS through 
incorporation into selenoproteins. Glutathion peroxidase for example catalyzes the 
degradation of peroxides, is involved in arachidonic acid metabolism and can affect 
leukotrine and prostaglandine synthesis (Kalpakcioglu and Senel 2008). Low levels of Se 
have been reported in plasma and cells of RA patients (Tarp et al. 1985). Selenoproteins can 
have various effects on the immune system such as stimulating a Th1-type response more 
than a Th2-type response. However Se supplements only seem to boost the immune system 
for people who already had low Se levels (Hoffmann and Berry 2008). Much still needs to be 
learned about the functions of the various selenoproteins.  
 
Metabolites and levels of system organization 
Van Ommen and others described a health space based on metabolomics phenotypes to 
organize metabolite data (van Ommen et al. 2008). The metabolites reviewed in the previous 
sections can be organized according to this approach in what might be called levels of system 
organization. In this review a distinction could be made between metabolites involved in 
metabolic processes, especially those located in the inflamed joints, oxidative stress processes 
and inflammatory processes (Table 1). As could be expected a number of compounds are 
upregulated or downregulated in RA patients that are involved in the inflammatory process. 
In addition, oxidative stress factors also seem to play an important role in RA. The 





RA and metabolomics 
Metabolomics techniques are recently becoming popular for biomarker discovery, also in the 
field of rheumatoid arthritis. Seven studies were found in PubMed in which metabolomics 
platforms were used to find metabolite profiles that distinguish rheumatoid arthritis patients 
from healthy controls. Four of these papers are dealing with synovial fluid samples 
(Williamson et al. 1989, Naughton et al. 1993a, Naughton et al. 1993b, Meshitsuka et al. 
1999), two papers with human serum samples (Lauridsen et al. 2010, Wietmarschen et al. 
2009) and one paper with mouse serum samples (Weljie et al. 2007). 
The synovial fluid of healthy people show elevated lactate levels, indicating a hypoxic status 
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in the joint. In RA patients this level of lactate is more elevated, glucose levels are diminished 
and ketone bodies are detectable indicating an even more hypoxic state and the utilization of 
fatty acids for energy. The inflamed joint of RA patients also contained lipoprotein associated 
fatty acids such as VLDL triacylglycerols, LDL, HDL, cholesterol and HDL phospholipids, 
which are not able to enter the joint space in healthy conditions (Naughton et al. 1993a). 
In serum of K/BxN arthritis mice several metabolic changes have been found compared to 
healthy control mice using NMR spectroscopy. Some lipid, fatty acid and carbohydrate 
metabolism markers were found: Glycerol, Choline, 2-hydroxybutyrate, acetylcarnitine, 
TMAO. Energy metabolism markers 2-oxoglutarate, acetylcarnitine were detected. The 
markers xanthine, hypoxanthine, uridine, uracil, TMOA are related to nucleic acid 
metabolism. Glutamate, serine, phenylalanine, glycine, methionine, asparagine are related to 
amino acid metabolism. Methionine, glycine, taurine, xanthine, hypoxanthine, TMAO, 
acetylcarnitine are important for dealing with oxidative stress (Weljie et al. 2007). 
Plasma from human RA patients has been shown to contain elevated lactate and cholesterol 
levels and decreased HDL levels. Elevated plasma lactate levels have been associated with 
increased oxidative damage and lowered synovial pH. Lower levels of HDL and 
consequently higher levels of cholesterol support the increased risk of cardiovascular diseases 
in RA patients (Lauridsen et al. 2010). The only study in which gas chromatography mass 
spectrometry (GC-MS) was used to detect metabolic differences between RA patients and 
healthy controls reported higher levels of heptanoic acid, l-Alanine, 2-oxy-butanoic acid, l-
asparagine, palmitic acid and lower levels of 2-butenoic acid, undecanoic acid, d-glucuronic 
acid, ribitol, stearic acid in RA patients (van Wietmarschen et al. 2009). 
 
Connecting the dots 
In the following section we will discuss the literature findings concerning metabolites and RA 
in an attempt to uncover relationships between metabolites and biological mechanisms 
relevant for studying RA. The interpretation of metabolite information from various sources 
is challenging for several reasons. For instance, publications often describe the role of classes 
of metabolites instead of specifying individual metabolites with appropriate database 
identifiers. Pathway analysis tools are not able to handle groups or families of metabolites. A 
second challenge is that many measured metabolites are not yet present in the databases 
connected to pathways analysis software. Therefore the actual list of metabolites that can be 
 
104 
analyzed by pathway construction tools usually represents only part of what is actually 
known. 
For 20 of the 25 metabolites related to human plasma changes in RA an identifier could be 
found in the Kyoto Encyclopedia of Genes and Genomes (KEGG). These metabolites were 
imported in the Ingenuity Pathway Analysis software and used for the subsequent analysis 
(Gehlenborg et al. 2010). Metabolites with higher levels in RA patients were given a fold 
change value of 2 while the metabolites with lower levels in RA were given a fold change 
value of minus 2 because the actual values could not be determined and compared between 
studies based on the literature.  
Several of the compounds were found to be involved with the key molecular and cellular 
functions cellular development, cellular growth and proliferation, cell death, lipid metabolism 
and molecular transport. In addition, the set of compounds was found to be mostly related to 
metabolic disease, inflammatory response, cardiovascular disease, endocrine system 
disorders and gastrointestinal disease.     
 
Figure 1. Ingenuity pathway analysis of the metabolites discussed in this review that are related to rheumatoid 
arthritis. Relationships are based on literature mining. Red colored nodes indicate up-regulated metabolites and 




The network (Figure 1) most closely related to the data set was characterized by the top 
functions cell death, lipid metabolism and small molecule biochemistry containing 9 of the 
reviewed metabolites: arachidonic acid, ascorbic acid, beta-carotene, cholecalciferol, 
hydrocortisone, keratan sulfate, melatonin, palmitic acid and stearic acid. These nine 
metabolites are highly connected to a number of canonical pathways related to immune 
functions, the production of nitric oxygen and reactive oxygen species in macrophages and 
pathways involved in arthritis. Specifically the role of macrophages, fibroblasts, endothelial 
cells, osteoblasts, osteoclasts and chondrocytes in rheumatoid arthritis are connected to this 




Many metabolites have been reported to play a role in rheumatoid arthritis. This review 
indicates groups of metabolites that could be interesting for metabolomics studies into the 
mechanism of and possible treatment options for rheumatoid arthritis. Eicosanoids, fatty 
acids, lipids, trace elements, vitamins and several hormones are interesting candidates for 
elucidating the mechanism of RA. Pathway analysis has provided an indication of biological 
processes related to the discussed collection of RA related metabolites. This review suggests 
that more clinical studies are needed to elucidate the effects of vitamin supplementation on 
RA activity and progression. In addition, circadian rhythms in hormone production and other 
metabolite levels are important to consider. For instance, the timing of glucocorticoid 
treatment is essential for obtaining an optimal effect (Cutolo 2008). This review also shows 
the complexity of the immune and hormonal processes that are changed in rheumatoid 
arthritis patients, suggesting that a move from single-target therapy towards multi-target 
therapy is needed. Finally, a more personalized medicine approach is needed to address the 
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5. Systems biology guided by Chinese Medicine reveals 
new  markers for sub-typing rheumatoid arthritis patients 
 
Abstract 
Background. Complex chronic diseases such as rheumatoid arthritis have become a major 
challenge in medicine and for the pharmaceutical industry. New impulses for drug 
development are needed. 
Objective. A systems biology approach is explored to find sub-types of rheumatoid arthritis 
patients enabling a development towards more personalized medicine.    
Methods. Blood samples of 33 RA patients and 16 healthy volunteers were collected. The RA 
patients were diagnosed according to CM theory and divided into two groups, the RA Heat 
and RA Cold group. CD4+ T-cells were used for a total gene expression analysis. Metabolite 
profiles were measured in plasma using gas chromatography/mass spectrometry (GC/MS). 
Multivariate statistics was employed to find potential biomarkers for the RA Heat and RA 
Cold phenotype. A comprehensive biological interpretation of the results is discussed. 
Results. The genomics and metabolomics analysis showed statistically relevant different gene 
expression and metabolite profiles between healthy controls and RA patients as well as 
between the RA Heat and RA Cold group. Differences were found in the regulation of 
apoptosis. In the RA Heat group caspase 8 activated apoptosis seems to be stimulated while 
in the RA Cold group apoptosis seems to be suppressed through the Nrf2 pathway.  
Conclusions. Rheumatoid arthritis patients could be divided in two groups according to CM 
theory. Molecular differences between the RA Cold and RA Heat groups were found which  
suggest differences in apoptotic activity. Subgrouping of patients according to CM diagnosis 
has the potential to provide opportunities for better treatment outcomes by targeting Western 
or CM treatment to specific groups of patients. 
 
Based on: van Wietmarschen H, Yuan K, Lu C, Gao P, Wang J, Xiao C, Yan X, et al. (2009) Systems biology 
guided by Chinese medicine reveals new markers for sub-typing rheumatoid arthritis patients. Journal of 




Complex chronic diseases such as rheumatoid arthritis have become a major challenge in 
medicine and for the pharmaceutical industry. New impulses for drug development are 
needed. Rheumatoid Arthritis (RA) is a chronic systemic autoimmune disease characterized 
by inflammatory polyarthritis of unknown etiology, affecting approximately 0.5 -1% of the 
population worldwide.[1]  
Although the currently favored treatment regime is believed to have a favorable result on 
disease course by influencing inflammation, patients assessment of disease activity and 
functional disability do not always support this result.[2] The target-centric approach seems 
to have reached its limit and a more personalized, system-based strategy provides a potential 
for a paradigm shift in drug discovery and development.[3, 4] An important bottleneck in 
moving towards patient stratification is diagnosis.  
Over the years several clinical features and molecular markers have been identified to sub-
type RA patients.[5, 6] Anti-citrullinated protein antibodies (ACPA) positive or negative 
status is found to be related to distinctive RA risk profiles.[7] More inflamed joints and a 
higher level of joint destruction was reported in ACPA positive RA patients.[8] A large 
heterogeneity between the INF-1 high and low sub-typed have been found in gene expression 
profiles of RA patients, but this is not very clear in the clinical features.[9] All this knowledge 
has yet to lead to more personalized health strategies in clinical practice. 
A systems biology approach has been advocated for managing RA.[10] Systems biology aims 
to increase our understanding of biological systems by looking at the many interactions 
between hundreds of genes, proteins and metabolites simultaneously.[3, 11, 12] Interestingly 
a systems approach already exists for several thousands of years in the practice of Chinese 
Medicine (CM), but the underlying theory is not yet understood from a biochemical basis. In 
CM theory diseases are called syndromes, which are based on patterns of various symptoms 
expressed by the entire body.[13] Treatment is usually personalized although more general 
strategies are also used. Systems biology could therefore be a bridge between CM and 
western medicine.[14][15] 
However simply copying CM treatments to the western practice is not feasible. Extracts of 
Tripterygium wilfordii Hook. F. is one of the commonly and successfully used CM 
intervention strategies for RA that has been studied extensively.[16, 17, 18]. Other examples 
are the use of preparations of Ganoderma lucidum (Leyss. Ex Fr.) Karst, an extract of 
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multiple herbs named San-Miao-Wan[19], Celastrus aculeatus Merr[20] and Forsythia 
suspense (Thunb.) Vahl[21] as immune modulators in RA. In these studies the benefits of 
standard CM preparations given to RA patients in general are not always that clear.[19] We 
think that the key issue here is the different diagnostic practices between CM and western 
medicine.[22]  
Several studies show that the diagnostic methods used in CM cannot be separated from the 
treatment strategies used.[23] A study with 396 RA patients shows that the treatment of RA 
patients with Tripterygium wilfordii Hook. F. is more effective when the patients were 
affected with joint pain and joint tenderness, but didn't have more urination at night and joint 
stiffness. Additionally a Western treatment consisting of diclofenac, methotrexate and 
sulfasalazine was found to be more effective in RA patients displaying joint tenderness and 
thirst, but less effective in RA patients with dizziness. These results also indicate that CM 
diagnosis can be used to discover sub-phenotypes of RA.[16]  
According to CM theory RA patients would fall in the Bi Zheng (Bi-syndromes), a collection 
of different syndromes that is characterized by obstruction of Qi and Blood in the Channels 
and Collaterals. The Bi-syndromes encompass diseases with Western descriptions such as 
myalgias, osteoarthritis, RA, repetitive strain injuries and nerve pain. Bi syndromes are 
described in CM theory as  the result of an attack by three out of the four external pathogenic 
factors: Wind, Cold, Damp and Heat.[24]  Several syndromes or patterns are therefore used 
for patients in CM such as a Wind pattern or a Cold pattern. Using the Bi syndrome patterns 
RA patients can be differentiated into various groups, which are also treated very differently 
with Chinese herbal medicine. In this study the two very distinct CM patterns cold and heat 
were chosen to divide the RA patients into an RA Cold and RA Heat group. These two 
patterns were chosen because the symptoms are very different and the patients are treated 
very differently based on Chinese herbal medicine practice. 
The Cold pattern can be described as severe pain in a joint or muscle that limits the range of 
comfortable movement which doesn't move to other locations. The pain is relieved by 
applying warmth to the affected area, but increases with exposure to cold. Loose stools are 
characteristic as well as an absence of thirst and clear profuse urine. A thin white tongue 
coating is seen, combined with a wiry and tight pulse. In contrast the Heat pattern is 
characterized by severe pain with hot, red, swollen and inflamed joints. Pain is generally 
relieved by applying cold to the joints. Other symptoms include fever, thirst, a flushed face, 
irritability, restlessness, constipation and deep-colored urine. The tongue may be red with a 
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yellow coating and the pulse may be rapid.[25]  
In this exploratory study genomics and metabolomics tools were used to find biomarkers that 
could indicate new sub-phenotypes of RA, related to the differentiation of RA patients into 
Cold and Heat pattern according to CM diagnosis. 
 
Patients and methods 
33 Female RA patients visiting the Institute of Traditional Chinese Medicine in Beijing for 
the first time and 16 healthy female volunteers, all residents of Beijing, age 24 to 64 years old 
(μ=43.6) participated in the study. All participants gave consent and the study was approved 
by the ethics board of the Institute of Basic Research In Clinical Medicine, China Academy 
of Chinese Medical Sciences. RA patients were eligible to participate if they had met the 
American College of Rheumatology (ACR) criteria for rheumatoid arthritis for at least one 
year with functional Class at level I, II, or III.[26] All patients completed a 115 item 
questionnaire and a tongue and pulse diagnosis was taken by a CM practitioner. The 
questions were related to joint issues, pain, response to weather, and other symptoms such as 
fever and thirst. Using this information the CM practitioner then classified the RA patients as 
heat pattern and cold pattern as described above. These groups are very different in the 
symptoms they expressed, for example the RA Heat patients experience severe pain in hot 
weather or when heat is applied and RA Cold patients in cold conditions. The two groups, the 
RA Cold and RA Heat patients, did not differ in mean age and erythrocyte sedimentation rate 
(tested with Mann-Whitney U test). For the control group healthy women living in Beijing, 
coming to the hospital for a regular health exam, were included if they had no diagnosed 
diseases. After the study the RA patients received CM treatment based on the diagnosed heat 
or cold pattern and some of them also received Western treatment, as is the regular practice in 
the CM hospital in China. 
Patients continuously receiving NSAID's, corticosteroids for over 6 months, or receiving the 
above mentioned medicines within one month were not included in the study. Also the 
patients were not on any CM medication yet. The patients with severe diseases of the 
cardiovascular system, lung, liver, kidney, mental and blood system, women who were 






Analysis of blood samples  
For the genomics analysis 8ml venous blood was collected in anticoagulation tubes before 
breakfast. CD4+T cells play a key role in inflammatory processes in RA.[5, 6] It is suggested 
that an altered CD4+T cell homeostasis in RA may contribute to the autoimmune response as 
well as to the immunodeficiency in RA patients.[27] Therefore CD4+T lymphocytes were 
extracted. The CD4+T cells were collected referring to StemSep® Rhesus CD4 T Cell 
Enrichment Cocktail Kit manual(StemCell Technologies, Inc. Canada).  
Total RNA was extracted from the 33 RA samples and 12 control samples that were at least 
95% purified, using the TRIzol kit (Life Technologies, Inc) in accordance with the 
manufacturer's procedure. Purity was checked by flow cytometry. Gene chips containing 
23232 cDNAs were hybridized according to the  Micromax ASAP RNA labeling kit 
procedure (PerkinElmer). Reverse transcription was done following the manufacturer's 
protocols of SuperScriptⅡFirst-strand Synthesis System (Invitrogen, Life Technologies). The 
Gene chips were scanned using Genepix4000B scanner. Picture information scanned was 
transformed into data using GenePix®Pro Micrroarray Image Analysis Software.[28, 29] 
 
Data analysis 
Data normalization to correct for technical variation among individual microarray 
hybridizations was conducted using a two-step procedure described in detail by Jarvis and 
colleagues.[30, 31, 32]  
Gene expression profiles of controls were compared with RA patients and the profiles of RA 
Cold patients were compared with RA Heat patients. The differences in gene expression 
levels were considered significant when the signal was increased or decreased more than 1.4 
compared to control (p<0.05 in Student's t-test). More than 1.4 increase in signal comparing 
controls with RA or RA Cold to RA Heat was recorded as up regulated, a decrease of more 
than 1.4 as down regulated. Also the gene expression fold change must be present in more 
than 50% of the patients. To determine differences in gene expression profiles between the 
Controls and RA patients as well as between the RA Cold and RA Heat patients hierarchical 






Analysis of blood samples  
For the metabolomics analysis blood samples of 21 RA patients and 16 healthy volunteers 
were used. The other 12 RA samples were used in another analysis. Blood plasma was treated 
as described elsewhere except this time a sample vs. acetonitrile ratio of 1:2 was taken.[34] 5 
μL decanoic acid (internal standard) was added to each 200μL sample followed by the 
addition of 65 μL of DMF and 65 μL of MTBSTFA (derivatization agent).GC-MS analysis 
was performed according to Yuan et al.[35] 
 
Data analysis  
Metabolomics experiments usually result in a large number of measured metabolites, in this 
study 255 metabolites were measured. Specific multivariate statistical techniques are needed 
to analyze this kind of data.  We first used Principal component analysis (PCA), a commonly 
used technique which is used to explore the data (SIMCA-P version11.0, Umetrics AB, 
Umea, Sweden). A PCA model attempts to project the maximum amount of variation in as 
few dimensions (principal components) as possible.[36, 37]  
Before applying PCA analysis all variables in the data set were scaled. This is to prevent 
certain variables from dominating the resulting model. The means of the variables were set to 
zero and the values were also divided by  the standard deviation. After this step partial least 
squares discriminant analysis (PLS-DA) was employed to find the variables that contribute 
most to the distinction between controls and RA patients [38]. PLS-DA was also used to find 
the most important variables that contribute to the distinction between the RA Cold and RA 
Heat group and then identified by mass spectrometry.  
Cross-validation and permutation tests were used to validate the PLS-DA models. For the RA 







Panel A in Figure 1 shows the 146 genes that were expressed significantly different between 
the RA patients and the control participants. The hierarchical cluster analysis results in a 
clustering of the control samples at the left and a clustering of RA patient samples at the right. 
In the first section of Table 1 the 10 most upregulated and downregulated genes are shown.  
In Panel B of Figure 1 the significant differences in gene expression between the RA Cold 
and RA Heat group is shown. The cluster analysis of the 64 genes involved shows different 
gene expression profiles for the RA Cold (left), RA Heat patients (middle) and the control 
participants (right). In the second section of Table 2 the 10 most upregulated and 




Figure 1. Panel A shows a hierarchical cluster analysis of the expression of all genes (146 
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genes) on the RA gene expression array. The tree structure reflects the similarity of the gene 
expression profiles. The horizontal axis represents the samples, and the vertical axis 
represents the gene expression. Red color in the figures means up-regulation and green color 
means down-regulation.12 control samples cluster together into a group on the left, while the 
remaining 33 RA samples at the right form a second group. Panel B shows a similar 
hierarchical cluster analysis of the expression of all genes (64 genes) on the cold-heat RA 
gene expression array. At the left side the RA Cold subjects are grouped, in the middle is the 








Figure 2 panel A shows a PCA score plot containing all the participants of the study.  Panel A 
indicates a grouping of control participants (more in the upper part) and RA patients (below 
the control participants). 
The PLS-DA score plot in Figure 2. panel B shows that the RA patients and control 
participants could be divided into two groups based on their metabolite profiles. Cross-
validation and 200 permutation tests show that the model, and thus the classification into a 
RA and Control group, is significant.  
Figure 2 panel C shows a PLS-DA score plot in which RA Cold patients are separated from 
RA Heat patients. Cross-validation and 200 permutation tests show that the model, and thus 
the classification into a RA Heat and RA Cold group, is significant. Panel D of figure 2 shows 
the contribution of the metabolites to the RA Heat and RA Cold classification. 
Identification of the metabolites that contribute most to the distinction between RA and 
control subjects resulted in 10 potential biomarkers. Additionally 7 potential biomarkers were 




Figure 2. Panel A shows a PCA score plot in which all the RA patients and control participants are represented 
by a point. Different colors and symbols are used to visualize the control, RA Cold and RA Heat participants. 
Panel B shows a PLS-DA score plot for the first two principal components. The RA group and control group are 
clearly separated. In Panel C the RA cold and RA heat group are separated in a PLS-DA score plot. Panel D 





The comprehensive systems analysis consisting of genomics and metabolomics profiling 
described in this paper reveals a number of features that distinguish rheumatoid arthritis 
patients from healthy volunteers, and those that discriminate these RA patients into two 
subgroups called the RA Heat group and RA Cold group. Figures 1 and 2 suggest that a 
biological basis underlies the CM differentiation into these subgroups.  
To understand more about the biology underlying RA and the sub-groups RA Heat and RA 
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Cold, we determined functionally related genes using DAVID's functional gene annotation 
tool (http://david.abcc.ncifcrf.gov/).[39] An interesting functional cluster of genes containing 
immune system processes was found, using the RA versus Control gene data. From the genes 
involved in this cluster a network was created using Cytoscape.[40] Additionally a cluster of 
genes involved in apoptosis was found using the RA Cold versus Heat gene data, and was 
added to the network and connected with dashed edges (Figure 3). The length of the edges 
connecting the nodes (genes) is determined by Kappa values, which expresses the strength of 
the relationship between the genes.  
 
Figure 3. A network illustrating the functional relationships between genes involved in processes of the immune 
system (solid lines) and apoptosis (dashed lines). Genes colored dark green are upregulated in RA patients, light 
green colored genes are downregulated in RA patients. Octahedrons denote genes differently expressed in the 
RA Heat and RA Cold groups, blue means more expression in RA Cold and red means more expression in RA 
Heat. The weight of the edges is determined by the relatedness between the nodes. A clustering of genes active 
in RA Cold are clustering in the upper left network. Many genes upregulated in RA Heat are involved in 
apoptosis. 
 
The great number of dark green nodes in the network shows that a lot of the genes involved 
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in immune processes are up-regulated in the RA patients in this study. Additionally the 
network shows that many of the genes up-regulated in RA Heat patients cluster together. Also 
4 genes up-regulated in RA Cold patients group together in a small cluster separated from the 
main network.  Interestingly 9 of the 11 up-regulated genes involved in apoptosis (dashed 
lines in Figure 3) are up-regulated in the RA Heat patients (red octahedrons), suggesting that 
activation of apoptosis plays a more significant role in the RA Heat subtype than in the RA 
Cold subtype. 
 
Figure 4. Apoptosis regulation in RA Heat and RA Cold patients. In RA Heat patients the expression of Caspase 
8 was increased which resulted in a stimulation of apoptosic processes. In RA Cold the combination of no 
enhanced expression of Caspase 8 and the increased expression of NFE2L2 (Nrf2) and HO-1 activated apoptosis 
resistance events. Arrows denote activation, lines with flat ends denote inhibition. (The gene symbols used 
correspond with: dars: Aspartyl-tRNA synthethase, BATF: basic leucine zipper transcription factor, Hspa1b: 




Figure 4 shows how apoptotic pathways are differently affected by the gene expression 
patterns in RA Heat and RA Cold patients. The discovery of the up-regulation of Caspase 8 
recruitment domain in RA Heat patients points to the death receptor pathway. Apoptosis via 
this pathway occurs through ligation of death receptors such as TNF receptor and Fas [41]. 
Activation of the death receptors leads to the recruitment of Caspase 8 which can then 
activate Caspase 3 or Bid, both leading to downstream apoptotic events.  
In contrast, two genes involved in apoptosis resistance, Heme oxygenase-1 and Nrf2 are up-
regulated in RA Cold patients.[42] There is no up-regulation of Caspase 8, BATF and 
Hspa1b. NfκB and JNK are important regulators of apoptosis in which JNK can play both a 
stimulating and inhibiting role.[43, 44] In RA Heat patients Caspase 8 will inhibit NfκB[45], 
which will in turn reduce the inhibiting activity of NfκB on JNK. At the same time the up-
regulated BATF and Hspa1b inhibit JNK activity.[46] The down-regulation of Aspartyl-tRNA 
synthetase in RA Cold patients, which is needed for the production of the aspartic acid rich 
caspases, is another finding that indicates reduced apoptosis activity.  It could be that JNK is 
more active in RA Cold patients which could stimulate apoptosis resistance through the Nrf2 
pathway.[47] RA Cold could be considered a more severe disease state as a lack of apoptosis 
in synovial fibroblasts, macrophages, fibroblasts, lymphocytes, neutrophils and osteoclasts 
has been proposed to contribute to the persistence of RA.[46]   
Metabolomics shows an increased urea production in RA Heat patients, indicating more 
protein breakdown than in RA Cold patients. Also Proline and oxo-Proline are increased in 
RA Heat patients which is abundantly released during collagen breakdown. Additionally in 
RA Cold patients L-Leucine levels are raised. On one hand this can indicate protein synthesis, 
which is in agreement with normal urea levels found in RA Cold patients. On the other hand 
it can indicate a state of inflammation, which is the case in all RA patients but perhaps with 
varying metabolic effects.  
The promising results of this study based on a limited number of patients were evaluated 
carefully. First a statistical evaluation was applied to show significance, but a major 
validation came from the coherent biological information found in this study. Further 
validation in future research will encompass also possible differences between patients from 
different cultural backgrounds. 
In conclusion, rheumatoid arthritis patients could be divided into two groups according to 
CM theory. Molecular differences between the RA Cold and RA Heat groups were found 
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which validates the subtyping. Both the gene and metabolite profiles have elucidated 
relationships between several of the markers, revealed insight in the mechanism of RA and 
have provided the first stepping stones for a biological interpretation of the CM groups RA 
Cold and RA Heat. This biological interpretation is a second validation of the subtyping of 
RA patients, which could also lead to an increased understanding and improvement of CM 
intervention strategies specifically directed at alleviating Cold and Heat symptoms. Further 
studies are needed to gain knowledge about the biology behind other sub-groups of RA 
patients. The different subtypes of RA patients might be considered in studying Western 




1. Hochberg MC, Silman AJ, Smolen JS, et al. Rheumatology. Mosby, Elsevier Limited; 2008. 
2. Welsing PMJ, Fransen J, van Riel PLCM. Is the disease course of rheumatoid arthritis becoming milder? 
Time trends since 1985 in an inception cohort of early rheumatoid arthritis. Arthritis Rheum 2005;52:2616-24. 
3. van der Greef J, McBurney RN. Innovation: Rescuing drug discovery: in vivo systems pathology and systems 
pharmacology. Nat Rev Drug Discov 2005;4:961-7. 
4. van der Greef J, Martin S, Juhasz P, et al. The art and practice of systems biology in medicine: mapping 
patterns of relationships. J Proteome Res 2007;6:1540-59. 
5. Gaston JSH. Cytokines in arthritis--the 'big numbers' move centre stage. Rheumatology (Oxford) 2008;47:8-
12. 
6. Lundy SK, Sarkar S, Tesmer LA, et al. Cells of the synovium in rheumatoid arthritis. T lymphocytes. Arthritis 
Res Ther 2007;9:202. 
7. van der Helm-van Mil AHM, Huizinga TWJ, de Vries RRP, et al. Emerging patterns of risk factor make-up 
enable subclassification of rheumatoid arthritis. Arthritis Rheum 2007;56(6):1728-35. 
8. van der Helm-van Mil AHM, Verpoort KN, Breedveld FC, et al. Antibodies to citrullinated proteins and 
differences in clinical progression of rheumatoid arthritis. Arthritis Res Ther 2005;7(5):R949-58. 
9. van der Pouw Kraan TCTM, Wijbrandts CA, van Baarsen LGM, et al. Rheumatoid arthritis subtypes 
identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a 
subpopulation of patients. Ann Rheum Dis. 2007;66(8):1008-14. 
10. Glocker MO, Guthke R, Kekow J, et al. Rheumatoid arthritis, a complex multifactorial disease: on the way 
toward individualized medicine. Med Res Rev 2006;26:63-87. 
11. Van der Greef J, Hankemeier T, McBurney RN. Metabolomics-based systems biology and personalized 
medicine: moving towards n = 1 clinical trials? Pharmacogenomics 2006;7:1087-94. 
 
128 
12. Van der Greef J. Systems biology, connectivity and the future of medicine. Syst Biol (Stevenage) 
2005;152:174-8. 
13. Maciocia G. The Foundations of Chinese Medicine: A Comprehensive Text for Acupuncturists and 
Herbalists. Second Edition. Churchill Livingstone; 2005. 
14. Wang M, Lamers RJAN, Korthout HAAJ, et al. Metabolomics in the context of systems biology: bridging 
traditional Chinese medicine and molecular pharmacology. Phytother Res 2005;19:173-82. 
15. Schumacher HR. West meets east – observations on integrative medicine in rheumatology from the USA. 
Chin J Integr Med 2008; 14:165-166. 
16. He Y, Lu A, Zha Y, et al. Correlations between symptoms as assessed in traditional chinese medicine (TCM) 
and ACR20 efficacy response: a comparison study in 396 patients with rheumatoid arthritis treated with TCM or 
Western medicine. J Clin Rheumatol 2007;13:317-21. 
17. Tao X, Younger J, Fan FZ, et al. Benefit of an extract of Tripterygium Wilfordii Hook F in patients with 
rheumatoid arthritis: a double-blind, placebo-controlled study. Arthritis Rheum 2002;46:1735-43. 
18. Gu WZ, Brandwein SR, Banerjee S. Inhibition of type II collagen induced arthritis in mice by an 
immunosuppressive extract of Tripterygium wilfordii Hook f. J Rheumatol 1992;19:682-8. 
19. Li EK, Tam L, Wong CK, et al. Safety and efficacy of Ganoderma lucidum (lingzhi) and San Miao San 
supplementation in patients with rheumatoid arthritis: a double-blind, randomized, placebo-controlled pilot trial. 
Arthritis Rheum 2007;57:1143-50. 
20. Tong L, Moudgil K. Celastrus aculeatus Merr. suppresses the induction and progression of autoimmune 
arthritis by modulating immune response to heat-shock protein 65. Arthritis Res Ther 2007;9:R70. 
21. Chen X, Oppenheim JJ, Howard OMZ. Chemokines and chemokine receptors as novel therapeutic targets in 
rheumatoid arthritis (RA): inhibitory effects of traditional Chinese medicinal components. Cell Mol Immunol 
2004;1:336-42. 
22. Lu A, Jia HW, Xiao C, et al. Theory of traditional Chinese medicine and therapeutic method of diseases. 
World J Gastroenterol 2004;10:1854-6. 
23. Yang W, Ouyang J, Zhu K, et al. TCM treatment for 40 cases of rheumatoid arthritis with channel blockage 
due to yin deficiency. J Tradit Chin Med 2003;23:172-4. 
24. Ni M. The Yellow Emperor's Classic of Medicine: A New Translation of the Neijing Suwen with 
Commentary. Shambhala; 1995. 
25. Jiang W. Therapeutic wisdom in traditional Chinese medicine: a perspective from modern science. Trends 
Pharmacol Sci 2005;26:558-63. 
26. Arnett FC, Edworthy SM, Bloch DA, et al. The American Rheumatism Association 1987 revised criteria for 
the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. 
27. Fournier C. Where do T cells stand in rheumatoid arthritis? Joint Bone Spine 2005;72:527-32. 
28. Whatmore AJ, Patel L, Clayton PE. A pilot study to evaluate Gene Expression profiles in peripheral blood 
mononuclear cells (PBMCs) from children with Growth hormone (GH) deficiency and Turner syndrome in 
response to GH treatment. Clin Endocrinol (Oxf). 2008.  
 
129 
29. Wang L, Zhang Z, Li Q, et al. Ethanol exposure induces differential microRNA and target gene expression 
and teratogenic effects which can be suppressed by folic acid supplementation. Hum Reprod. 2008;1:1-18. 
30. Jarvis J, Dozmorov I, Jiang K, et al. Novel approaches to gene expression analysis of active polyarticular 
juvenile rheumatoid arthritis. Arthritis Res Ther 2004;6:R15-R32. 
31. Dozmorov I, Centola M. An associative analysis of gene expression array data. Bioinformatics 2003;19:204-
11. 
32. Knowlton N, Dozmorov IM, Centola M. Microarray Data Analysis Toolbox (MDAT): for normalization, 
adjustment and analysis of gene expression data. Bioinformatics 2004;20:3687-90. 
33. Do JH, Choi DK. Clustering Approaches to Identifying Gene Expression Patterns 
from DNA Microarray Data. Molecules and Cells 2008;25:279-88. 
34. Gao P, Lu C, Zhang F, et al. Integrated GC-MS and LC-MS plasma metabonomics analysis of ankylosing 
spondylitis. Analyst 2008;133:1214-1220. 
35. Yuan KL, Shi XZ, Lu X, et al. [Assessment of therapeutic effect of losartan on diabetes mellitus with gas 
chromatography-based metabonomics]. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2007;29:719-724. 
36. Van den Berg RA, Hoefsloot HCJ, Westerhuis JA, et al. Centering, scaling, and transformations: improving 
the biological information content of metabolomics data. BMC Genomics 2006;7:142. 
37. Bijlsma S, Bobeldijk I, Verheij ER, et al. Large-scale human metabolomics studies: a strategy for data (pre-) 
processing and validation. Anal Chem 2006;78:567-74. 
38. Westerhuis JA, Hoefsloot HCJ, Smit S, et al. Assessment of PLSDA cross validation. Metabolomics 
2008;4:81-89. 
39. Sherman BT, Huang DW, Tan Q, et al. DAVID Knowledgebase: a gene-centered database integrating 
heterogeneous gene annotation resources to facilitate high-throughput gene functional analysis. BMC 
Bioinformatics 2007;8:426. 
40. Suderman M, Hallett M. Tools for visually exploring biological networks. Bioinformatics 2007;23:2651-9. 
41. Liu H, Pope RM. The role of apoptosis in rheumatoid arthritis. Current Opinion in Pharmacology 
2003;3:317-22. 
42. Fang J, Akaike T, Maeda H. Antiapoptotic role of heme oxygenase (HO) and the potential of HO as a target 
in anticancer treatment. Apoptosis 2004;9:27-35. 
43. Chang L, Karin M. Mammalian MAP kinase signalling cascades. Nature 2001;410:37-40. 
44. Liu J, Lin A. Role of JNK activation in apoptosis: a double-edged sword. Cell Res 2005;15:36-42. 
45. Fontalba A, Martinez-Taboada V, Gutierrez O, et al. Deficiency of the NF-kappaB inhibitor caspase 
activating and recruitment domain 8 in patients with rheumatoid arthritis is associated with disease severity. J 
Immunol 2007;179:4867-73. 
46. Liu H, Pope RM. Apoptosis in rheumatoid arthritis: friend or foe. Rheum Dis Clin North Am 2004;30:603-
25. 






6. Sub-typing of rheumatic diseases based on a systems 
diagnosis questionnaire   
 
Abstract 
Background: The future of personalized medicine depends on advanced diagnostic tools to 
characterize responders and non-responders to treatment. Systems diagnosis is a new 
approach which aims to capture a large amount of symptom information from patients to 
characterize relevant sub-groups. 
Methodology: 49 patients with a rheumatic disease were characterized using a systems 
diagnosis questionnaire containing 106 questions based on Chinese and Western medicine 
symptoms. Categorical principal component analysis (CATPCA) was used to discover 
differences in symptom patterns between the patients. Two Chinese medicine experts where 
subsequently asked to rank the Cold and Heat status of all the patients based on the 
questionnaires. These rankings were used to study the Cold and Heat symptoms used by these 
practitioners. 
Findings: The CATPCA analysis results in three dimensions. The first dimension is a general 
factor (40.2% explained variance). In the second dimension (12.5% explained variance)  
'anxious', 'worrying', 'uneasy feeling' and 'distressed' were interpreted as the Internal disease 
stage, and 'aggravate in wind', 'fear of wind' and 'aversion to cold' as the External disease 
stage. In the third dimension (10.4% explained variance) 'panting s', 'superficial breathing', 
'shortness of breath s', 'shortness of breath f' and 'aversion to cold' were interpreted as Cold 
and 'restless', 'nervous', 'warm feeling', 'dry mouth s' and 'thirst' as Heat related.  'Aversion to 
cold', 'fear of wind' and 'pain aggravates with cold' are most related to the experts Cold 
rankings and 'aversion to heat', 'fullness of chest' and 'dry mouth' to the Heat rankings. 
Conclusions: This study shows that the presented systems diagnosis questionnaire is able to 
identify groups of symptoms that are relevant for sub-typing patients with a rheumatic 
disease. 
 
Based on: van Wietmarschen HA, Reijmers TH, van der Kooij AJ, Schroën J, Wei H, Hankemeier T, et al. 




Pharmacological disease management strategies for rheumatoid arthritis (RA) are for an 
important part based on trial and error. In general less than 53% of RA patients with a disease 
duration of less than one year show a positive ACR20 response to treatment [1]. This number 
goes down to 38% for patients with 5-10 years of RA. Even 30% of RA patients initiating the 
most effective and expensive treatment option available, anti-TNF therapy, fail to respond 
[2]. Non-responders are switched to other drugs until one is found that gives the desired 
effect [3]. A similar trial and error approach is often used for the treatment of osteoarthritis 
and fibromyalgia as well. The result is that a considerable number of patients experience no 
benefits from a treatment but just the side effects. 
Rheumatoid arthritis patients as well as patients with other rheumatic diseases could benefit 
substantially from a shift towards a personalized medicine approach which aims to get the 
right treatment to the right patient, in the right dose, at the right time and via the right route 
[4,5]. In the traditional approach, patients are classified as according to criteria specified by 
the American College of Rheumatology (ACR). A single disease management strategy that is 
specifically developed for treating the particular type of rheumatic disease will then be 
applied. A more personalized approach will go beyond the ACR classification and will 
require much more information about the patient and his or her environment [6]. Specific 
individual patient situations require specific types of treatment, which can consist of specific 
drugs, life-style changes, psychological support and other interactions depending on the wish 
of the patient [7].  
The challenge for personalized medicine is to characterize groups of patients and relate these 
groups to certain treatment options. Modern systems biology technologies such as genomics, 
proteomics and metabolomics [8-10] are currently able to generate an enormous amount of 
data, which can be seen as signs defined as manifestations that are measured. Several clinical 
features and molecular markers have been identified for example to sub-type RA patients 
[11,12]. Anti-citrullinated protein antibodies  positive or negative status is found to be related 
to distinctive RA risk profiles [13]. More inflamed joints and a higher level of joint 
destruction was reported in Anti-citrullinated protein antibodies  positive RA patients [14]. A 
large dissimilarity has been found in gene expression profiles of INF-1 high and low sub-
types of RA patients, but this is not very clear in the clinical features of patients [15]. 
Unfortunately, this knowledge has not resulted in personalized health strategies in clinical 
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practice yet, which illustrates that searching for clinically relevant subtypes without clear 
indications of what to look for and based mostly on signs is difficult. 
Symptoms, manifestations that are observed by the patient himself, are on the other hand a 
subjective type of information which is actually much closer to the phenotype of the patient 
than signs. Symptoms therefore provide an extra dimension of information. A wide variety of 
symptoms can be collected related to physical manifestations but also to the psychology, the 
family, the environment, and worldview of the patient which is well known to play a large 
role in arthritis [16-19]. 
Diagnosis is the key process in which symptoms and signs are used by a medical practitioner 
to distinguish the state of a person as different from the 'normal' situation. It is used to 
differentiate one disease from another and it is used to base treatment on. A move towards 
personalized medicine needs an optimization and refinement of this diagnostic process. One 
way is to expand it by including more symptoms than currently in use [20]. 
Chinese medicine diagnosis is a systems diagnosis approach that takes into account a broad 
spectrum of symptoms (as reported by the patient)  as well as signs observed by the 
practitioner by listening to the body, feeling the body and observation of the patient [21]. 
Constitutional, behavioral and social aspects are also considered in the diagnosis and the 
choice of treatment. In Chinese medicine, rheumatoid arthritis as well as other rheumatic 
diseases fall  into a group of diseases termed Bi-syndromes. A Bi-syndrome is characterized 
by the presence or absence of over 100 symptoms [22]. 
Symptoms are related to one or more symptom patterns which are called syndromes in 
Chinese medicine. These patterns or syndromes lead to treatment principles on which 
particular treatments are based. Recently two particular patterns of symptoms have been 
studied more closely [23]. These patterns are called Cold and Heat and are general patterns of 
symptoms much used in Chinese medicine [21,24]. The Cold pattern can be described as 
severe pain in a joint or muscle that limits the range of comfortable movement, the pain does 
not move to other locations. The pain is relieved by applying warmth to the affected area, but 
increases with exposure to cold. Loose stools are characteristic also, as well as an absence of 
thirst and clear profuse urine. A thin white tongue coating is seen, combined with a wiry and 
tight pulse. In contrast, the Heat pattern is characterized by severe pain with hot, red, swollen 
and inflamed joints. Pain is generally relieved by applying cold to the joints. Other symptoms 
include fever, thirst, a flushed face, irritability, restlessness, constipation and deep-colored 
urine. The tongue may be red with a yellow coating and the pulse may be rapid [25]. 
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In a recent study [26] differences have been found between RA Cold and Heat patients when 
looking at symptoms, gene expression, and metabolomics profiles. Interestingly, the 
differences turned out to be related to apoptosis, an important biological process. The RA 
Heat group showed more activity of apoptosis related genes than the RA Cold group. Lu and 
others found that RA patients with the Cold pattern responded better to biomedical 
combination therapy (diclofenac, methotrexate, sulfasalazine) than did patients with RA with 
a Heat pattern, at 12 weeks and 24 weeks of treatment [27]. These findings show that sub-
grouping of RA patients using knowledge from Chinese medicine diagnosis can lead to more 
personalized treatment in RA. Especially the Cold and Heat groups are promising for 
optimizing treatment.   
The objective of the study is to analyze similarities and differences between patients with a 
rheumatic disease with respect to their symptoms. A questionnaire was therefore designed to 
establish a systems diagnosis of patients with a rheumatic disease based on a range of 
symptoms that are used in Chinese and Western medicine. A second objective is to analyze 
the Cold and Heat status of these patients based on the questionnaire results and an evaluation 
of the questionnaires by Chinese medicine experts.  
Network analysis concepts were used to visualize the relationships between the symptoms 
and the corresponding syndromes according to Chinese medicine theory, as well as the 
relationships observed in patients. Categorical principal component analysis was used to find 
similarities and differences between the patients. The results were interpreted using 
theoretical and expert knowledge about symptoms and syndromes. 
The following part of the analysis focused on the absence and presence of Cold and Heat 
related symptoms in the patients. Two Chinese medicine experts were asked to rank the Cold 
and Heat status of each patient on a seven point scale, based on the questionnaire results. 
These Cold and Heat rankings were introduced as an extra source of information in the 
categorical principal component analysis. The results were interpreted using Western and 
Chinese perspectives on arthritis-like diseases. Finally, several suggestions for creating 
diagnostic tools using the presented systems diagnosis approach will be discussed, which can 




Materials and Methods 
Design of the questionnaire 
The questionnaire was designed to establish a systems diagnosis of patients with rheumatic 
diseases. Symptoms described as related to Bi-syndromes [28] and reviewed by two Chinese 
medicine experts were used to create a list of 106 questions related to these symptoms 
divided into nine areas: location of the symptoms, breathing, climate, digestion, emotions & 
behaviour, quality of the symptoms, changes in the symptoms, pain, and urination. For most 
of these questions the 7-point Likert scale [29], was used to assess the frequency or the 
strength of a symptom. A score of 1 means never or not present, while a score of 7 would 
mean very frequent or very strongly present. Some of the questions were in binary, yes or no, 
format.  
The questionnaire also represents a number of symptoms used in Western medicine to assess 
disease activity and the response to treatment, for example 'stiff joints', 'joint pain' and 
'swollen joints' [30]. In addition to the questions related to symptoms, some general questions 
were included concerning disease history, medication, and arthritis related blood factors. The 
full questionnaire is added as supplementary information. 
The questionnaire was designed to reflect Chinese thinking and diagnosis by extensive 
discussions with two Chinese medicine experts. Additionally, the questionnaire was reviewed 
by the scientific committee of the two Dutch professional organizations for Chinese medicine 
practitioners in the field of acupuncture (Nederlandse Vereniging voor Acupuntuur) and 
Nederlandse Artsen Acupunctuur Vereniging).  
The medical ethical committee of the Leiden University Medical Center was notified of the 
study before the questionnaire was send out to patients and waived the need for further 
approval of the study by the medical ethical committee. All participants were informed about 
the study the data was going to be used for either by e-mail or verbal communication. All 
participants gave an informed consent in an e-mail or verbally to this use of the data.  
 
Study sample 
People with one or more rheumatic diseases were invited to participate in this study by 
completing a questionnaire. A small invitation text was published on the website of the 
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Osteo- and Rheumatoid Arthritis Foundation in Amsterdam, the Netherlands, 
http://www.reuma-stichting.nl. The invitation was also published in one of the newsletters of 
the foundation. Additionally, the questionnaire accompanied with an explanation of the 
purpose of the study was send to all members of the Netherlands Acupuncture Society.  
A total of 91 people requested to participate in the study. A questionnaire was send of which 
52 were returned. Three questionnaires could not be used for the analysis: one was missing a 
full page of answers, of another one only the first page was completed and a third 
questionnaire contained 11 incorrectly filled answers. Table 1 summarizes the types of 
rheumatic diseases most prevalent in the respondents and the most used medication. 
 
Table 1  Characteristics of the respondents 
Rheumatic disease*  Medication 
Osteoarthritis 24  Diclofenac 11 
Rheumatoid arthritis 11  Ibuprofen 7 
Fibromyalgia 5  Paracetamol 6 
Systemic lupus erythematosus 2  Prednison 6 
Missing entry 4  Methotrexate 5 
Other rheumatic disease 10  Hydroxychloroquine 4 
   Tramadol 4 
   Etoricoxib 3 
   Naproxen 2 
   Celecoxib 2 
   Other medication 15 
   No medication 6 
   No entry 5 




Data screening and recoding 
Before data analysis, the consistency of the data was checked. Inconsistent answers to follow-
up questions or to questions requiring a severity and frequency score for the same symptom 
were converted  to missing. For example, if the answer to the question 'Do you feel cold?' is 
no, the answer to the follow-up question 'Is this cold located mostly in the feet or legs?' 
should only be no, which is not always the case. The question labeled 'sighing' was removed 
because multiple interpretations were possible and 'affected parts heavy' was completely 
covered by 'heavy feeling' and therefore also removed.  
Most questions contain categories  in which only a few  patients had a score, which is 
unfavorable in CATPCA because it  may lead to unstable results [31]. Therefore, we merged 
categories with a frequency less than 7 (the square root of the number of patients)  with an 
adjacent category. This resulted in 10 variables with only a single category which were 
therefore removed: 'vomiting', 'nightmares', 'joints bend', 'joints stretch', 'tired with slight 
exertion', 'symptoms wander', 'upper part affected', 'symptoms appear suddenly', 'pain appears 
slowly', 'pain with redness and swelling'. The variable 'joint pain' was removed because one 
of the two categories had only four observations. The final dataset used for the CATPCA 
analysis contained 93 variables. 
 
Network analysis 
In Chinese medicine the focus is more on relationships between symptoms than on the 
symptoms themselves. The symptoms involved in the Bi-syndromes form a network of 
relationships. Network theory [32-34] therefore offers a perfect set of concepts to visualize 
and analyze the network properties of the Bi-syndromes. Cytoscape version 2.6.3 [35], an 
open source network visualization and annotation package, was used to create a network 
(graph) of the questionnaire. The position of the nodes was calculated using an algorithm [36] 
implemented in Cytoscape which minimizes the total length of the edges in the graph. An 
example is given of how the symptom scores of a patient can be mapped on the network. The 
questionnaire scores are represented in the graph as the weights of the relationships (edges) 
between symptoms and the corresponding syndromes. Such a symptom fingerprint can be 




Categorical principal component analysis 
To explore the similarities and differences between the patients with respect to the set of 93  
variables, Principal Component Analysis (PCA) would be the appropriate method. However, 
since our data are categorical, standard PCA is not suitable. Nonlinear Principal Component 
Analysis (NLPCA) is a method that can deal with categorical data and is therefore the 
method of choice. NLPCA finds the parameters of the PCA model in an iterative process in 
which "Optimal Scaling" is incorporated. Optimal Scaling is a technique that finds optimal 
quantifications for categorical variables. The quantifications are optimal in the sense that the 
percentage of variance of the quantified variables accounted for by the principal components  
is maximal. NLPCA is available in SAS [37] as PRINQUAL [38,39], and in SPSS [40] as 
CATPCA [41,42]. In this study we have used CATPCA in SPSS version 17.0. 
The number of principal components was determined using parallel analysis [43,44] with 
permuted data [45]. We used 100 data sets with random permutation within all variables. 
Because CATPCA maximizes the eigenvalues of the first P components (with P the number 
of components specified by the user), solutions with different numbers of components are not 
nested. For instance,  the two components in a two-component solution are not equal to the 
first two components of a three-component solution. Therefore, multiple parallel analyses 
might be required: If the parallel analysis for the one-component solution shows a significant 
eigenvalue (greater than the 95
th
 percentile of the random eigenvalues) for the  second 
component, the parallel analysis is repeated for the two-component solution. Then the 
significance of the third eigenvalue is checked, etc., until the (P+1)
th 
eigenvalue of  a P-
component solution is not significant, then P is the chosen number of components. 
After determining the number of principal components, variables with a total variance 
accounted for (VAF) ≥ 50% and another set of variables with a total VAF ≥ 60% were 
selected for further analysis. With these two sets of variables the procedure of determining 
the number of components as described above was repeated (Figure 1). 
The loadings resulting from the two CATPCA models were compared with the theoretical 
relationships between symptoms and syndromes. The two resulting models were interpreted 
by a Chinese medicine expert. The interpretability determined which of the two sets of 




Figure 1. CATPCA data analysis strategy flowchart. 
 
The next part of the analysis focused on the Cold and Heat status of patients and the ability of 
the questionnaire to provide information on this status. Two Chinese medicine experts (expert 
1 and expert 2) were asked which symptoms they deemed most important for Cold and Heat. 
The two Chinese medicine experts were also asked to determine the Cold and Heat status of 
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each patient based on the questionnaire scores. In the subsequent analysis therefore there are 
four sources of information: 1) the patient scores on the questionnaire, 2) theoretical Cold and 
Heat related symptoms, 3) Cold and Heat related symptoms according to experts and 4) Cold 
and Heat ranking of each patient questionnaire by two experts. 
The symptoms that the experts used to rank the Cold and Heat status of the patients were 
compared with the symptoms connected with Cold and Heat according to theory. 
Furthermore, to examine the relationship between the symptoms and the Cold and Heat 
ranking by the experts, these rankings were plotted as ordinally scaled supplementary 
variables in the CATPCA solution [46]. Supplementary treatment of variables implies that 
they are projected into the component space, but do not participate in defining the component 
space. The locations of the Cold and Heat rankings of both experts were then examined 
respective to each other and the other variables. 
To find out  which symptoms are most related to the experts Cold and Heat ranking, a semi-
supervised analysis was performed. In this analysis the Cold and Heat rankings of the two 
experts did participate in the model building with a large weight (the ranking variables were 
included a large number of times in the model) [46]. For this analysis the number of principal 
components was also determined using the permutation testing approach described above. 
Due to the large weight of the four ranking variables, they almost completely determine the 
solution, causing the VAF of the other variables to decrease compared to the unsupervised 
solution. Questionnaire variables with a total VAF ≥ 25% in one of both dimensions were 
selected to build a final model. 
 
Results and discussion 
Similarities and differences between patients with a rheumatic disease 
The theoretical relationships between symptoms used in the systems diagnosis questionnaire 
and syndromes were visualized as a graph (Figure 2) [20]. The resulting Bi-syndrome 
network is a bi-partite graph consisting of two types of nodes, the syndromes (red hexagons) 
and the symptoms (yellow circles). This graph visualizes the relationships between symptoms 
and syndromes according to Chinese medicine theory. Some symptoms are related to more 
than one syndrome which might  in some instances be referred to as bridge symptoms or 
bifurcation points. The appearance of such a bridge symptom can indicate a strengthening of 
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the pattern itself, an upcoming change towards another pattern or a complication of the 
pattern. Many other symptoms are unique for particular syndromes. Certain related 
syndromes according Chinese medicine theory are positioned close together in the graph. For 
example prolonged Bone Bi develops into Kidney Bi, two syndromes which are closely 
related in theory and thus close together in the network. Heart Bi can develop after a long 
period of Vascular Bi. Intestine and Bladder Bi are two late stages of the disease related to the 
Hollow Organs [28].  
To visually explore the symptom pattern of a patient, the scores on the questionnaire can be 
mapped on the network. An example of one patient is shown in Figure 2. Edges that are 
thicker and darker blue denote high scores while light and thin edges represent low scores.  
 
Figure 2. Example of a personalized Bi-syndromes network based on Vangermeersch 1994. The red hexagonal 
nodes represent the Bi-syndromes (Bi prefix was omitted for brevity), and the yellow circles represent the 
symptoms and signs related to the Bi-syndromes. The blue lines (edges) represent the relationships between 
symptoms and syndromes according to theory while the thickness of the lines represent the symptom scores of 





The results of the CATPCA analyses are as follows. Parallel analysis showed four significant 
principal components for the model containing all the variables. Two sets of variables were 
selected, one set consisting of 44 variables with a total VAF > 50% and another set consisting 
of 30 variables with a VAF > 60% (see Supplementary information for the total VAF tables of 
both sets of variables). Parallel analysis revealed four significant components for the first set 
of variables and three significant components for the second set. After discussing both models 
with the Chinese medicine experts the model with fewer variables and components was 
retained for further analysis. 
 
Figure 3. Loading plot of the first two dimensions (panel A) and the second and third dimension (panel B) of 
the CATPCA model for the 30-variables set. In Panel A, the loading vectors of the symptoms are colored 
according to their contribution (as indicated by one of the experts)  to the Internal or External nature of the 
disease state. In Panel B, the loading vectors of symptoms which are theoretically related to Cold or Heat are 
pictured as thin blue or red lines. The supplementary Cold and Heat rankings of the two experts are plotted as 
thick blue or red lines. 
 
In the component score plots (not shown) no clear groups of patients could be observed. The 
location of the objects  in the score plots was compared with the type of arthritis the patients 
suffered from. No grouping of patients with a similar type of arthritis could be found. The 
loadings of the first two components of the CATPCA model are shown in Figure 3A. The 
length of a loading indicates the amount of variance explained by that loading and the 
 
143 
distance between two loadings indicates their similarity. All the loadings are positive in the 
first dimension (40.2% explained variance) indicating a general factor for which no clear 
interpretation was found. When the loadings in the second dimension (12.5% explained 
variance) are compared with the theoretical relationships between symptoms and the 
corresponding syndromes, two groups of loadings stand out. Five variables are theoretically 
related to the external pathogens Wind ('aggravate in wind', 'fear of wind'), Cold ('aversion to 
cold') and Heat ('thirst', 'dry mouth s'). Three of these symptoms, 'aggravate in wind', 'fear of 
wind' and 'aversion to cold', have a fairly high negative loading in the second dimension. 
Nine variables are related to Chinese Organ concepts such as Heart ('anxious', 'restless', 
'excited', 'nervous'), Vascular ('anxious', 'uncomfortable', 'distressed', 'uneasy feeling') and 
Lung ('panting s', 'worrying'). Four of these symptoms, 'anxious', 'worrying', 'uneasy feeling' 
and 'distressed', have a fairly high positive loading in the second dimension. Two symptoms 
which are related to Damp, 'heavy feeling' and 'tired feeling', have a very low loading in the 
second dimension.  
Looking at the distribution of symptoms from a Western medicine perspective reveals that  
the most common symptoms for rheumatoid arthritis (RA) 'joint pain', 'swollen joints' and 
'stiff joints' do not contribute to the variation between the patients. On the other hand two 
other RA symptoms 'tired feeling' and 'weak limbs' are present but close together. The main 
osteoarthritis symptoms 'pain' and 'stiffness' are not present. Fibromyalgia is characterized by 
pain and stiffness as well, but also by 'anxious' and 'distressed', which have a high loading in 
the second dimension. 
According to the Chinese medicine experts the second dimension is related to the Internal or 
External stage of the disease, one of the key diagnostic concepts used in Chinese medicine 
[21]. In the Internal stage the organs are affected while in the External stage the skin, muscles 
and channels are affected. The reaction of the body to the external pathogens Wind, Cold, and 
Damp that cause the arthritis is expressed by the symptoms that can be observed in the lower 
right part of Figure 3A. This indicates the first, external stage of the disease when the body 
defends itself against the invasion of the external pathogens. The appearance of Heat ('dry 
mouth s' and 'thirst') and Damp ('heavy feeling' and 'tired feeling') symptoms, indicates a 
transformation of Cold into Heat via Damp. Patients in this stage of the disease will have a 
low score in the second dimension. A high positive loading in the second dimension indicates 
a more chronic stage of the disease, in which patients will present Organ symptoms. If the 
position of the objects in the component score plots is compared to the loadings, it is possible 
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to get an indication of the stage of the disease according to Chinese medicine theory for each 
patient. The Internal versus External interpretation of the second dimension is in agreement 
with the distribution of the symptoms that are in theory related to the External or Internal 
stage of the disease as marked with different colors in Figure 3.  
 
The Cold and Heat status of rheumatic patients 
Figure 3B shows the second and third dimension of the CATPCA model. While the second 
dimension is mostly related to the Internal and External stage of the disease, the third 
dimension (10.4% explained variance) is related to the Cold or Heat status of the patients. 
Symptoms related to Heat and Cold according to theory are colored red and blue respectively 
in Figure 3 and are indicated in Figure 4. Five symptoms that are theoretically related to Heat 
have a negative loading in the third dimension ('restless', 'nervous', 'warm feeling', 'dry mouth 
s' and 'thirst'). The group of symptoms with the highest positive loadings in the third 
dimension ('panting s', 'superficial breathing', 'shortness of breath s' and 'shortness of breath 
f') are related to Qi deficiency. One symptom ('aversion to cold') theoretically related to Cold 




Figure 4. Cold and Heat related symptoms. In the first and third column the symptoms used by the experts for 
the Cold (blue) and Heat (red) ranking are marked. The importance is shown as a number behind the Cold and 
Heat label and by the color, dark blue or red is more important. The second column shows the names of the 
symptoms. Symptoms with a blue background are related to Cold according to theory, the red background ones 
are related to Heat according to theory. Symptoms with a brown background are related to both Cold and Heat. 
The table also shows which symptoms are important for the Cold and Heat ranking according to the forced 
classification model in bold type face and in red or blue. 
 
Figure 5. Panel A shows a bi-plot based on a semi-supervised CATPCA model including 19 variables and the 4 
expert ranking variables. The four expert rankings are shown on which the categories after transformation are 
marked by circles. The outline of the group of rheumatoid arthritis (RA) patients is shown as well as the outline 
of the group of osteoarthritis patients (OA). In Panel B the loadings are shown. The loadings corresponding to 
symptoms which are related to Cold or Heat according to theory are represented by thin blue or red lines 
respectively. The Cold and Heat expert rankings are the thick blue en red lines respectively. 
 
The Cold and Heat rankings of the experts, plotted as supplementary variables in Figure 3, 
have fairly high loadings in the third dimension indicating that this dimension is related to the 
Cold and Heat rankings. The Cold rankings are related to the other high positive loadings in 
the third dimension ('panting s', 'superficial breathing', 'shortness of breath s' and 'shortness of 
breath f'). One expert indicated to have used these symptoms to rank the Cold status of the 
patients (Figure 4). The Cold rankings are much closer together than the Heat rankings 
indicating that the two experts agree more on the Cold status of the patients than on the Heat 
status.   
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The experts were asked to indicate which symptoms they used for the ranking of the Cold and 
Heat status of the patients. In Figure 4 the symptoms reported by the two experts are given. 
Additionally, the symptoms theoretically related to Cold and Heat are indicated by the red 
and blue color in the center column. In the figure the overlap in symptom use between theory 
and the experts is visualized, as well as the overlap between the two experts. The Cold 
symptom 'aversion to cold' with a large loading in dimension three shown in Figure 3B was 
indeed indicated by both experts as important, although one expert assigned this symptom a 
lower status. Of the Heat symptoms with a large loading in dimension three 'warm feeling' 
was deemed important by both experts. 'Dry mouth s', 'nervous' and 'restless' were important 
for one expert, while 'thirst f' was mentioned by neither expert. Figure 4 also shows that both 
experts used a larger set of symptoms to rank Cold and Heat than indicated by theory. 
Furthermore, both experts indicated to have used symptoms that are not related to Cold and 
Heat according to theory. This might be due to differences between various Chinese medicine 
schools and to experience with using symptoms in daily practice.  
 
In the following analysis the Cold and Heat rankings are introduced into the model with a 
large weight to find the symptoms that are most closely related to the expert rankings, based 
on the patients scores. Figure 5A is a bi-plot in which the patients scores and Cold and Heat 
ranking loadings are both plotted in the component space. The position of a patient point 
relative to the Cold and Heat loadings indicates the Cold and Heat ranking of the patient. 
Patients in the upper part of the figure for example have a high Cold ranking while patients in 
the right part of the figure have a high Heat ranking. Figure 5A shows that the distances 
between the various ranking categories is not equal. Additionally the distance between  
category 3 in Heat 1 and Heat 2 is large indicating that a Heat ranking of 3 for expert 1 
should be interpreted very different from a Heat ranking of 3 for expert 2. To see whether the 
Cold or Heat ranking has any relationship with the type of arthritis the patients suffer from 
the outline of the largest groups of patients, the rheumatoid arthritis (RA) and osteoarthritis 
(OA) patients, are marked by lines. Clearly, the scores of the OA and RA patients are 
overlapping and is therefore unrelated to the Cold and Heat rankings. 
In Figure 5B shows the loadings resulting from the forced classification analysis. The Heat 
rankings have a high positive loading in the first dimension and the Cold rankings have a 
high positive loading in the second dimension. This loadings plot reveals which symptoms, 
and related questions, are most related to the Cold and Heat rankings. 'Aversion to cold', 'fear 
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of wind' and 'pain aggravates with cold' are most related to the Cold rankings and 'aversion to 
heat', 'fullness of chest' and 'dry mouth' to the Heat rankings. 'Aversion to cold' and 'fear of 
wind' also have a fairly high positive loading in the third dimension (indicating Cold) of the 
unsupervised approach (Figure 3B). 'Fullness of chest' and 'dry mouth' have a fairly high 
negative loading in the third dimension (indicating Heat) of the unsupervised approach. 
The results of this study are summarized in Figure 4. First of all the symptoms used in theory  
to determine the Cold and Heat status of patients are indicated with a blue and red 
background respectively. 'Fever' and 'swollen joints' have a brown background since they are 
bridge symptoms between Heat and Cold. Secondly, the figure shows that both experts 
reported they used most of the theoretical symptoms. Seven symptoms that were not used by 
either expert are placed at the bottom of the list. Thirdly, the figure shows the agreement and 
disagreement between the experts on symptom use. In the fourth place, the symptoms 
resulting from the forced classification analysis are marked by bold type face.  
Of the Western symptoms for rheumatoid arthritis 'joint pain' is indicated as a Heat symptom 
in Chinese diagnosis, 'stiff joints' is indicated as a Cold symptom and 'swollen joints' is 
indicating both Cold and Heat. However neither expert used 'swollen joints' and 'joint pain' to 
rank the Cold or Heat status of the patients. 'Weak limbs', another RA symptom showed up in 
the forced classification as an important indicator for Heat. Some pain related symptoms 
which can be present in various rheumatic diseases appear to be relevant for Cold and Heat 
ranking. 'Pain with redness and swelling' is indicated by both experts and theory as an 
important Heat symptom. 'Stabbing pain' on the other hand is indicated by one expert as a 
Cold symptom. 'Heavy pain' was not mentioned by the experts, but according to theory it is a 
Cold symptom. Additionally the results of the analysis show that emotional symptoms more 
prevalent in fibromyalgia patients are more related to Heat, especially the symptom 'nervous' 
is mentioned in theory as a Heat symptom and is also an important Heat indicator in the 
forced classification results.  
The combination of the patient questionnaire scores information with the analysis and expert 
rankings resulted in a set of symptoms that are most qualified to develop into a tool to 
determine the Cold and Heat status of patients in a clinical setting. 
 
Conclusions 
This study introduced a systems diagnosis approach, the collection of a large number of 
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symptoms that are usually not used in clinical diagnosis in Western medicine, as an additional 
dimension of looking at patients with a rheumatic disease. Individual patient scores on this 
questionnaire can be visually presented in a graph to help the interpretation of the 
relationships between the symptoms occurring in that patient (Figure 2). This new method of 
'symptom fingerprinting' is comparable to other systems biology fingerprinting tools to 
determine disease state, risk for a disease, and chances of treatment effect [47-49]. 
The systems diagnosis questionnaire results of 49 patients with a rheumatic disease in this 
study reveal two interesting and significant dimensions of information. One dimension is  
related to the stage of the disease with the key symptoms 'anxious', 'worrying', 'uneasy 
feeling' and 'distressed' for the Internal stage, and 'aggravate in wind', 'fear of wind' and 
'aversion to cold' for the External stage. The concept of Internal and External is widely used 
in Chinese medicine to choose the right treatment option. The fact that this concept explains 
12.5% of the total variation in the data shows that it might be a relevant difference in other 
patients with rheumatic diseases as well.  
The second interesting dimension is related to the Cold and Heat status of the patients, 
explaining 10.4% of the variation in the data. The key symptoms are 'panting s', 'superficial 
breathing', 'shortness of breath s', 'shortness of breath f' and 'aversion to cold' for the Cold 
status and 'restless', 'nervous', 'warm feeling', 'dry mouth s' and 'thirst' for the Heat status. A 
forced classification approach revealed that 'Aversion to cold', 'fear of wind' and 'pain 
aggravates with cold' are related to the Cold rankings and 'aversion to heat', 'fullness of chest' 
and 'dry mouth' are related to the Heat rankings by two Chinese medicine experts in these 49 
patients. The characterization of the Cold and Heat status in this study is limited by the 
patient reported symptoms and might be improved by including observations of an expert of 
the patient. 
We believe that the future of medicine lies in an integration of perspectives on disease, health, 
prevention and medicine. Looking in more detail and at the same time more comprehensively 
at patients is the way forward towards personalized medicine [5,50]. One step in that 
direction is finding new sub-groups of patients and optimizing treatment for these sub-
groups. For Chinese medicine practitioners it is standard to take the Internal or External 
status as well as the Cold or Heat status into account for choosing the best treatment option. 
This study characterizes the symptoms related to these subgroups which might be used to 
develop a diagnostic tool to diagnose these subgroups in clinical practice. Further studies are 
needed to examine differences in response to medication by Cold and Heat sub-groups of 
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arthritis patients. In this way the combination of Chinese medicine concepts with Western 
therapeutic options offers exciting opportunities for more personalized treatment and 
eventually personalized health. 
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Hartelijk dank voor het meewerken aan dit onderzoek naar de diagnose van patiënten met een 
reumatische aandoening. Het invullen van de vragen zal ongeveer een kwartier duren. 
 
Gelieve alle vragen in te vullen. Indien geen antwoord mogelijk is dit graag vermelden. Alle informatie 
zal vertrouwelijk worden behandeld. 
 
Voor het beantwoorden van de vragen wordt regelmatig gevraagd naar de Mate en of Frequentie van 
een symptoom. Hiertoe dient u een waarde van 1 tot en met 7 in te vullen, waarbij 1 overeenkomt met 






1. Algemene informatie 
Leeftijd aanvang ziekte  C-reactive protein   
Reumafactor  Hb  
ESR  ACR klasse  
 
Reguliere medische diagnose  
  
Wie heeft de diagnose gesteld?  
  
Reguliere medicatie + bijwerkingen  
  
Overige medicatie  
  









2. Locatie van de symptomen Antwoord  
Ervaart U een vol gevoel in de borst? 
- is dit gevoel vooral gelocaliseerd in het midden boven deel van de buik? 
Mate (1-7):             [  ] 
                          Ja/Nee 
 
Ervaart U een druk op de borst? Mate (1-7):             [  ]  
Ervaart U hoofdpijnen? Mate (1-7):             [  ] 
Frequentie (1-7):    [  ] 
 
Ervaart U een abnormaal bewustzijn van het kloppen van uw hart, stoort dit 
andere gedachten? 
Mate (1-7):             [  ] 
Frequentie (1-7):    [  ] 
 
Ervaart U een brandend gevoel van de huid? Mate (1-7):             [  ]  
Heeft U haaruitval? Mate (1-7):             [  ]  
Heeft U rode of paarsachtige plekken in of onder de huid? Mate (1-7):             [  ]  
  
3. Ademhaling Antwoord  
Is uw ademhaling oppervlakkig? Mate (1-7):             [  ]  
Heeft U last van hijgen? Mate (1-7):             [  ] 
Frequentie (1-7):    [  ] 
 
Ervaart U kortadmenigheid? 
 
- Vindt dit plotseling plaats? 
Mate (1-7):             [  ] 
Frequentie (1-7):    [  ] 
                          Ja/Nee 
 
Ervaart U een droge mond? Mate (1-7):             [  ] 
Frequentie (1-7):    [  ] 
 
Ervaart U regelmatig een droge keel? 
- Is deze droogheid gelocaliseerd in het bovenste deel van de keel? 
Frequentie (1-7):    [  ] 
                          Ja/Nee 
 
Geeft U slijm op bij het hoesten? Frequentie (1-7):    [  ]  
  
4. Klimaat Antwoord  
Voelt U zich koud? 
- Is deze koude vooral in de voeten of benen aanwezig? 
Mate (1-7):             [  ] 
                          Ja/Nee 
 
Ervaart U dorst? Mate (1-7):             [  ] 
Frequentie (1-7):    [  ] 
 
Ervaart U rillingen? Mate (1-7):             [  ] 
Frequentie (1-7):    [  ] 
 
Voelt U zich warm? Mate (1-7):             [  ]  
Heeft U soms koorts? 
- Gaat de koorts soms gepaard met rillingen? 
Frequentie (1-7):    [  ] 
                          Ja/Nee 
 
Ervaart U moeilijkheden met bewegen? Mate (1-7):             [  ]  
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Heeft U afkeer van hitte? Mate (1-7):             [  ]  
Heeft U afkeer van koude? Mate (1-7):             [  ]  
Ervaart U spontaan zweten of zweten bij de geringste inspanning? Mate (1-7):             [  ] 
Frequentie (1-7):    [  ] 
 
  
5. Spijsvertering Antwoord  
Is uw onderbuik pijnlijk of erg gevoelig? 
- Wordt dit gevoel versterkt door er op te duwen? 
Mate (1-7):             [  ] 
                          Ja/Nee 
 
Voelt uw buik gezwollen of uitgezet aan? Mate (1-7):             [  ]  
Ervaart U een vol gevoel in de buik? Mate (1-7):             [  ]  
Heeft U last van diarree? Frequentie (1-7):    [  ]  
Hoe vaak moet U boeren laten? Frequentie (1-7):    [  ]  
Hoe vaak moet U overgeven? Frequentie (1-7):    [  ]  
Ervaart U een onverzadigbare drang om te eten? Frequentie (1-7):    [  ]  
Ervaart U een slechte vertering? Mate (1-7):             [  ]  
  
6. Emoties & Gedrag Antwoord  
Bent U altijd in beweging? Mate (1-7):             [  ]  
Bent U gemakkelijk geïrriteerd? Frequentie (1-7):    [  ]  
Voelt U zich ongemakkelijk? Frequentie (1-7):    [  ]  
Vreest U wind of tocht? Mate (1-7):             [  ]  
Bent U bang? Mate (1-7):             [  ]  
Raakt U gemakkelijk in paniek? Frequentie (1-7):    [  ]  
Voelt U zich gestrest? Frequentie (1-7):    [  ]  
Maakt U zich zorgen? Frequentie (1-7):    [  ]  
Heeft U een ongemakkelijk gevoel? Frequentie (1-7):    [  ]  
Piekert U veel? Frequentie (1-7):    [  ]  
Voelt U zich nerveus? Frequentie (1-7):    [  ]  
Voelt U zich rusteloos? Frequentie (1-7):    [  ]  
Ervaart U nachtmerries? Frequentie (1-7):    [  ]  
Voelt U zich opgewonden? Mate (1-7):             [  ]  
Moet U vaak zuchten? Frequentie (1-7):    [  ]  
  
7. Kwaliteit van de symptomen Antwoord  
Kunt U de aangedane gewrichten buigen? 
- Kunt U de aangedane gewrichten strekken? 
                          Ja/Nee 
                          Ja/Nee 
 
Is het buigen en strekken van uw gewrichten beperkt? Mate (1-7):             [  ]  
Ervaart U een zwaar gevoel in uw ledematen, lichaam en of hoofd? Mate (1-7):             [  ]  
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Voelen de aangedane delen van uw lichaam zwaar aan? Mate (1-7):             [  ]  
Ervaart U een moe gevoel in uw ledematen, lichaam en of hoofd? Mate (1-7):             [  ]  
Ervaart U gevoelloosheid in het lichaam en ledematen? Mate (1-7):             [  ]  
Voelt uw huid gevoelloos en koud aan? Mate (1-7):             [  ]  
Voelt U stijfheid in uw gewrichten? Mate (1-7):             [  ]  
Heeft U gezwollen gewrichten? Mate (1-7):             [  ]  
Heeft U zwellingen in uw lichaam? Mate (1-7):             [  ]  
Voelt U zich moe na de geringste inspanning?                           Ja/Nee  
Voelen uw vier ledematen zwak? Mate (1-7):             [  ]  
Voelen uw pezen zwak? Mate (1-7):             [  ]  
Ervaart U moeilijkheden met het lopen? Mate (1-7):             [  ]  
Heeft U een gebogen rug en middel? 
- Heeft U moeite met recht op staan na buigen? 
Mate (1-7):             [  ] 
Mate (1-7):             [  ] 
 
  
8. Veranderingen in de symptomen Antwoord  
Verplaatsen de symptomen zich?                              
Ja/Nee 
 
Worden de symptomen erger wanneer het buiten winderig is? Mate (1-7):             [  ]  
Is het bovenste deel van uw lichaam gemakkelijker aangedaan dan het 
onderste deel van uw lichaam? 
                            
Ja/Nee 
 
Verschijnen de symptomen plotseling?                              
Ja/Nee 
 
Verandert het type symptomen? Mate (1-7):             [  ]  
  
9. Pijn Antwoord  
Heeft U last van lage rugpijn? Mate (1-7):             [  ]  
Heeft U pijn? Mate (1-7):             [  ]  
Waar ervaart U pijn? [Spieren] [gewrichten] [botten] [onderrug] [zij]  
Wat voor soort pijn ervaart U? [Zeurend] [stekend] [scherp] [diep] [zwaar] 
[dof] 
Komt de pijn langzaam, gradueel op?                           Ja/Nee  
Ervaart U verlamming in uw spieren? Mate (1-7):             [  ]  
Wordt de pijn erger met vochtig, mistig weer? Mate (1-7):             [  ]  
Wordt de pijn 's nachts erger? Mate (1-7):             [  ]  
Wordt de pijn erger bij koude en koud weer? Mate (1-7):             [  ]  
Wordt de pijn erger door te rusten? Mate (1-7):             [  ]  
Gaat de pijn gepaard met roodheid en zwelling?                           Ja/Nee  




10. Urineren Antwoord  
Hoe vaak moet U plassen? Frequentie (1-7):    [  ]  
Is de urine helder van kleur? Mate (1-7):             [  ]  
Ervaart U moeilijkheden bij het plassen? Mate (1-7):             [  ]  
Ervaart U pijn bij het plassen? Mate (1-7):             [  ]  
 











Hartelijk dank voor uw medewerking! 
Drs. Herman van Wietmarschen 
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7. Characterization of rheumatoid arthritis subtypes using 




Objective. The aim is to characterize subgroups or phenotypes of rheumatoid arthritis (RA) 
patients using a systems biology approach. The discovery of subtypes of rheumatoid arthritis 
patients is an essential research area for the improvement of response to therapy and the 
development of personalized medicine strategies. 
Methods. In this study 39 RA patients are phenotyped using clinical chemistry measurements, 
urine and plasma metabolomics analysis and symptom profiles. In addition a Chinese 
medicine expert classified each RA patient as a Cold  or Heat type according to Chinese 
medicine theory. Multivariate data analysis techniques are employed to detect and validate 
biochemical and symptom relationships with the classification. 
Results. The questionnaire items 'Red joints', 'Swollen joints', 'Warm joints' suggest 
differences in the level of inflammation between the groups although c-reactive protein 
(CRP) and rheumatoid factor (RHF) levels were equal. Multivariate analysis of the urine 
metabolomics data revealed that the levels of 11 acylcarnitines were lower in the Cold RA 
than in the Heat RA patients, suggesting differences in muscle breakdown. Additionally, 
higher dehydroepiandrosterone sulfate (DHEAS) levels in Heat patients compared to Cold 
patients were found suggesting that the Cold RA group has a more suppressed hypothalamic-
pituitary-adrenal (HPA) axis function. 
Conclusion. Significant and relevant biochemical differences are found between Cold and 
Heat RA patients. Differences in immune function, HPA axis involvement and muscle 
breakdown point towards opportunities to tailor disease management strategies to each of the 
subgroups RA patient. 
 
Based on: Herman A van Wietmarschen, Weidong Dai, Anita J van der Kooij, Theo H Reijmers, Yan Schroën, 
Mei Wang, Zhiliang Xu, Xinchang Wang, Hongwei Kong, et al. (2012) Characterization of rheumatoid arthritis 




Discovering subtypes of rheumatoid arthritis (RA) patients is considered a key research area 
for the improvement of response to therapy (1,2). RA is a heterogeneous disease which is 
illustrated by the very good response of some patients to a biological therapy, but a complete 
lack of response in a large number of other patients (3). Another striking observation is that in 
a large group of RA patients low disease activity or remission can be achieved using a single 
conventional disease-modifying anti-rheumatic drug (DMARD), which contrasts with the 
current viewpoint to offer aggressive therapy in an early stage of the disease to all patients 
(4). Personalized medicine aims to provide the information that allows targeting the right 
treatment option to the right patient (5). The first step in this approach is to find relevant 
subtypes of patients for which a different treatment strategy would clearly be beneficial. 
Several subtypes of RA patients have been identified based on particular clinical and 
molecular features (6,7). Markers such as disease duration and age have been identified that 
predict response to treatment (8,9). Although some molecular markers have been found to 
predict functional and structural outcomes, these markers rarely find their way into clinical 
practice. One reason is the difficulty to translate markers found in trial populations to 
routinely measurable and cost-effective predictors for individuals (10). This indicates that 
there is a need to develop new robust and reliable clinically applicable tools to identify 
subtypes of patients.  
Discovery of novel relevant subtypes of RA patients could be improved by using prior 
knowledge. In this study a Chinese perspective on subtypes of RA patients is used to focus 
the analysis of the data. According to this perspective RA patients can be divided in two 
groups (Cold RA and Heat RA) which are treated very differently in Chinese medical practice 
(11,12).  
Cold and Heat are general concepts used in Chinese medicine to distinguish between two 
types of reactions of the body to some disturbance (13). A Cold reaction is characterized by 
pallor, intolerance of cold, absence of thirst, loose stools, clear profuse urine, a pale tongue 
and a slow pulse. A Heat reaction is characterized by flushed face, fever, thirst, irritability, 
restlessness, constipation, deep-colored urine, reddened tongue and a rapid pulse (14). These 
two types of reactions are expressed in any type of disease to a certain extend. However, Cold 
and Heat are especially important for rheumatoid arthritis because this disease is perceived in 
classical Chinese medicine as the result of an invasion of three out of the four existing 
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external pathogens: Wind, Cold, Heat and Damp (13). 
Some work has been done to elucidate biological mechanisms related to Cold and Heat types 
of RA patients. In 2009 we measured 64 differently expressed genes in CD4 positive T-cells 
of RA patients. This set of genes was enriched for the immune system functions and 
especially for apoptosis regulation. In Heat RA patients apoptosis related genes were 
upregulated while in Cold patients apoptosis resitance genes were upregulated (11). 
Additionally, a number of plasma metabolite concentrations was significantly different 
between Cold and Heat RA. Later, genes related to calcium signaling, cell adhesion, PPAR 
signaling and fatty acid metabolism were found in CD4 positive T-cells of Heat RA patients 
(15). Toll-like receptor signaling related genes were found in the T-cells of Cold RA patients. 
In a similar study, Cold RA was related to Alanine, aspartate and tyosine metabolism and 
Heat RA to the MAPK pathway, Wnt signaling and insulin signaling, also found by 
measuring gene expression in CD4 positive T-cells (16). A GC-MS analysis of Cold and Heat 
RA plasma revealed elevated plasma levels of glycochenodeoxycholate, proline, saturated 
and mono-unsaturated phosphatidylcholine (PC) but decreased levels of urea, free fatty acid 
(FFA) and polyunsaturated PC in Heat RA compared to Cold RA (17). 
Recently it was shown that Cold RA patients respond much better to a combination therapy 
with diclofenac, methotrexate and sulfasalazine than Heat RA patients (18). However, in 
clinical studies and clinical practice the  features of Cold and Heat might be valued 
differently by each Chinese medicine practitioner . To improve acceptance of this 
classification in Western clinical practice it is important to standardize the classification. 
Further characterization of the physiological, constitutional and biological differences 
between the Cold and Heat subtypes of RA patients is valuable for increasing our 
understanding of the disease mechanism. 
In this study a systems biology strategy is employed to study the differences between Cold 
and Heat types of RA patients, classified by a Chinese medicine expert. Data were collected 
on symptoms, clinical blood parameters and urine metabolites. Multivariate statistics were 
employed to discover the most discriminating features for the two groups. In particular, a 
categorical principal component analysis (19,20) was used for the questionnaire and clinical 
chemistry data and partial least squares discriminant analysis is used for the metabolomics 
data (21). The questionnaire was used to determine symptom patterns related to Cold and 
Heat RA that could be used in clinical practice to determine these subtypes in an objective 
manner. The metabolomics and clinical results were related to biological processes and 
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related to current understanding of the heterogeneity of rheumatoid arthritis. 
 
Subjects and methods 
Subjects 
Female subjects were recruited in the Zhejiang Xinhua Hospital in 2010. The institutional 
review board of the hospital gave written approval and judged that the study was conducted 
according to the ethical guidelines. A doctor explained the details of the study to the subjects 
and ensured written informed consent of each subject. All eligible subjects were diagnosed by 
a rheumatologist as rheumatoid arthritis patients according to the ACR criteria (22). Inclusion 
criteria were a female gender due to the much higher prevalence of RA in women and age > 
18 years. Each patient was classified by the same Chinese medicine expert as either a Heat 
subtype or a Cold subtype. When the subtype was unclear the patient was not included in the 
study. General information such as age, disease duration, medication, etc. was collected using 
a standard form. Student's t-Test (two-tailed) was used to evaluate the differences between the 
two groups. Furthermore, a symptom questionnaire was completed by all the patients. Blood 
and urine samples were taken from each patient after fasting overnight for routine clinical 
measurements and metabolomics analysis. 
 
Symptom Questionnaire 
A short version of a recently developed systems diagnosis questionnaire was used in this 
study (23). The 106 item questionnaire was shortened to 57 items by two Chinese medicine 
experts to target it more directly to Cold and Heat related symptoms. The final version of the 
questionnaire contained  items related to five categories of symptoms: breathing, digestion, 
climate, quality of the symptoms and pain. The questionnaire was translated into Chinese. An 
English language version of the questionnaire is added as supplementary information (Text 
S1). The consistency of the data was checked and the data were recoded (23).  
 
Clinical measurements 
Routine clinical chemistry measurements were conducted on fasting blood samples by the 
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Zhejiang Xinhua Hospital. These measurements consisted of the complete blood count and 
the following serum measurements: uric acid (URIC), creatinine (CREA), blood urea 
nitrogen (BUN), triglycerides (TG), cholesterol (CHOL), total protein (TP), albumin (ALB), 
globulines (BIB), aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatine 
kinase (CK), creatine kinase-MB (CKMB), lactate dehydrogenase (LDH), immunoglobulin A 
(IGA), Immunoglobulin G (IGG), immunoglobulin M (IGM), complement 3 (C3), 
complement 4 (C4), antistreptolysin O (ASO), rheumatoid factor (RHF), c-reactive protein 
(CRP), anti-cyclic citrullinated protein antibodies (CCP). The results of each clinical 
parameter were uniformly binned into 19 categories to increase the robustness (19). 
 
Metabolomics measurements 
Urine samples were prepared for Ultra Fast LC/MS-IT-TOF (Shimadzu, Japan) analysis (24). 
The technical variation of the analysis over time was monitored by a pooled quality control 
(QC) sample strategy (25). The analysis was performed on a Ultra Fast LC/MS-IT-TOF  with 
gradient elution using 0.1% formic acid in water as mobile phase A and 0.1% formic acid in 
acetonitrile as mobile phase B. For the LC a T3 column (ACQUITY UPLC HSS T3 1.8um, 
2.1x100 mm, Waters) was used. Ion mode was switched between positive and negative mode 
between each scan (24). 
Sample preparation for the plasma metabolomics analysis was conducted as follows: 200 μL 
plasma was mixed with 800 μL acetonitrile, then the mixture was centrifuged at 14000 rpm 
(Biofuge Stratos, Thermo Scientific, USA) for 10 min at 4℃. The supernatant was freeze-
dried and redissolved with 200 μL of 20% acetonitrile. 
Chromatographic separation was performed on a BEH C8 column (10 cm×2.1mm, 1.7 μm, 
Waters, USA) using a Thermo Fisher Accela LC system. The gradient duration was 31 min at 
a flow rate of 300 μL/min with mobile phase (A) 0.1% formic acid solution and (B) 
acetonitrile. The injection volume was 6μL. The samples were analyzed randomly and the 
same QC strategy was used as in the urine analysis. 
An LC-MS method was used to measure the plasma metabolites. The LTQ-Orbitrap XL 
(Thermo-Fisher Scientific) settings were as follows: capillary temperature 325 ℃, source 
voltage 4.5 kV, capillary voltage 49 V for ESI+ analysis; capillary temperature 325 ℃, source 
voltage -3.5 kV, capillary voltage -40 V for ESI- analysis. The mass range was set at 100-
1000 m/z. The resolution of the Orbitrap was set at 30000. 
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The urine metabolomics measurements resulted in a list of features after preprocessing the 
data using Profiling Solution (Shimadzu, Japan) (24). The plasma metabolomics data were 
processed by SIEVE software (V1.2, Thermo-Fisher Scientific) for peak picking and peak 
alignment. The parameter of MZ width was set at 0.01 Da and RT width was set at 0.6 min. 
Gradient peaks were removed. Features not present in at least 80% of the samples in one 
class were removed. Zeros were replaced by the smallest measured value divided by 2, the 
urine data were mean centered and the plasma data was autoscaled. Principal component 
analysis was then used to screen the data for outliers (objects with scores deviating from the 
scores of the bulk of the samples) (26), to determine the stability of the analysisover time (by 
comparing the scores of the QC samples) and monitor possible batch effects (by checking 
possible time trends in the scores of the objects). 
 
Statistical analysis 
Questionnaire and clinical chemistry data. The focus of the data analysis is to identify 
questionnaire items and clinical parameters that distinguish between the subgroups of RA 
patients classified by the CM expert. A forced classification approach (27) using Nonlinear 
Principal Component Analysis (NLPCA) was chosen.  NLPCA is a Principal Component 
Analysis method that is suitable for variables with mixed measurement level and variables 
that may have nonlinear relationships to each other (19). The possibility to capture nonlinear 
relationships is important because the human body is a nonlinear system expressing complex 
behavior (28). Such complex behavior has been observed in the immune system that plays a 
key role in rheumatoid arthritis. For instance cytokine dose response curves show an initial 
threshold and stable attractors have been found in cytokine systems (29). More important is 
the ability of NLPCA to deal with the questionnaire data that are measured on an ordinal 
scale or as binary data. The questionnaire data analysis approach using NLPCA is described 
in detail in a previous paper (23). 
NLPCA uses an 'optimal scaling' approach to find quantifications for categorical variables 
and optimal transformations for interval variables, which means that the percentage of 
variance of the transformed variables accounted for by the principal components is maximal 
(30). The questionnaire items and clinical parameters were all included in a single NLPCA 




The use  of a the classification variable with a very large weight, here 1000 will cause the 
objects to cluster together into subclouds in the object space. The weight was chosen such 
that the objects of both classes were separated completely. As the classification variable is a 
binary variable, one principal component is sufficient to describe the class differences. In this 
study we used CATPCA in SPSS version 17.0 (31). 
An important consideration in NLPCA is the analysis level chosen for the variables (20). For 
the questionnaire variables the analysis level was kept the same as the measurement level (39 
ordinal and 3 nominal). Subsequently the presence of nonlinear relationships between the 
clinical chemistry variables and the classification variable was examined by comparing 
numerical, spline ordinal and spline nominal transformations of the clinical chemistry 
variables (i.e., from most restricted to least restricted transformations). A substantial increase 
in the total variance accounted for (total VAF) due to an analysis level with more degrees of 
freedom then verifies that a less restrictive model is more appropriate.  
After choosing the appropriate analysis level, variables with a proportion variance accounted 
for (VAF) > 0.20 were selected for further analysis to increase the stability of the model and 
to focus on the most important variables. Leave two out cross validation was used to estimate 
the classification error of the model. In this approach two objects are reserved as a validation 
set while a NLPCA model is built using the other 37 objects. The class of the two left out 
objects is then predicted using the NLPCA model. This procedure is repeated until each of the 
objects is left out once and the class of each object is predicted. An overall classification error 
is subsequently calculated and a final model is built using all the available objects. 
Permutation testing was used to check whether this final model is different from a model 
based on a random classification. 
Metabolomics data.  A partial least squares discriminant analysis (PLS-DA) model was built 
for both the urine and plasma data set to find the most discriminating features between the 
Cold RA and Heat RA groups , a standard, well accepted technique used in the metabolomics 
field to discover characteristic differences between groups (32). A separate model for the 
urine and plasma data was built to examine the performance of a metabolite profile measured 
in one compartment in a single analysis. Such a profile would be much easier to develop into 
a diagnostic tool that can be applied in a clinical setting than a combination of two 
metabolomics profiles.  
A tenfold double cross-validation scheme was followed by permutation testing (250 times) 
(33). The inner loop of the cross-validation scheme is used to estimate the optimal number of 
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principal components. In this inner loop two objects are left out to validate the number of 
principal components. The outer loop is used to estimate the error rate of the model. Again, in 
the outer loop two objects are left out to independently estimate the error rate. Variables were 
selected using a jack-knifing procedure in which variables with a standard error in the 
regression vector above a threshold were removed from the dataset. This threshold is 
decreased stepwise until the error rate of the model starts to increase. The model with the 
lowest error rate is then chosen as the optimal model and a final model is then built for the 
corresponding set of variables and including all the objects. Subsequently, the significance of 
the resulting model is determined by permutation testing. The same double cross-validation 
procedure is used to build a model of the same data set but with a permuted classification. 
After 250 times permuting the classification, the classification error of the 250 models 
resulting models is compared with the classification error of the model based on the correct 
classification. The error rate of the correct classification model should be lower than 95% of 
the distribution of error rates resulting from the permuted classifications.  
Identification of the most discriminating features indicated by the PLS-DA model was then 
attempted for both the urine and plasma model (34). Evidence for the identity of features was 
accumulated by integrating information on the following: accurate mass of the ions and some 
fragments, retention time, HMDB database and in house human urine compound lists. The 
identification of some compounds was then verified by authentic standards. Finally, a 




In total 50 patients were enrolled in the study. Eleven of these patients did not fulfill the 
inclusion criteria and were removed from the analysis. Seven of those eleven patients were 
male and therefore excluded, of two persons there was no RA diagnosis available, one patient 
was in the hospital for other reasons and therefore excluded and finally one person was 
excluded from this analysis because the symptom questionnaire was not completed. Finally, 
20 RA patients of the Cold subtype and 19 of the Heat subtype were retained in the study.  
Table 1 shows the patient characteristics per group expressed as the means of the age, disease 
duration, height and weight. None of these characteristics were significantly different (p-
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value < 0.05) between the Cold RA and Heat RA patient groups. 34 patients received western 
medication such as methotrexate, sulfasalazine. other DMARD's and NSAID's. 36 patients 
received Chinese herbal medicine. 
 
Clinical and symptom differences between RA subtypes 
After merging scoring categories containing less than 7 observations, 15 variables were left 
with only a single category. There is no variation between the objects for these variables 
which were therefore removed from the analysis: 'Sudden shortness of breath', 'Amount of 
phlegm', 'Sticky phlegm', 'Colored phlegm', 'Tender lower abdomen', 'Aggravated with 
pressure', 'Smelly diarrhea', 'Chills S', 'Chills F', 'Fever with Chills', 'Pain aggravates at night', 
'Stabbing pain', 'Sharp pain', 'Deep pain', 'Heavy pain'. After recoding, the data set used for 
further analysis contained 42 variables.  
In the forced classification model the use of a 2nd degree (quadratic) nonmonotonic spline 
(nominal analysis level) with 2 interior knots for the clinical measurements shows 
substantially larger variance accounted for (11.8%) than a monotonic spline (ordinal analysis 
level) (8.2%), indicating a nonmonotonic relationship between the measurements. Also, a two 
interior knot spline shows a larger variance (11.8%) than a one interior knot spline (9.8%) 
(more knots allow for more freedom in the transformation). Therefore a 2nd degree spline 
nominal analysis level with two interior knots was chosen for the clinical chemistry variables. 
A new model was then built using this analysis level and used to select variables with a 
proportion of VAF > 0.20. A model was subsequently built including the 18 selected 
variables. The model using splines with 2 interior knots for the clinical chemistry variables 
was then compared once more with a model using one interior knot. The results showed that 
the increase in total VAF in the model with 2 interior knots was mostly due to the variable 
MCHC. Therefore the final analysis level of the clinical variables was adjusted to a 2nd 
degree spline with 1 interior knot, except for MCHC which was set to 2 interior knots. The 
final model had a total VAF of approximately 21% (see Table 2 for the loadings of the 18 
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variables). The transformation plots of the clinical chemistry variables of this model are 
included as supplementary information (Figure S1). Leave two out cross validation resulted 
in a classification error of 15%, which is substantially lower than the expected error rate 
based on random classification (which is 50%).  
RA patients that are classified as Heat by the Chinese medicine expert are characterized with 
higher optimal quantifications on average on the symptoms 'red joints', 'swollen joints', 'warm 
feeling', 'warm joints', 'dull pain' and 'pain that worsens with warmth and movement', and 
with higher levels of the optimally scaled clinical parameters mean corpuscular hemoglobin 
concentration (MCHC), IgG, lymphocyte number (LY#), IgM, platelet count (PLT) and 
cholesterol. Cold RA patients are best characterized with higher optimal quantifications on 
average on the symptoms 'cold feeling' and 'aversion to cold', and higher levels of the 
optimally scaled clinical variables blood urea nitrogen (BUN), alanine aminotransferase 




Both groups of patients have a similar average score on the symptoms 'pain' and 'stiff joints' 
as well as on the clinical parameters rheumatoid factor and c-reactive protein. 
 
Urine and plasma metabolite differences between RA subtypes 
Urine samples of 14 of the 19 Heat RA and 14 of the 20 Cold RA patients included in the 
analysis described above were collected successfully for the LC-MS analysis. In total 11 
urine samples were either not collected at the hospital or the samples were not send to the 
laboratory for metabolomics analysis. PLS-DA analysis resulted in a  final model containing 
793 features. A classification error of 14% was obtained by a double cross-validation 
procedure. Permutation testing indicated that the error rate of this model is significantly 
(p<0.05) different from the distribution of models based on permuted classifications.  
The tentative identification of the top 50 most discriminating metabolites resulted in three 
metabolites that were verified by comparing authentic standards with the samples: 
acetylcarnitine, riboflavin and pantothenic acid. Thirteen of the top features measured in 
positive ion mode as well as the acetylcarnitine standard showed the same neutral loss of 
mass 59.0747 by fragmentation, which is highly indicative of acylcarnitine compounds 
(35,36). The retention times of the features showing this loss was increasing with the mass, 
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indicating higher mass features were less polar. This agrees with the fact that larger mass 
acylcarnitines have longer fatty acid chains and are therefore less polar. Furthermore, several 
glucuronides and soy isoflavones are suspected, but the identity was not further determined 
(Table 3).  
 
An LC-MS analysis of the plasma samples of 11 Cold RA and 14 Heat RA patients from the 
same set of patients that are used in the urine metabolomics and questionnaire analysis was 
performed. Three plasma samples were not available for analysis. Positive ion mode features 
were not included in the multivariate analysis because the QC samples were not stable. The 
PLS-DA analysis resulted in a  model containing 214 features (classification error of 28%). 
Permutation testing indicated that the error rate of this model is significantly (p<0.05) 
different from the distribution of models based on permuted classifications. Some of the top 
50 features resulting from the PLS-DA model could be identified with authentic standards 
(Table 4).  
 
Discussion 
The subtypes of RA patients are characterized by four sets of features: clinical symptoms 
(questionnaire items), clinical chemistry measurements in blood, metabolite measurements in 
urine and in plasma. One hypothesis is that the Cold RA and Heat RA groups have a different 
inflammatory status. Of the most discriminating symptoms in the analysis, 'warm joints', 
'swollen joints' and 'red joints' indicate a difference in inflammatory status. However, c-
reactive protein (CRP), an important inflammation marker, was not retained in the final 
model because of  a low proportion of total variance accounted for, based on the two groups. 
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Rheumafactor (RF), an important marker for RA disease activity (37), was not retained in the 
model either. On the other hand, the lymphocyte numbers are higher in Heat RA patients, 
although this level is not considered elevated and indicative of inflammation in standard 
evaluation (38). A comparable average disease duration of 90 and 100 months for the two 
groups suggests that not one of the groups can be considered an early arthritis or early 
aggressive arthritis group. These observations indicate that the severity of inflammation 
might be different between the groups when the joint symptoms are considered despite 
similar levels of rheumatoid factor and c-reactive protein. 
 
Swollen joint counts are routinely used to establish disease activity in rheumatoid arthritis 
(39). In Table 5 the percentages of Cold and Heat patients with a positive score on zero to 
three of the symptoms 'warm joints', 'swollen joints' or 'red joints' are given. Even though 
high scores on the three symptoms are indicative for the Heat group of RA patients, 40% of 
the Cold patients also have a positive score on at least one of the three symptoms (frequencies 
of the scored categories per class are included as supplementary information Figure S2 and 
the raw symptom score data for 'swollen joints', 'warm joints' and 'red joints' is included as 
supplementary Table S1). The data indicate that the same number of patients in both groups 
are in pain and score a similar severity of pain (data not shown). These symptom observations 
indicate that the Heat RA group has much more joint problems than the Cold RA group. It 
would be interesting to further study the role these joint symptoms could play in sub-typing 
RA.  
Our study shows that the important symptoms for the sub-typing are 'warm feeling', 'pain 
worsens by warmth and movement', 'cold feeling' and 'aversion to cold'. This is in agreement 
with a previous study in which a systems diagnosis of 49 patients with rheumatic diseases 
revealed 'aversion to cold', 'aversion to heat' and 'cold feeling' as highly relevant for the Cold 
and Heat ranking of the subjects (23). The symptom 'aversion to cold' and coldness in general 
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was found by others as well (12,40). Our study and other studies of the biology of Cold and 
Heat types of RA patients lead to the hypothesis that the currently unclear effectiveness of 
cold and heat therapy might be improved by targeting it to the right sub-type (41-43).  
Anti-citrullinated protein antibody (CCP) is extensively studied as a  predictor of disease 
progression in RA (44). In our multivariate model, CCP levels were higher in RA Heat 
patients suggesting that there might be a difference in disease progression between the two 
subtypes. The clinical parameters with the highest positive loadings were MCHC and IgG, 
while RDW showed the highest negative loading next to CCP.  Some relationships between 
the Cold and Heat subtype and clinical measurements are nonlinear (see supplementary 
Figure S1 for the transformations of the variables). High as well as low serum levels off 
MCHC result in a positively transformed value, which is related to the Heat class. The 
highest levels of IgG are related to the Cold RA type, while lower levels are not so clearly 
Cold or Heat related. Blood urea nitrogen (BUN) levels increase in plasma with serious 
kidney damage (45). Higher or lower levels of BUN are related to the Heat RA group, 
average levels are related to the Cold RA group. Alanine aminotranferase (ALT) is an 
important parameter to distinguish Cold and Heat patients, which has been found to be 
related to insuline resistance and atherosclerosis risk in RA patients (46). 
The metabolomics analysis in this study revealed higher urine levels of 11 acylcarnitines in 
the Heat group of RA patients. The enzyme carnitine palmitoyltransferase I (CTP I), located 
in the outer mitochondrial membrane, transfers acyl groups from coenzyme A to carnitines 
allowing the transport of fatty acids into the mitochondria for β-oxidation. Plasma carnitine 
levels are maintained by a combination of dietary intake, endogenous synthesis by the liver 
and kidneys and active renal reabsorption. Acylcarnitines can leave the mitochondria, enter 
the blood stream and can be excreted in urine (47). 
Significantly lower total carnitine and acylcarnitine excretion in urine of RA patients 
compared to healthy controls has been reported , while free carnitine levels in urine and 
plasma are equal in both groups (48, 49). Because dietary intake of carnitines was equal in 
both groups, an impaired carnitine synthesis was suggested which is controlled by skeletal 
muscle breakdown. Decreased muscle mass and increased muscle turnover are observed in 
RA patients, which might be explained by a reduced CTP I activity. This was confirmed by a 
decreased creatinine and 3-methylhistidine excretion (49). In this study we find that the levels 
of a range of acylcarnitines are lower in the Cold RA group than in the Heat RA group. These 
findings suggest that Cold RA patients have less muscle mass and/or a more pronounced 
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muscle breakdown than RA Heat patients. A limitation of this study is that the plasma 
acylcarnitine levels are not known. Further studies should therefore be performed to validate 
the hypothesis that Cold and Heat subtypes of RA patients are related to muscle mass or 
muscle breakdown. 
Decreased urine pantothenic acid  and acylcarnitine levels have been shown to indicate an 
increase in beta-oxidation in patients using PPARα agonist drugs (50). Peroxisome 
proliferator-activated receptors (PPAR) activate fatty acid and cholesterol catabolism in the 
liver, activate gluconeogenesis and regulate amino acid metabolism. In addition, PPAR 
activates CTP I and CTP II activity. We report lower levels of pantothenic acid and 
acylcarnitine levels in Cold RA patients which might therefore indicate a difference in the 
activation of PPAR between the groups. 
Interestingly, CTP I activity is inhibited by omega-6 fatty acids while an increased ratio of 
omega-3 versus omega-6 fatty acids consumption stimulates fatty acid oxidation regulated by 
CTP I activity (51). A decrease in CTP I activity also seems to play a role in Chronic Fatigue 
Syndrome patients. In these patients supplementation with carnitine and acylcarnitine was 
found to decrease fatigue symptoms (52). These findings suggest that fatigue in rheumatoid 
arthritis might be related to a decreased CTP I activity and a changed carnitine homeostasis. 
Fatigue is one of the most important factors in the disease experience of RA patients (53). 
Our findings indicate that urine acylcarnitine levels are an important discriminator between 
two subtypes of RA patients, which might explain differences in the experience of fatigue. 
These findings also suggest that carnitine and acylcarnitine supplementation might be 
beneficial for Cold RA patients and less so for Heat RA patients. Further confirmatory studies 
should be conducted to prove this hypothesis and develop this targeted treatment option. 
Significantly lower DHEAS levels have been reported in premenopausal RA patients and are 
correlated to low morning cortisol levels and high IL-6 levels indicating a suppression of 
HPA-axis function (54). Decreased HPA-axis function is associated with a decreased stress 
response which results in an inadequate response to stress factors. It is hypothesized that this 
inadequate response can lead to autoimmune and inflammatory disorders (54). This study 
shows a higher DHEAS levels in Heat RA patients compared to Cold RA patients suggesting 
that the Cold RA group has a more suppressed HPA-axis function. A text mining study (55) 
has shown that diseases related to Cold according to Chinese medicine theory are more 
related to hormone function disturbances and Heat related diseases to immune function 
disturbances, which is in agreement with our findings. 
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This study provides  metabolite, symptom and clinical chemistry profiles for two subtypes of 
rheumatoid arthritis. The profiles indicate a number of biological processes that seem to be 
regulated differently in the two groups. RA therapy could be optimized for the two groups in 
various ways. This study suggests differences in the effects of carnitine and acylcarnitine 
supplementation for the two groups as well as differences in the effects of hormone 
treatments such as prednison. We think that the better characterization and biological 
understanding of Cold and Heat RA offered in this study can be used to tailor therapy to each 
subgroup. Additionally, this study offers a new subtype to include in studies aiming for an 
improvement of response to treatment. Finally, the mechanism and effect of specific Cold RA 
and Heat RA treatment options used in Chinese medicine should be studied and might be 
integrated in standard disease management strategies by using a standardized Cold RA and 
Heat RA diagnostic profile.   
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Figure S1. Transformation plots of the clinical chemistry variables. On the x-axis the 
categories of the original discretized variables are represented while on the y-axis the 
optimally scaled quantifications are shown. A negative quantification corresponds to the Cold 















Table S1. Raw data of 'swollen joints', 'warm joints' and 'red joints' scores acquired by the 
symptom questionnaire. 
Patients were asked to give a score between 1 and 7. For the construction of Table 5 the 
positive scores, scores higher than 1, were counted for the Cold RA and Heat RA group. In 
Table S1 mean ranks for the Cold RA and Heat RA groups are given for each symptom and 
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the differences between the groups are evaluated with the Mann-Whitney U test. The scoring 
of the three symptoms is significantly different between the Cold RA and Heat RA group. 
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Text S1:  
Questionnaire diagnosis of Rheumatoid Arthritis patients Patient Nr: 
______ 
 
This questionnaire is meant to be filled in under the supervision of your caretaker. Please 
answer all the questions. When an answer is not possible, please note this as well. All 
information will be handled with care and treated with respect. 
 
The questions often require an estimation of the Severity and Frequency of the symptoms. 
Select a number between 1 and 7 for this, 1 meaning never or not and 7 meaning very severe 
or very often. 
 
 
1. Breathing Answer 
Do you experience shortness of breath? 
 




Do you experience dryness of the mouth? Severity (1-7): 
Frequency (1-7): 
Do you experience dryness of the throat frequently? 
- Is this dryness located in the upper throat? 
Frequency (1-7): 
yes/no 
Do you cough with expectoration of phlegm? 
- How much phlegm? 
- How sticky is the phlegm? 





   
2. Digestion Answer 
Does your lower abdomen feel tender or very sensitive? 
- Is this feeling aggravated by pressure? 
Severity (1-7): 
yes/no 
Does your abdomen feel swollen or distended? Severity (1-7): 
Do you have a feeling of fullness in your abdomen? Severity (1-7): 
Do you have diarrhea? Frequency (1-7): 
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- Is the diarrhea smelly? Yes/No: 
Do you have loose stools? Severity (1-7): 
   
3. Climate Answer 
Do you feel cold? 
- Is this cold located especially in the feet or lower limbs? 
Severity (1-7): 
yes/no 
Do you experience thirst? Severity (1-7): 
Frequency (1-7): 
Do you experience chills? Severity (1-7): 
Frequency (1-7): 
Do you feel warm? Severity (1-7): 
Do you experience fever occasionally? 
- Is the fever accompanied by slight chills sometimes? 
Frequency (1-7): 
yes/no 
Do you dislike heat? Severity (1-7): 
Do you dislike cold? Severity (1-7): 
Do you experience spontaneous sweating or sweating at the lightest exertion? Severity (1-7): 
Frequency (1-7): 
Is there a preference for cold drinks? Severity (1-7): 
Is there a preference for warm drinks? Severity (1-7): 
Is there a preference for cold food? Severity (1-7): 
Is there a preference for warm food? Severity (1-7): 
   
4. Quality of the symptoms Answer 
Do the affected parts of your body feel heavy? Severity (1-7): 
Does your skin feel numb and cold? Severity (1-7): 
Do you feel stiffness in your joints? Severity (1-7): 
Do you have swollen joints? Severity (1-7): 
Is the joint red? Severity (1-7): 
Is the joint warm? Severity (1-7): 
Do you have swellings in your body? Severity (1-7): 
Do your four limbs feel weak?  Severity (1-7): 
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Do your tendons feel weak? Severity (1-7): 
   
5. Pain Answer 
Do you experience pain? Severity (1-7): 
What kind of pain do you experience?  soreness, stabbing, sharp, deep, heavy, dull, 
tingling feeling 
Does the pain aggravate with foggy, humid weather? Severity (1-7): 
Does the pain aggravate at night? Severity (1-7): 
Does the pain aggravate by coldness and cold weather? Severity (1-7): 
Is the pain accompanied with redness and swelling? yes/no 
Does the pain improve by warmth and movement? Severity (1-7): 
 










8. Conclusions and perspectives 
 
Rheumatoid arthritis sub-types 
The main aim of the research presented in this thesis was to find and characterize relevant 
sub-types of rheumatoid arthritis patients. Instead of an unsupervised approach for finding 
such sub-types knowledge from Chinese medicine was used to direct the research. In Chinese 
medicine diagnosis Cold and Heat are key concepts consisting of specific symptom patterns 
that are used to characterize patients. Consequently, the Cold and or Heat status of patients is 
very important for choosing the right therapy. In this thesis a systems biology approach was 
applied to characterize Cold and Heat types of rheumatoid arthritis patients. Multivariate 
statistical analysis was used to validate the classification of the two patient sub-types. 
In Chapter 5 the first biochemical characterization of Cold and Heat RA patients has been 
presented. From the gene expression profiles measured in CD4+ T-cells, apoptosis turned out 
to be a key mechanism that is differently regulated in Cold and Heat RA patients. In Heat RA 
patients apoptosis was found to be stimulated compared to Cold RA patients, in which more 
apoptosis resistance genes were expressed in the particular subset of T-cells. In Chapter 7 a 
second study is presented in which Cold and Heat RA patients were characterized, this time 
with a more extensive LC-MS analysis of urine and plasma samples. This study reveals 
higher levels of 11 acylcarnitines in the urine of Heat RA patients compared to Cold RA 
patients. These findings suggest that Cold RA patients have less muscle mass and/or a more 
pronounced muscle breakdown than RA Heat patients. Carnitine homeostasis has been related 
to fatigue in chronic fatigue patients and might also be related to fatigue experience in RA, 
which is a major issue for RA patients. It would be interesting to study whether fatigue is 
particularly related to one of the Cold or Heat RA sub-types. 
Additionally, it was found that levels of DHEAs in Heat RA patients were higher  than in 
Cold RA patients suggesting that the Cold RA group has a more suppressed HPA-axis 
function. Decreased HPA-axis function is associated with an inadequate response to stress 
factors. It is hypothesized (Cutolo 2000) that this inadequate response can lead to 
autoimmune and inflammatory disorders.  
In Chinese medicine Cold and Heat RA patients are treated very differently. The results 
described in Chapter 5 and 7 indicate substantial biochemical differences between the two 
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types of patients. A text mining study (Li 2007) shows that diseases related to Cold according 
to Chinese medicine theory are more related to hormone function disturbances and Heat 
related diseases to immune function disturbances, which is in agreement with our findings. It 
is hypothesized that Cold RA patients might benefit more from hormone based therapies 
(such as prednisone) and Heat RA patients from immune based therapies (such as anti-TNF 
agents). 
Recently a new study was started but not yet completed to study the response of Cold and 
Heat RA patients to anti-TNF treatment. Currently 40-50% of the RA patients fail to respond 
adequately to these drugs, resulting in side effects but no beneficial effects for the patients. 
The RA patients have been classified in Cold and Heat based on a questionnaire and response 
is measured at several time points. The ability to predict these differences in response to 
treatment with one of the most expensive drugs on the market today would have an enormous 
impact on health care costs. 
This unique approach of targeting therapy to sub-groups of patients based on Chinese 
diagnostic information could be extended in future studies. In the presented work only two 
general sub-types of RA are explored, which could be expanded with more sub-types. The 
study presented in Chapter 6 suggests that the key Chinese medicine concepts Internal and 
External constitute another important source of variation between RA patients. In addition, 
the more chronic stages of RA could be studied by exploring disturbances on the level of the 
Chinese concepts for Organ functions. Such studies might reveal certain clearly characterized 
sub-types of RA patients that can be treated differently. 
 
Systems biology as a bridge between Western and Chinese medicine 
The gene expression and metabolomics profiles of rheumatoid arthritis sub-types provide a 
biochemical view of some Chinese diagnostic principles. This biochemical view firmly 
grounds Chinese diagnosis in biology and makes acceptance easier. Recently this approach 
was discussed in a Nature publication (van der Greef 2011). The scientific community is 
clearly opening up for the integration of different views on health and science. The 
foundation of this integration is systems thinking and systems biology. Systems thinking is 
typical of Chinese medicine in which diagnosis and treatment is based on changing patterns 
of symptoms. Western science is recently rediscovering the principles and usefulness of 
systems thinking by developing comprehensive measurement platforms, and data analysis 
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approaches for studying relationships between measurements. 
Besides an open mind, analytical platforms are needed that are able to capture a wide variety 
of types of information of the system. In this thesis, a gene expression study is described in 
which the expression of all the genes of CD4+ T-cell were measured. Additionally, several 
untargeted liquid chromatography and gas chromatography mass spectrometry methods were 
used to measure metabolite levels in urine and plasma. Although the results are promising, 
the options for measuring the system could be greatly improved. For instance, the interactions 
between 'compartments' such as the liver, urine, blood, muscle, brain, could reveal 
compensation mechanisms. Additionally, analytical platforms could be developed to measure 
less abundant metabolites. Especially the identification of unknown metabolites proves to be 
a challenge (Kind 2010). 
Systems biology science will reveal much more information about a system when 
measurements in time become a more viable option. Rheumatoid arthritis as an example of a 
chronic disease, daily rhythms in the symptoms (Cutolo 2005) are well known, and 
relationships with disturbances of hormonal rhythms are extensively studied (Cutolo 2008). 
This has for instance resulted in glucocorticoid chronotherapy with optimal medication at 3 
am (Cutolo 2012). More understanding of the rhythmicity of  biological systems and 
disturbances of the system will result in new options for optimizing treatment. Several studies 
in this area of chronobiology are showing the dynamics in metabolite levels during the day 
(Eckel-Mahan 2012, Bass 2010, Froy 2010). However, it is a challenge to develop stable 
analytical platforms to measure large series of samples and analyze the huge amount of data 
resulting from such measurements.   
The systems biology bridge can be strengthened by including the rich Chinese theoretical 
development and experience with symptom patterns. Symptom patterns seem to behave like 
attractors with stable states that can change to other states when certain bridge symptoms 
express themselves. It would be interesting to study changes in symptom patterns and 
changes in metabolomics and other -omics patterns simultaneously. A challenge here is to 
design an expert system that is able to easily capture relevant symptom information to 
prevent the use of extensive questionnaires.  
Another approach to strengthen the bridge lies in an integration of nonlinear mathematics and 
complexity theory with biology to improve the analysis of patterns of relationships. Living 
systems are inherently nonlinear, where the output is usually not proportional to input, and 
which cannot be described by linear differential equations. Such systems consist of a large 
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and variable numbers of components, showing a large degree of connectivity (Higgins 2002). 
Living systems are also energetically open and organizationally closed, but in a state far from 
equilibrium. There is a constant uptake and incorporation of substances in the body while 
other substances are excreted. Systems biology needs to move away from only studying 
linear relationships and should include nonlinear possibilities.  
Figure 1. Integration of Chinese and Western concepts of arthritis. Patient information is 
collected on several levels (left panel). Symptoms which relate Chinese concepts (orange 
hexagons) with Western concepts (blue hexagons) are visualized in a network (right panel). 
 
Finally, systems biology thrives by good visualization methods that can convey clear 
messages extracted from the usually huge amount of data. In several studies presented in this 
thesis, concepts from network theory were applied. In Chapter 2 the relationships between 
Western and Chinese concepts of arthritis were visually explored (Figure 1). Chapter 5 
contains a network view of the genes expressed differently between the Cold RA and Heat 
RA patients. The relationships between the symptoms used in the questionnaire described in 
Chapter 6 were also visualized in a network view. Several tools for static network 
visualization such as Cytoscape (www.cytoscape.org), Pajek (pajek.imfm.si/ 
doku.php?id=pajek) and Grephi (grephi.org) are developing rapidly, however dynamic 
visualization is much more challenging. New options for visualizing dynamic data were 
explored in the artist project Aqua Vita (www.theaquavitaproject.com), which used a 
combination of metabolomics and Chinese diagnosis data. This effort has resulted in an 
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appealing interactive visualization, novel ideas, and an exhibition with a large amount of 
public outreach. Bringing disciplines together enhances the creative process and can result in 
a better embedding of research in the society. 
 
Personalized medicine and health promotion 
The introduction of this thesis started out with describing some of the challenges the health 
care system is facing today. Slowly, scientists and clinicians start to realize that every patient 
is different and that therefore medicine needs to be developed that is personalized. In this 
thesis a step was taken in the direction of personalized medicine by characterizing two groups 
of rheumatoid arthritis patients (Figure 2). Instead of treating all patients in the same manner, 
a distinction can now be made between the Cold and Heat RA patients. Similarly, two pre-
diabetes sub-types based on Chinese diagnosis have been characterized by metabolomics 
measurements (Wei 2012). A next step might be to find even more subtle sub-types of 
patients for which treatment can be optimized.  
Figure 2. Steps from the current Western 'one-size-fits-all' concept to targeted care and 
eventually to a personalized health care system. 
 
The development of health promotion strategies will have a major impact on the structure of 
the health care system and the well-being of people. Chinese medicine is especially 
developed as a health promotion strategy and contains the knowledge to monitor changes in 
the healthy state of the body. This knowledge of diagnosis, which includes the development 
of symptom patterns, is essentially lacking in Western medicine. In this thesis, first steps are 
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taken to integrate this knowledge with Western systems biology information. Symptom 
patterns can further direct biomarker research in the area of disease prevention and health 
promotion. In addition, Chinese medicine includes life-style advice and herbal medicine that 
are aiming for health promotion and can be used in very early stages of shifting towards an 
unhealthy state.  
 
A movement towards health promotion invites the question of who is responsible for which 
part of the health care options. A shift towards a more equal patient-practitioner relationship 
is already happening and will place the doctor more in the role of a health coach. Health 
promotion strategies will be much more integrated in daily life by, for example, health apps 
on mobile phones, courses in stress reduction techniques that people can take, personalized 
nutrition advice, etc. 
As health care will become patient-centered, integrated, preventive and personalized, the role 
of scientists also needs to change. Science conducted in multidisciplinary teams, including 
patients, consumers and health care organizations, allows the development of health care 
products that are actually desired by patients and consumers. The scientist will act as a 
knowledge organizer and integrator. Discoveries will more easily lead to strategies that can 
enter clinical practice and reach the consumer. The future health of the society and of the 
participants therein will emerge from the many interconnected relationships between various 
actors and the inspiration these relationships will bring about. 
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De huidige geneeskunde richt zich vooral op het bestrijden en managen van ziekten. 
Ontwikkelingen op dit vlak hebben geleid tot een enorme verlenging van de levensduur van 
mensen met bijvoorbeeld kanker, hart- en vaatziekten en diabetes. Echter, zoals de 
vicepresident van GlaxoSmithKline in 2003 al opmerkte, werken 90% van de medicijnen in 
slechts 30-50% van de patiënten. Er is dus veel ruimte voor verbetering. 
Een recente ontwikkeling is de gedachte dat medicijnen meer op het individu toegesneden 
moeten worden. Het is van belang wie welk medicijn krijgt, op welk moment en in welke 
dosis. De effectiviteit van medicijnen kan enorm verhoogd worden door de juiste categorie 
patiënten te vinden voor een bepaald medicijn. Voor de ontwikkeling van deze 
geïndividualiseerde zorg is goede diagnose essentieel. In dit proefschrift staat diagnose 
centraal.  
In China heeft zich de afgelopen millennia een geneeswijze ontwikkeld met een meer 
beschrijvend diagnostisch systeem. Patronen van symptomen hebben een betekenis gekregen 
en kunnen vertaald worden in een behandeling. In dit proefschrift wordt getracht Chinese 
kennis van diagnostiek te vertalen naar manieren om de Westerse zorg te optimaliseren.  
Systeem biologie is bij uitstek een geschikte werkwijze om deze vertaling te bewerkstelligen. 
Deze benadering berust op het meten van informatie op verschillende niveaus van een 
systeem, waarbij het meten van metabolieten in bloed en urine in dit proefschrift de nadruk 
heeft. Deze benadering kan gebruikt worden om biologische verschillen tussen patiënten 
groepen te vinden en te karakteriseren. In dit proefschrift wordt een systeem biologische 
benadering gepresenteerd waarbij reumatoïde artritis patiënten kunnen worden ingedeeld in 
twee groepen op basis van Chinese diagnostische eigenschappen. Metabolomics en gen-
expressie analyses werden uitgevoerd om mogelijke biologische verschillen tussen deze twee 
groepen te ontdekken. Hieronder volgt een overzicht van de gepresenteerde hoofdstukken van 
het proefschrift. 
Hoofdstuk 2 is een zoektocht naar een visie op geïndividualiseerde geneeskunde en de 
mogelijkheden om deze visie vorm te geven. Diagnose wordt beschouwd als een 
sleutelbegrip. Een betere integratie van systeemdenken in de levenswetenschappen en 
medische wetenschappen wordt voorgesteld, wat uit kan groeien tot een systeemwetenschap. 
Daarnaast wordt de waarde van het systeemdenken in de Chinese geneeskunde voor de 
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ontwikkeling van geïndividualiseerde geneeskunde uitvoerig belicht en worden methoden 
beschreven voor het integreren van het Chinese denken in de Westerse wetenschap. 
Metabolomics is naast andere -omics technologieën zoals genomics en proteomics één van de 
hoekstenen van systeembiologie. In hoofdstuk 3 wordt een overzicht gegeven van het 
metabolomicsveld vanuit het perspectief van 30 jaar metabolomics ontwikkeling bij TNO. De 
omslag van een door technologie gedreven ontwikkeling van metabolomics naar een door 
biologie getrokken ontwikkeling wordt beschreven. Dit alles geïllustreerd met een 
verscheidenheid aan metabolomics toepassingen en afgesloten met een visie op de rol van 
metabolomics in het veranderende landschap van de zorg. 
In hoofdstuk 4 wordt dieper ingegaan op metabole processen die betrokken zijn bij 
reumatoïde artritis. Een gedetailleerd overzicht wordt gepresenteerd van metabole processen 
die de afgelopen tientallen jaren beschreven zijn. Een geïntegreerde analyse van de 
informatie resulteerde in een belangrijke rol voor celdood en vetmetabolisme in reumatoïde 
artritis. Een andere conclusie van de literatuurstudie was het belang van de dynamiek van 
bepaalde metabolieten voor het ziekte proces evenals voor de behandeling. 
Hoofdstuk 5 beschrijft de eerste klinische studie waarin twee subtypen van reumatoïde 
artritis patiënten worden beschreven die gebaseerd zijn op een Chinese diagnose. De twee 
subtypen worden gekenmerkt door verschillende genexpressie profielen gemeten in CD4 
positieve T-cellen en verschillen in een GC-MS metabolomics analyse van bloed plasma. De 
studie beschreven in dit hoofdstuk is het eerste bewijs voor biologische verschillen tussen 
deze twee subgroepen van RA patiënten, gebaseerd op een combinatie van Westerse en 
Chinese diagnose. 
Hoofdstuk 6 beschrijft het logische vervolg op de resultaten van hoofdstuk 5, het 
standaardiseren van de Chinese diagnose waarmee de subtypen van RA patiënten kunnen 
worden vastgesteld. Hiertoe is een systeemdiagnose-vragenlijst ontwikkeld en toegepast 
waarmee uitgebreide symptoomprofielen van reumapatiënten zijn verzameld. De grootste 
variatie in symptoomprofielen tussen de patiënten bleek te corresponderen met de Chinese 
basis concepten Intern en Extern en de concepten Koude en Hitte. Deze twee algemene 
indelingen die gebruikt worden in de Chinese diagnose en behandeling bleken dus duidelijk 
terug te vinden te zijn met deze systeem diagnose vragenlijst. 
In hoofdstuk 7 wordt een klinische studie beschreven vergelijkbaar met die van hoofdstuk 5. 
In deze studie werden wederom RA-patiënten ingedeeld in Koude en Hitte typen patiënten op 
basis van een Chinese diagnose. Daarnaast werd een systeemdiagnose-vragenlijst ingevuld 
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door de patiënten. In deze studie werden standaard klinisch chemische bepalingen gedaan op 
bloedmonsters. Plasma en urine werd geanalyseerd met een globale LC-MS methode. De 
meest opvallende bevinding was de lagere hoeveelheid van 11 acylcarnitines in de urine van 
Hitte RA patiënten, in vergelijking met de Koude RA patiënten. Daarnaast werd een lagere 
hoeveelheid dehydroepiandrosterone sulfate (DHEAS) gevonden in Koude RA patiënten, wat 
kan duiden op een meer onderdrukte HPA-as functie in deze patiënten. 
In dit proefschrift wordt laten zien hoe relevante subtypen van reumatoïde artritis patiënten 
kunnen worden gevonden door te kijken naar Chinese diagnostische kenmerken. 
Systeemdenken en systeem biologie blijkt een goede methode te zijn om biologische 
verschillen tussen deze subtypen te vinden en beschrijven. Het indelen van patiëntengroepen 
in kleinere subgroepen met specifieke kenmerken is een eerste stap richting 
geïndividualiseerde geneeskunde. In de toekomst kan de response van deze subgroepen op 
medicatie worden onderzocht en zo nodig de medicatie worden aangepast aan de subgroep. 
Bovendien kan deze methode helpen met het beschrijven en in kaart brengen van meer 
subgroepen met ieder een toegesneden behandelstrategie. In een verdere toekomst kan deze 
methode bijdragen aan het ontwikkelen van een persoonlijk zorg ecosysteem waarin de 
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Dan opeens is het proefschrift klaar, een stuk onderzoek is afgerond. Althans zo lijkt het. 
Inmiddels hebben drie nieuwe aio’s het stokje overgenomen. Zij zullen het thema opnieuw 
vormgeven en uiteraard spannende nieuwe ontdekkingen doen. Dit kan alleen met 
ondersteuning van vele anderen in de afdeling. Veel dank voor iedereen die dit mogelijk heeft 
gemaakt en gaat maken. 
Inmiddels ben ik bij TNO aan de slag gegaan met onderwerpen die erg in het verlengde 
liggen van het werk beschreven in dit proefschrift. Naast nieuwe TNO uitdagingen kan ik 
deel blijven uitmaken van het SDPPM team en mijn steentje bijdragen aan het werk in 
Leiden.  
Zonder mensen bij naam te noemen wil ik uiteraard iedereen bedanken die ik op mijn pad ben 
tegengekomen. Ik heb vele interessante, soms provocerende, ook treurige, inspirerende 
momenten meegemaakt. Sommige koffiepauzes zijn onvergetelijk waarbij alle politieke 
kleuren uit de samenleving verstrengeld waren in soms hevige discussies. 
Het SDPPM team wil ik in het bijzonder bedanken. De stijl van werken en de culturele 
uitwisseling met Chinese partners in het onderzoek heeft mij enorm aangesproken en 
geïnspireerd. Het palet van verschillende talenten aan boord is uniek, een waar genoegen om 
met jullie allemaal samen te werken. 
Tenslotte heeft dit proefschrift niet tot stand kunnen komen zonder support van mijn lieve 
partner Klaartje. Tijdens deze jaren hebben wij een zoontje en dochtertje mogen krijgen en 
ook zij hebben bijgedragen aan de vorm waarin het onderzoek gegoten werd. 
 
